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Abstract
Nowadays, the most common form of radiotherapy used in clinics employs high energy linear
accelerators (LINACs) to generate and precisely target a photon beam to the tumor mass. Each year, 
thousands of patients are routinely treated with photon-based radiotherapy alone and in combination 
with chemotherapy and surgery for curative or palliative purposes. On the other hand, particle beam 
therapy, especially proton and carbon ions have evolved in the past decades from a niche treatment to 
a valid option. Currently, several centers worldwide employ high energy protons for the treatment of 
cancer. Protons display special particle kinetics, with strong deceleration after tissue penetration leading 
to a differential dose distribution, which is called the Bragg peak, allowing highly selective dose 
deposition in the tumor, while sparing the surrounding normal tissue from damage. This localized dose 
delivery of radiation to the tumor site allows treatment of selected tumors, like uveal melanomas and 
chondrosarcomas that are seated near critical organs and for which protons represent a valid and safe 
treatment option. 
The physical and technological knowledge of proton radiotherapy steadily increased during the last 
decade. However, radiobiological research of proton irradiation is minimal. Several preclinical (in vitro)
experiments have pointed out an enhanced efficacy for proton radiation, compared to conventional 
photon radiation. Currently, there are still a lot of uncertainties regarding the biological and mechanistic 
basis of protons, thus limiting further expansion of this powerful technology from the radiobiological 
point-of-view. DNA is the key target for ionizing radiation, and it has been speculated that proton 
radiation-induced DNA damage might be quantitatively or qualitatively different from photon-induced 
damage, but only a few studies have been performed to elucidate this issue.
The aim of the present PhD work is to elucidate the molecular and cellular effects of high-energy, low-
LET proton radiation in defined human cancer cellular systems, compared to photon radiation.
We initially have shown that exponentially growing  mutant Chinese hamster ovary cells (CHO cells)
deficient in homologous recombination repair (HRR) were significantly more sensitive to proton 
irradiation than photon irradiation, compared to cells with intact HRR (relative biological effectiveness, 
RBE10 of 1.44±0.06 vs. 1.24±0.03). When these HRR-deficient cells were irradiated in plateau (growth 
arrested) phase, there was no longer a difference in the RBE of the two cell lines (RBE10 of 1.29±0.03
vs. 1.27±0.03), indicating a more critical role of HRR after proton vs. photon irradiation in exponentially 
growing cells, as HRR is only active in S/G2 phase. In contrast, exponentially growing non-homologous 
end joining (NHEJ)-deficient cells did not show a specifically enhanced sensitivity to proton irradiation 
(RBE10 of 1.2±0.05, vs. 1.09±0.10). Analysis of initially induced JH2AX and 53BP1 foci revealed no 
difference in response to the two types of radiation. The repair kinetics of DNA damage in wild type cells 
were the same after both types of radiation (JH2AX, Rad51, and 53BP1 foci), even though proton 
irradiation resulted in more residual chromosomal DNA fragments and lethal chromosome aberrations. 
Interestingly, the repair kinetics in HRR-deficient cells was significantly delayed after proton irradiation, 
leading to an elevated amount of residual JH2AX-foci 24 h after irradiation. These data demonstrated 
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that photon and proton radiation induce the same amount of initial DNA DSBs but most of a differential 
quality of the DNA damage.
In the second part of this work, we have investigated several end points in human cancer cells with a 
particular focus on DNA damage and its repair by the two major pathways, homologous recombination 
repair and non-homologous end joining. We used a panel of different human cell lines with defined 
mutations or downregulated selected genes by the small interfering RNA approach. Our work revealed 
a differential sensitivity of cells to proton versus photon radiation, which depends on the specific cellular 
repair capacity linked to the genetic background of the cell. 
We primarily focused on the non-small cell lung cancer cell line A549. A549 cells represent a good 
model for in vitro and in vivo studies. They are p53 wild-type, but harbor a mutation in the KRAS
oncogene. Irradiation of A549 cells with high-energy proton radiation (136 MeV) in the middle of the 
spread out Bragg peak led to an RBE10 of 1±0.04 over photon radiation (200 KeV). Treatment of A549 
cells with 1Gy of both photon and proton radiation induced the same amount of initial JH2AX and 
53BP1-foci. Likewise, removal of these foci over time was similar in response to both types of 
irradiation. This was coupled with an identical cell cycle profile after both proton and photon radiation, 
with approximatively 50% of cells in G2-phase after 24 hours. Thus, proton-induced damages in wild-
type A549 cells are repaired in a similar fashion than photon-induced damages.
To further investigate the involvement of the two main DSB repair pathways in response to proton and 
photon irradiation in detail, we analyzed repair kinetics for DNA-PKcs phosphorylation at both Ser-2056 
and Thr-2609 loci along with RAD51 and RPA32-foci formation. We observed a time-dependent 
increase of RAD51 and RPA32-foci formation in these cells 1 hour and 4 hours after photon ionizing 
radiation. Proton irradiation induced a similar amount of foci, suggesting that HRR is activated in a 
similar way after both types of radiation. In contrast, DNA-PKcs activation was strongly hampered after 
proton radiation in comparison to photon radiation, with a reduction of about 40% after 1 hour for both 
phosphorylation clusters analyzed. Therefore, even if the cell killing in A549 cells appears to be equal
after both types of irradiation, there is a differential activation of the DNA repair pathways, especially for 
the DNA-PKcs-dependent NHEJ in response to the two types of irradiation.
We therefore investigated the role of DNA-PKcs and NHEJ in more detail by selectively inhibiting the 
catalytic subunit with the novel compound NU7026, which interferes with the capacity of the enzyme to 
autophosphorylate at Ser-2056, thereby blocking the synaptic resolution process.
We observed a potent sensitization toward photon radiation, but to much a smaller extent toward proton 
radiation (DMF10 of 1.91±0.05 versus 1.49±0.06) by cellular pretreatment with DNA-PKcs inhibitor. As 
expected, JH2AX-and 53BP1-foci removal was strongly delayed in cells pretreated with NU7026 after 
photon radiation, but was surprisingly only minimally affected in NU7026-pretreated cells after proton 
radiation. Analysis of pDNA-PK (Thr-2609) foci revealed a strong delay in cells pretreated with NU7026 
after photon radiation, but again only minimally affected in NU7026-pretreated cells after proton 
radiation, therefore suggesting that NU7026 directly blocks the catalytic subunit to the damage site, 
avoiding its release.
Analysis of RPA32-foci formation, a known marker for HRR, revealed that DNA-PKcs inhibition by 
NU7026 strongly reduced RPA32-foci formation after photon irradiation, with only about 35% of foci 
detectable 4 hour after irradiation in comparison to cell not treated with the DNA-PKcs inhibitor. In cells 
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irradiated with protons, almost no reduction in RPA32-foci formation was observed after pretreatment 
with NU7026. 
We then investigated the effect of NHEJ deficiency by downregulating the NHEJ-factor DNA-PKcs in 
A549 cells. Although significantly more radiosensitive than siLuc-transfected cells, siDNA-PKcs-
transfected cells were equally sensitive to both types of irradiation (RBE10=0.94±0.07 versus 1±0.04 in
wild-type cells). The repair kinetics of DNA damage (JH2AX foci) was comparable after both types of 
radiation in DNA-PKcs-knockdown cells, although strongly delayed compared to siLuc-treated cells. 
RPA32-foci resolution analysis showed that siDNA-PKcs-transfected cells had a much slower activation 
of HRR, compared to control cells. 
To validate the importance of HRR for the repair of proton irradiation-induced DNA damages in a human 
system, we have downregulated the key HRR-recombinase RAD51 by siRNA treatment. SiRAD51-
treated A549 cells were markedly hypersensitive toward proton than photon radiation.
To confirm a differential sensitivity to proton and photon irradiation in NU7026-pretreated, thus DNA-
PKcs-inhibited cells in comparison to DNA-PKcs-knockdown cells, we have investigated cell survival 
and JH2AX-focus repair in the DNA-PKcs-deficient M059J cells and their proficient, isogenic counterpart 
M059K cells. Similarly to siDNA-PKcs-treated A549 cells, we observed no difference between photon 
and proton radiation at the level of clonogenic survival and JH2AX-foci repair (RBE10=0.88±0.05 versus 
1.02±0.11 for wild-type). Similarly to A549 cells, pretreatment of the proficient M059K cells with NU7026 
resulted in a stronger radiosensitizing effect toward photon radiation than toward proton radiation
(DMF10 of 1.49±0.02 versus 1.2±0.1). 
To additionally validate the importance of HRR for the repair of proton-induced DNA damage, we took 
advantage of the BRCA2-deficient ovarian cancer cells PEO1 and their wild-type, isogenic counterpart 
the ovarian cancer cells PEO4. As expected, BRCA2-deficient PEO1 cells were in general much more 
sensitive towards irradiation than BRCA2-proficient PEO4 cells. But again, exponentially growing cells 
deficient in BRCA2 were significantly more sensitive to proton irradiation than wild-type PEO4 cells, with 
have an intact HRR (RBE10 of 1.2±0.02 versus 1.08±0.06).
To test the effect of direct pharmacological targeting of the HRR pathway, we exposed cells to SAHA
(Vorinostat), a broad-range histone deacetylase inhibitor known to downregulate RAD51 protein. 
Pretreatment of A549 cells sensitized cells only mildly to photon irradiation, whereas sensitization to 
proton irradiation was much stronger (DMF10 of 1.11±0.07 vs. 1.45±0.15).
This work demonstrates that the cellular background strongly determine a differential sensitivity toward 
proton or radiation, respectively. We first demonstrated in a defined system using CHO cells that there 
is a differential quality of DNA damage by proton- versus photon irradiation with a specific requirement 
for homologous recombination for DNA repair and enhanced cell survival. In the second part of the work 
we have validated these results in human tumor cell lines. These results suggest an essential role for 
HRR to properly repair a certain percentage of proton-induced DNA damages, which cannot be properly 
recognized and repaired by NHEJ. Furthermore, we demonstrate for the first time that selective 
inhibition of the catalytic subunit of DNA-PKcs by NU7026 can strongly impair photon-induced but not 
proton-induced DNA damage repair, further indicating that damage complexity is a key factor 
determining which pathway will actively repair damage, with HRR being more important for the repair of 
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proton-induced DSBs. These data provide a new, biology-based rationale for further stratification of 
patients in a clinical setting, where proton therapy may become relevant for patients carrying specific 
mutations in the DNA damage repair pathways. Likewise, our research provides the biological 
background for novel combined treatment modalities to be defined for a specific type of ionizing 
radiation.
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Zusammenfassung
Die Strahlentherapie gehört mit der Chemotherapie und Chirurgie zu den wichtigsten 
Behandlungsoptionen bei soliden Tumoren. Jedes Jahr profitieren Tausende von Patienten von einer 
Strahlentherapie allein oder in Kombination mit einer weiteren Modalität in einem kurativen oder 
palliativen Ansatz. Meist wird mittels hochenergetischen Linearbeschleunigern ein Photonenstrahl
erzeugt, der präzise gegen das Tumorgewebe gerichtet wird. Weitere Strahlenarten, die in der 
Strahlentherapie verwendet werden, sind Partikelstrahlen wie Elektronen, Neutronen, Pi-Mesonen, 
Protonen und schwere, geladene Ionen wie Carbon-Ionen (12C). Von diesen ist die Protonentherapie 
die bekannteste Form und erlangt immer mehr an Bedeutung. Protonen haben spezielle physikalische 
Eigenschaften, welche eine exaktere Bestrahlung des Tumors möglich machen als dies mit Photonen-
basierter Strahlentherapie möglich ist. 
Während Photonen das Gewebe gleichmäßig durchdringen, zeigen Protonen eine besondere Partikel-
Kinetik, mit einer starken Abbremsung und Verzögerung nach Eindringen in das Gewebe, welche zu 
einer Differentialdosisverteilung führt, dem sogenannten Bragg-Peak. So findet eine hochselektive
Dosisdeposition im Tumor statt, wobei das umliegende Gewebe weitgehend geschont werden kann.
Diese lokalisierte Dosisabgabe von Strahlung im Tumor ermöglicht auch die Behandlung von 
ausgewählten (mit Photonen schwierig zu behandelnden) Tumoren wie Aderhautmelanomen und
Chondrosarcomas, die in der Nähe von kritischen Organen liegen. Für diese Tumorentitäten stellt die 
Protonentherapie bereits heute eine akzeptierte und sichere Behandlungsoption dar. In den letzten 
Jahrzehnten haben sich die physikalischen und technologischen Kenntnisse in der Protonen-
Strahlentherapie stetig weiterentwickelt, so dass immer mehr Patienten mit weiteren klinischen 
Indikationen von der Protonenbestrahlung profitieren konnten. Auf der biologischen Ebene ist das Feld 
aber weitgehend unerforscht geblieben. Einige präklinische (in vitro) Experimente haben eine bessere
Wirksamkeit für die Protonenbestrahlung im Vergleich zur herkömmlichen Photonenbestrahlung 
gezeigt. Derzeit gibt es aber noch eine Menge Unsicherheiten bezüglich der biologischen und 
mechanistischen Wirkung von Protonen, was die Verbreitung und Etablierung dieser Technologie noch
verzögert. 
DNA ist die kritische Zielstruktur für ionisierende Strahlung, und es wird spekuliert, dass sich protonen-
induzierte DNA-Schäden möglicherweise quantitativ oder qualitativ von Photonen-induzierten DNA-
Schäden unterscheiden. Es gibt nur wenige Studien, welche diese Frage bisher untersuchten.
Das Ziel der vorliegenden PhD-Dissertation ist es, die molekularen und zellulären Wirkungen der 
Protonenbestrahlung in definierten humanen Zell-Systemen aufzuklären und mit der Photonenstrahlung 
zu vergleichen. Das Augenmerk wird dabei vor allem auf verschiedene DNA-Reparatursysteme 
gerichtet. Wir haben bereits gezeigt, dass exponentiell wachsende HRR (Homologe Rekombination 
Reparatur)-defiziente CHO-Zellen signifikant sensitiver sind gegenüber Protonenbestrahlung als Zellen 
mit intakter HRR (relative biologische Effektivität, RBE10 von 1.44±0.06 vs. 1.24±0.03). Wurden diese 
HRR-defiziente Zellen in der Plateauphase (wachstumsarretiert) bestrahlt, war der Unterschied im 
RBE10 zwischen den beiden Zelllinien nicht mehr vorhanden (RBE10 von 1.29±0.03 vs.1.27±0.03). Dies 
zeigt, dass HRR eine wichtigere Rolle in exponentiell wachsende Zellen nach Protonen als nach 
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Photonenbestrahlung spielt, da HRR nur in der S/G2 Phase aktiv ist. Andererseits waren exponentiell 
wachsende NHEJ (non-homologous end joining)-defiziente Zellen nicht signifikant sensitiver gegenüber 
Protonenbestrahlung verglichen mit Photonenbestrahlung (RBE10 von 1.2±0.05 vs. 1.09±0.10). 
Dieselben Zellen waren nach Bestrahlung in der Plateauphase viel radiosensitiver und signifikant 
sensitiver gegenüber Protonenbestrahlung als der Wildtyp (RBE10 von 1.32±0.05 vs. 1.25±0.03).
In den wildtyp-Zellen wurde kein Unterschied in der Anzahl von initialen DNA-Schäden (JH2AX und 
53BP1 Foci) nach Bestrahlung mit den beiden Strahlentypen festgestellt. Auch die DNA 
Reparaturkinetiken waren in den wildtyp-Zellen gleich (JH2AX, RAD51 und 53BP1-Foci), obwohl die 
Protonenbestrahlung zu mehr verbleibenden Chromosomenfragmenten und letalen
Chromosomenaberrationen führte. Interessanterweise war die Reparaturkinetik in HRR-defizienten 
Zellen nach Protonenbestrahlung signifikant langsamer, was sich 24 Stunden nach Bestrahlung in einer 
erhöhten Anzahl an nicht aufgelösten JH2AX-Foci zeigte. Folglich zeigen die Daten gleich viele DNA
DSB (Doppelstrangbrüche) (Quantität) nach beiden Bestrahlungsarten und deuten eher auf eine 
unterschiedliche Struktur (Qualität) des Schadens hin.
Im zweiten Teil dieser Arbeit wurden verschiedene Endpunkte in humanen Krebszelllinien untersucht, 
im Speziellen die Beteiligung von DNA Doppelstrangbruch Reparatur Systemen, namentlich der 
Homologen Rekombination Reparatur und dem Nicht-Homologen End Joining nach Photonen- und
Protonenbestrahlung. Dafür wurden verschiedene humane Zelllinien mit definierten Mutationen 
verwendet, oder spezifische Gene wurden mit Hilfe von small-interfering RNA (siRNA) runterreguliert, 
um Unterschiede in der Strahlenempfindlichkeit (Protonen vs Photonen) aufgrund der 
Reparaturkapaziät (genetischer Background) zu zeigen.  
Die vorliegende Arbeit hat sich hauptsächlich auf die nicht-kleinzellige Lungenkrebszelllinie A549 
fokussiert. A549 Zellen sind ein gutes Modell für in-vitro- und in vivo-Studien. Sie sind p53-wildtyp, 
tragen jedoch eine Mutation im KRAS-Onkogen. Die Zellen wurden in der Mitte des Spread-Out Bragg-
Peaks mit Hoch-Energie Protonen bestrahlt, was zu einer RBE10 von 1 ± 0,04 führte. Es wurden keine 
Unterschiede in der Anzahl von initialen JH2AX und 53BP1-Foci nach Bestrahlung mit beiden 
Strahlentypen festgestellt. Dies zeigte sich in einem identischen Zellzyklus-Profil sowohl nach Protonen-
als auch nach Photonenstrahlung, mit etwa 50% G2-Phase Zellen nach 24 Stunden. Diese Daten 
zeigen, dass Protonen-induzierte Schäden in A549-Zellen in ähnlicher Weise wie Photonen-induzierte 
Schäden repariert werden können. Die beiden DSB-Reparaturwege wurden nach Protonen- und 
Photonenbestrahlung im Detail untersucht: DNA-PKcs an beiden Ser-2056 und Thr-2609 
Phosphorylierungsstellen für NHEJ und RAD51 und RPA32 für HRR.
Wir beobachteten eine zeitabhängige Zunahme der RAD51 und RPA32-Foci-Bildung in den Zellen 1
Stunde und 4 Stunden nach Photonen- und Protonenbestrahlung. Die DNA Reparaturkinetik war in den 
A549 Wildtypzellen gleich (ähnlich wie bei JH2AX und 53BP1), was darauf hindeutet, dass die HRR auf 
ähnliche Weise nach beiden Arten von Strahlung aktiviert wird. Die DNA-PKcs-Aktivierung war 
hingegen stark beeinträchtig nach Protonenstrahlung verglichen mit Photonenstrahlung, mit einer 
Reduktion von etwa 40% nach 1 h an beiden Phosphorylierungsstellen.
Die Rolle von DNA-PKcs und NHEJ wurde detaillierter untersucht durch die selektive Hemmung der
katalytischen Einheit von DNA-PKcs mit dem neuartigen, hochselektiven Inhibitor NU7026, der die 
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Autophosphorylierung von Ser-2056 des Enzyms hemmt und damit eine Blockierung des synaptischen
Auflösungsprozesses induziert. NU7026-Behandlung führt zu einer starken Sensibilisierung in 
Kombination mit Photonenstrahlung, in viel geringerem Maße jedoch mit Protonenstrahlung (DMF10 von 
1,91±0,05 gegenüber 1,49±0,06). 
Wie erwartet, verzögert sich die JH2AX-und 53BP1-Foci Ablösung stark in NU7026 vorbehandelten 
Zellen nach Photonenstrahlung, aber nur minimal nach Protonenstrahlung. Das gleiche Muster wurde 
bei pDNA-PKcs-Foci (Thr-2609) beobachtet, was darauf hindeutet, dass NU7026 direkt die katalytische 
Untereinheit blockiert.
Die RPA32-Foci Analyse, ein bekannter Marker für HRR, zeigte, dass in mit NU7026 vorbehandelten 
A549 Zellen, die DNA-PKcs Inhibition zu einer stark reduzierten RPA32-Foci-Bildung nach
Photonenbestrahlung führt, mit nur noch ca. 35% der Foci nachweisbar nach 4 Stunden, im Vergleich 
zu unbehandelten Zellen. Nach Protonenbestrahlung wurde nahezu keine Abnahme nach 
Vorbehandlung mit NU7026 beobachtet.
Um die erhöhte Empfindlichkeit der HRR-mutierten Zellen gegenüber Protonenstrahlung in 
menschlichen Krebszellen zu bestätigen, wurde die HRR-Rekombinase RAD51 in A549-Zellen 
runterreguliert. A549-Zellen mit niedrigem RAD51 waren deutlich empfindlicher auf Protonenstrahlung, 
im Vergleich zu Kontrollzellen, welche nur einen minimalen Unterschied in der Strahlenempfindlichkeit 
zeigten (DMF10 von 1.49±0.02 versus 1.2±0.1).
Der Einfluss von NHEJ wurde durch die Runterregulierung der NHEJ-Faktor-DNA-PKcs mittels siDNA-
PKcs in A549-Zellen untersucht. Obwohl deutlich strahlenempfindlicher als siLuc-transfizierte Zellen,
waren exponentiell wachsende NHEJ-defiziente Zellen nicht sensitiver gegenüber Protonen- (RBE10 =
0,94 ± 0,07 vs. 1± 0,04 für Wildtyp) als Photonenbestrahlung. Die JH2AX-Foci Reparaturkinetik war in 
den siDNA-PKcs-behandelten Zellen nach Photonen- und Protonenbestrahlung gleich, wenn auch im 
Vergleich zu siLuc behandelten Zellen stark verzögert. Die RPA32-Foci Analyse zeigte, dass siDNA-
PKcs-transfizierte Zellen eine viel langsamere Aktivierung der HRR hatten, im Vergleich zu 
Kontrollzellen. Um eine differentielle Empfindlichkeit gegenüber Protonen und Photonen in NU7026-
behandelten DNA-PKcs-gehemmten Zellen im Vergleich zu genetisch runterregulierte siDNA-PKcs 
Zellen zu bestätigen, wurde das Überleben und die JH2AX-Foci Reparatur von DNA-PKcs-defizienten 
M059J Zellen und ihren kompetenten, isogenen M059K Zellen untersucht. Wie erwartet, waren M059J
Zellen deutlich strahlenempfindlich als M059 Zellen, zeigten jedoch wieder auf dem klonogenen
Überleben (RBE10 = 0,88±0,05 vs. 1.02± 0,11 für Wildtyp) und der JH2AX-Foci Reparatur keinen 
Unterschied zwischen Photonen- und Protonenstrahlung. Ähnlich zu den A549-Zellen, führte die 
Vorbehandlung von kompetenten M059K Zellen mit NU7026 zu einer stärkeren radiosensibilisierenden
Wirkung nach Photonenstrahlung im Vergleich zu Protonenstrahlung (DMF10 von 1,49±0,02 gegenüber
1,2±0,1).
Um zusätzlich die Bedeutung der HRR für die Reparatur von Protonen-induzierten DNA-Schäden zu 
validieren, wurden BRCA2-defiziente Eierstockkrebs Zelllinie PEO1 Zellen und BRCA2-profizienze 
Eierstockkrebs Zelllinie PEO4 untersucht. PEO4 und PEO1 Zellen waren im klonogenen Überleben
generell sensitiver gegenüber Protonen- als Photonenbestrahlung. Interessanterweise waren aber 
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exponentiell wachsende BRCA2-defiziente Zellen signifikant sensitiver gegenüber Protonenbestrahlung 
verglichen mit den BRCA2-profizienten Zellen (RBE10 von 1,2 ± 0,02 gegenüber 1,08 ± 0,06).
Zusätzlich wurde die Wirkung von SAHA (Vorinostat), ein Histone-deacetylase Inhibitor untersucht, 
welcher ebenfalls RAD51 runterreguliert. Vorbehandlung von A549-Zellen mit SAHA konnte die Zellen 
nur leicht für die Photonenbestrahlung sensibilisieren, wohingegen die Strahlensensibilisierung für
Protonenbestrahlung deutlich stärker war (DMF10 von 1,11±0,07 vs. 1,45±0,15).
In dieser Arbeit wird zum ersten Mal gezeigt, dass die genetischen Voraussetzungen der Zellen die
Zellantwort gegenüber Protonenbestrahlung stark beeinflusst. Fehlt HRR in schnell proliferierenden 
Zellen, ist deren Sensitivität gegenüber Protonenbestrahlung (im Vergleich zu Wildtypzellen) signifikant 
erhöht. Dies zeigt, dass HRR für die korrekte Reparatur eines bestimmten Anteils von vermutlich hoch-
komplexen Protonen-induzierten DNA-Schäden essentiell ist. Weiterhin zeigt die Arbeit zum ersten Mal, 
dass eine selektive Inhibition der katalytischen Untereinheit von DNA-PKcs durch NU7026 die 
Reparatur von photoneninduzierten, aber nicht von protoneninduzierten DNA-Schäden stark
beeinträchtigen kann. Diese Daten stellen eine neue, Biologie-basierte Rationale für die weitere
Stratifizierung von Patienten in der Klinik dar und weisen darauf hin, dass Patienten mit aggressiven, 
schnell wachsenden Tumoren, denen HRR und deren Zellzykluskontrollmechanismen fehlen, von einer 
Protonentherapie profitieren können. Ebenso bietet unsere Forschung die biologisch fundierte 
Grundlage für neuartige, kombinierte Behandlungsmethoden mit verschiedenen Bestrahlungsarten. 
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1 Introduction
1.1. Cancer and Cancer treatment
1.1.1. What is cancer?
A neoplasm (from Ancient Greek, meaning “new formation”) commonly referred to as a tumor, is a new 
abnormal growth of tissue, which usually do not respond to external and internal stimuli and have lost a 
clear structural and functional organization. Typically, neoplasms form a distinct, solid mass that can
either be benign or malign. The malignant, invasive and disruptive form of a neoplasm is called cancer.
Cancer cells are typically defined by two heritable properties: they reproduce in defiance of the normal 
restraints on the controlled cell division, and so do their progeny, and have the ability to invade and 
colonize tissues and organs normally reserved for other cells [1].
As long as the neoplastic entity remains clustered in a single mass, it is defined as a benign tumor and it 
can usually be removed by surgery, leading to full recovery. When tumor growth leads to organ invasion 
and its disruption and in case of an essential organ, the disease becomes lethal. 
Often, cancer cells acquire the ability to leave their primary site trough bloodstream or lymphatic 
vessels. This invasive, exaggerated and uncontrolled ability of the cancerous mass to spread and 
invade distant parts of the body is called the metastatic process, which makes cancer usually very 
difficult to be eradicated and thus often lethal.  
Nowadays, more than 100 different types of cancer have been described [2]. Cells from almost every 
tissue of the body can give rise to cancer. Cancers of the different types are classified according to the 
site of origin: carcinomas are cancer of epithelial origin; sarcomas typically originate from mesenchymal 
tissue. Leukemias are derived from hematopoietic cells, and cancers from the nervous system.
1.1.2. Cancer Epidemiology
Cancer is the leading cause of death in the economically developed countries (“first world”) and stands 
only behind cardiovascular diseases [3]. Incidence of cancer is constantly rising due to several factors. 
People are getting older, thus increasing the probability of developing cancer. Diagnostic 
methodologies, especially for some cancer types like breast or colon cancer are also steadily improving. 
Cancer-promoting behaviors, like tobacco smoking, alcohol consumption or unhealthy eating styles
coupled with sedentary lifestyles are also vastly spread, especially in developed countries.
Worldwide, the incidence of cancer rate was estimated to be at almost 12.7 million new cases in 2008
(Figure 1.1), with a trend toward increasing of about 100-150% in the next 15 years [4].
The annual number and cancer type distribution of newly diagnosed cancers strongly varies among 
geographical regions. The most common cancer is breast cancer in women and lung and prostate 
cancer in men, followed by colorectal cancer. These four types of cancer account altogether for about 
half of the newly diagnosed cancers worldwide, with a major prevalence in Europe and the US. Cervix 
and stomach cancers, whose etiology is strongly dependent on factors like viral infections (HPV and the 
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different hepatitis strains among them), are much more common in developing countries like Russia and 
West Africa.
Figure 1.1 Cancer Incidence worldwide (2008) classified by world regions. First-world regions 
(Australia, US and Europe) have the highest registered rate of cancer per 100’000 population, 
compared to second and third world regions (Africa and South America). As the world’s population 
continues to grow and age, the burden of cancer is predicted to inevitably increase, even if current 
incidence rates will remain the same (due to increasing cancer prevention). Currently, more than half of 
all cancers worldwide are already diagnosed in the developing countries, and without intervention this 
proportion is predicted to rise in the coming decades. It is estimated there will be almost 22.2 million 
new cases diagnosed annually worldwide by 2030. 
From: Cancer Research UK. Sources: kch.illinois.edu and thecancerian.org
The causes of cancer are numerous and can partly explain the diversity in distribution and prevalence 
observed. Cancer arises primarily from somatic DNA lesions, acquired serially, which if left unrepaired 
or misrepaired, lead to alterations of the genetic material and finally to malignancies. Often, a key factor 
in the development of cancer are also germline (inherited) mutations, which often associate with specific 
tumors, like BRCA1 and BRCA2 mutations in breast and ovarian cancer [5]. However, cancer distribution 
varies among geographical and cultural regions, with men living in different countries or adopting 
different habits often lead to the risk of developing cancer. This supports the theory that inherited 
mutations renders people prone to developing some types of cancer, and environmental factors 
promote their development. One of the most known causative agents of cancer is tobacco consumption, 
which causes lung or head and neck cancer. Viral infections from the hepatitis B virus (HBV) and 
hepatitis C virus (HCV) are typically associated with uterine cancers among women. Continuous 
exposure to sun or UV radiation is a primary cause of melanoma, a highly invasive cancer if left 
untreated. 
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The immune system plays a key role in the control and development of neoplasms, as it has become 
evident from immunocompromised patients, which typically displays much higher rates of cancer 
compared to the normal population [6].  Chronic inflammation, for example due to exposure to asbestos 
or other environmental agents, is associated with certain, otherwise rare, types of cancers.
In summary, cancer is a multifactorial and multifaceted disease with both inherited and acquired 
contributing factors. Some are preventable, like social behavior or exposure to environmental agents, 
whereas others, for example genetic predisposition, may be evaded.
1.1.3. Tumor biology: The hallmarks of cancer
Cancer is rarely a single entity, but rather more an ensemble of different diseases. Hanahan and 
Weinberg suggested that the astonishing complexity of cancer can be reduced to six different traits, 
further extended to ten (figure 1.2), which together govern and promote the development of cancer [7-8].
Cancer is a multistep process and the hallmarks are factors that may intervene during this process in 
different order and combinations to promote its growth. Typically, one of the first steps for cells to evolve 
toward malignancy is by acquiring self-sufficiency in proliferation through growth factor receptor up-
regulation or altered autocrine signaling loops. This step is usually accompanied by an increased 
insensitivity towards growth-arrest signals, allowing them to divide independent of the environment. The 
increased activation of proto-oncogenes to oncogenes, which are mostly responsible for the 
proliferation-prone behavior, accompanied to increased DNA damage normally leads to increased cell 
death. Bypassing apoptosis or acquiring the capacity of limitless reproduction, thus rendering the cell 
immortal, are important aspects toward malignant development. Nutrient supply and energetic or 
metabolic control is a key aspect for a cell to be able to growth without any restrain. Cancer cells adapt 
their energetic metabolism by switching from the relatively slow process of oxidative phosphorylation to 
fast glycolysis followed by lactic acid fermentation. Furthermore, these malignant growing tumor mass 
can induce secretion of pro-angiogenic factors, like VEGF leading to neovascularization into the tumor 
site, which in turn allows better nutrient delivery [9]. Neovascularization and the increased nutrient and 
growth factor supply is a key step in promoting detachment from the primary site and invasion of new 
areas. In order to be able to survive and proliferate in new environments, cancer cells need to create a 
niche by promoting vascularization, but also need to acquire the capacity to avoid immune cell 
destruction, a very effective mechanism of tumor control. Identification of these keystone steps in the 
development of malignancies not only allows a better understanding the etiology of the disease, but also 
to improve efficacy of treatment by selectively targeting the tumor cells.
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Figure 1.2 The hallmarks and enabling characteristic of cancer. In order to survive and proliferate, the 
cancer cells needs to be able to acquire certain characteristics, first described by Hanahan and 
Weinberg in 2001. Research in the past years led to the identification and description of new hallmarks 
of cancer in 2011: avoidance of immune destruction and deregulation of cellular energetics. Enabling 
characteristics include tumor promoting inflammation and genome instability. Adapted from [7-8].
1.1.4. Modalities of cancer therapy
Standard cancer treatment mainly consists of three different approaches, which are often combined with 
each other: surgery, chemotherapy and radiotherapy (Figure 1.3). Usually, local, early-stage diagnosed 
cancer can be easily treated with high success, typically by surgery alone. The most important aim for 
curative purposes is to completely eradicate all the tumor cells, in order to avoid recurrence. Therefore, 
surgery is often coupled with either chemotherapy or radiotherapy, and sometimes with both of them. 
Chemotherapy is a treatment modality which has remarkably developed during the last decades, from 
unspecific cytotoxic compounds like mustard gas (Iprit) to highly specific targeted biodrugs, which are 
able to specifically recognize and kill tumor cells. Chemotherapy is based on the use of toxic 
compounds which acts on highly proliferating cells, as is the case for most tumor cells, but also other 
healthy cells, e.g. hair follicles, gut mucosa or nails. Therefore often very strong side effects are 
observed with this systemic treatment modality, which on the other side allows treating not only the 
primary site of the tumor, but also eventual metastatic sites. As for chemotherapy, radiation treatment is 
based on the use of ionizing radiation to damage DNA and induce cell death. But differently from 
chemotherapy, radiation treatment can be designed to cover the whole tumor area, sparing healthy 
tissue, and is therefore often used if a particular tumor cannot be excised due to the same being 
situated close to or within a critical organ (e.g. brain tumors). Usually, the use of radiotherapy allows a 
good tumor control over long period of time. Furthermore, often the combination of chemotherapeutic 
agents with radiation results in a synergistic (supraadditive) effect, increasing the probability of tumor 
control.
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Figure 1.3 Cancer treatment options. Therapy of cancer is based primarily on surgery, chemotherapy 
and radiotherapy, often in combination together to allow better efficacy of treatment (by exploiting 
additive effects). Source: radiationtherapytumor.blogspot.org
1.1.5. Five R’s of radiotherapy
The five R´s determine the final response of the tumor entity and surrounding normal tissue after 
irradiation. By modulating these four main biological response mechanisms to radiation, tumor control 
can be improved while normal-tissue toxicity can be minimized.
Recovery (or Repair) is a very fast process, usually taking place within the first 4-6 hours after the 
radiation dose has been delivered. Typically, radiation fractions are usually given in an interval of 24 
hours. Because normal cells have a better capacity to fix the damages (in form of sublethal and 
potentially lethal damages) compared to tumor cells, the healthy tissue can be mostly spared [10].
Repopulation is the proliferation of cells to fill the gap left by cells died because of radiation treatment. It 
usually takes place in the days or even weeks following treatment. Ionizing radiation causes cells to die 
through well-defined mechanisms of programmed cell death. Healthy, surrounding cells then starts to 
proliferate and repopulate the area left by death cells, in order to keep the tissue intact. Repopulation is 
not elusive of healthy tissue, but it also occurs in the tumor. Rapid, uncontrolled repopulation of the 
cancer cells over normal cells can lead to tumor growth and bad outcomes.
Redistribution of cells within the cell cycle is the rapid, usually happening within few hours, return toward 
an even cell cycle distribution. Cells which happen to be in the radiosensitive, M/G1/early-S phase of the 
cell cycle will die, whereas cells in late-S/G2 phase, which are more radioresistant, will continue to 
proliferate and redistribute throughout the cell cycle. Healthy tissue toxicity is usually the limiting factor 
in radiotherapy, and it is not sensitized by redistribution. Therefore, by using small and frequent doses 
the greatest effect can be obtained. However, prolonged treatment may not be positive because of 
regenerative response in the tumor. Therefore, giving one or eventually two fractions a day typically 
allows cell to redistribute and increase the probability of irradiating cycling cells in the sensitive phases.
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Reoxygenation of the tumor is a major determinant of the effectiveness of radiotherapy. It is the process 
in which hypoxic (radioresistant) tumor cells become more exposed to oxygen by coming into closer
proximity to the vasculature after cellular death and loss of other tumor cells due to previous irradiation 
treatment. Oxygenated cells are more radiosensitive, because oxygen takes part in the radical 
reactions, therefore leading to better damage fixation and more efficient cell killing, a phenomenon 
called the oxygen enhancement ratio (OER) [11]. Typically, Radiation with higher linear energy transfer
(LET) tends to have a lower OER, because it causes mainly direct damages to the DNA, which do not 
require oxygen. After treatment with ionizing radiation, reoxygenation appears to precede rapidly, its 
rate and extent depending upon the treatment scheduling applied. Therefore, long treatment breaks 
(e.g. over week end) are helpful with regard to tumor tissue reoxygenation.
Intrinsic radiosensitivity is the inherent radiosensitivity of cells to ionizing radiation. It is the sum of 
several different genetic and molecular factors (DNA repair ability, cell-cycle checkpoints, cell death 
mechanisms and signal transduction or the hypoxic status) which influence the cellular response to 
ionizing radiation. The cell survival curves are mathematically described and compared by their shape 
using the parameters D0 and N (Figure 1.4). D0 describes the slope of the exponential portion of the 
curve after the initial shoulder, and it is the dose required to reduce the surviving fraction to a value of 
1/e, which equals 0.37. Therefore, D0 is the mean lethal dose for that cell population (extra dose 
required to reduce survival level from 10% to 3.7% or 1% to 0.37%).The initial size of the shoulder of a 
cell survival curve is described by extrapolating the exponential portion upwards to the vertical axis of 
the graph. This point on the graph is called the extrapolation number, N. The D0 value can be seen as a 
measure of the intrinsic radiosensitivity of a cell population.
Figure 1.4 Parameters of cell survival curve in response to single doses of X-rays radiation. After an 
initial shoulder region, the larger the dose on a linear scale, the smaller the surviving fraction on a 
logarithmic scale. Source: quizlet.com.
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1.2. Radiotherapy and cancer management
Treatment of cancer has greatly evolved during the last decades. For several years, surgery has been 
preferred treatment for almost every tumor, and for most cancers it remains as such [12]. Radiation 
treatment has experienced constant development since the discovery of X-rays by Wilhelm Roentgen in 
1895 and it has been used for cancer treatment since [13]. To begin with, X-rays were developed and 
used with diagnostic purposes, but soon their potential in altering healthy tissue was reported, and soon 
they were employed in the treatment of several conditions.
Nowadays, Radiotherapy has consistently remained one of the most effective treatments for cancer, 
with almost half of the cancer patients receiving radiotherapy with curative or palliative intents [14]. One 
of the main advantages in using radiation for cancer is the ability to spare as much healthy tissue as 
possible, which is also possible thank to the fractionation approach: instead of delivering the whole dose 
(usually around 60Gy) in one single shot, which would be deadly for the patient, it is delivered in single 
2Gy-fractions over 5-6 days a week over several weeks. This is carried out for several important 
reasons which led to the development e refinements of the 4 R’s of radiobiology.
1.2.1. Physics and biological aspects of ionizing radiation
Modern, photon-based radiation therapy is usually given by linear accelerators producing X-rays with 
energy of 4-25 MeV, which employs higher energies than for diagnostic purposes [15]. X-rays, as Ȗ–rays, 
are uncharged electromagnetic radiations with a very short wavelength (around 10-12 m) and enough 
energy to penetrate tissues and ionize the molecules they encounter. Ionization is the process by which 
a molecule acquires a negative or positive charge by gaining or losing electrons to form ions [16]. It is 
exactly this ionization process within the cell that results in the biological effects observed with 
radiotherapy. This can be achieved in two different ways, namely a direct effect on the DNA molecule 
and in indirect effect, primarily on the surrounding water molecules (Figure 2.1). 
Figure 2.1 Direct and indirect actions of ionizing radiations on the cell. IR can act by directly damaging 
the DNA (direct action) or by ionizing surrounding water molecules, initiating a cascade of event which 
leads to DNA damage (indirect action). In this respect, oxygen and water molecules surrounding the 
DNA play a key role in the generation of active reactive oxygen species (ROS). Adapted from [20].
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Typically, high energetic photon beams work by indirect ionization. By passing through the cell, they 
interact with electrons of atoms or molecules and give energy to these electrons, which can now leave 
the atom, becoming ionized. This step can be further repeated if the photon possesses enough initial 
energy, and it will stop as soon it is exhausted. Typically, about 1000 of these sparse tracks are 
produced per gray of absorbed dose. The predominant interaction takes place with water molecules, 
which compose the most abundant medium in the cell. Ionized water molecules are very reactive, and 
can annex hydrogen atoms or electrons from other surrounding molecules which, by diffusing within the 
cell can damage almost any component of the cell, including the DNA, proteins and lipids. If oxygen is 
present, even more damage can be created through the creation of reactive oxygen species (ROS) [17-18]
by fixing the oxygen radicals with DNA, which renders the DNA molecule very difficult or even 
impossible to be correctly repaired, therefore inducing cell death by different mechanisms [19].
LET is used to describe the density of the ionizing radiation in particle tracks. It is the average energy 
(expressed in keV) given up by a charged particle traversing a distance of 1μm. typically, LET varies 
among a range between 0.3 keV/μm and 150 keV/μm for heavy ions, and it is strongly dependent on 
the particles type (molecular weight), its charge and the beam energy used (figure 2.2) [21-24].
Figure 2.2 Primary and secondary electron tracks producing clusters of ionization events (Panel A) and 
of clustered damage (Panel B). Due to the electron cascade, ionization events produces by photon 
radiation are usually dispersed within a large volume, therefore show a low LET. On the other side, 
cluster damage is usually generated by energy deposition within a very narrow volume, rendering it very 
difficult to be repaired. Adapted from [21].
1.2.2. Conventional photon radiotherapy
Radiation therapy developed in the course of the last century out of simple X-rays machines. Treatment 
planning was based on a two-dimensional X-ray image and calculated by hand so that often other than 
tumor, healthy tissue could also be irradiated. With the introduction of high-resolution methodologies like 
CT, MRI or PET and the application of computer algorithms to create 3D plans, the field of radiation 
oncology quickly improved to its current status.
Historically, Radiation therapy has been divided in three main fields: External beam radiation therapy 
(EBRT or XRT), brachytherapy and systemic radioisotope therapy. XRT is the main field of application 
of radiation therapy. 
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Conventional external beam radiation therapy is delivered via two-dimensional beams using linear 
accelerator machines from several directions, usually front and back of the patient. To shape the beam 
in order to achieve the best coverage of the tumor, high energy electrons become abruptly stopped by a 
metal target usually made of tungsten or other high Z materials. This process allows the “design” of 
treatments fields similar to boxes, which cannot completely spare healthy tissue (Figure 2.3). The 
conformation of these boxes (fields) is due to depth-dose distribution of X-rays, which deposit most of its 
energy just under the skin and some residual dose to the tissue behind the tumor, with the depth of 
maximum energy deposition depending on beam energy (Figure 2.4). Thanks to 3D planning 
techniques as the beam’s eye view [25], a more accurate dose delivery around the target mass can be 
delivered [26]. 
Figure 2.3 Difference in dose conformality using conventional 3D planned photons, IMRT or protons. 
For the posterior cranial fossa boost (circled area), the proton beam is able to spare both the cochlea 
and dose to the rest of the brain compared with conventional 3D photons, and IMRT, due to better dose 
homogeneity. The arrows depict the cochlea. Adapted from [27].
A further improvement from 3DCRT is the intensity-modulated radiation therapy (IMRT) technique. 
IMRT allows for the radiation dose to conform more precisely to the three-dimensional (3-D) shape of 
the tumor by modulating the intensity of the radiation beam in multiple small volumes using collimators, 
a device that narrows a beam of particles or waves. IMRT also allows higher radiation doses to be 
focused to regions within the tumor while minimizing the dose to surrounding normal critical structures. 
Therefore, despite being very time-consuming in planning, IMRT is growing as the treatment option of 
choice for many tumor sites as CNS tumors. An important issue in radiation therapy regards tumors 
located in or near organs naturally moving due to breathing motions, such as lung or colon tumors. The 
Four-dimensional conformal radiation therapy (4DCRT) measures the motion of tumors, usually by 
sensors applied on the patient’s body, and includes this in the treatment formula configurations. This 
ensures sparing as much healthy tissue as possible for those tumors which are usually very difficult to 
be targeted.
Brachytherapy consists on placing the radiation source directly inside or very next to the patient. It 
allows usage of high dose with minimal side effects, which make it useful for the treatment of cervix and 
prostate cancer [28-29]. A whole course of brachytherapy is completed in a shorter period of time 
compared to XRT, reducing chances of tumor relapse during treatment.
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Systemic radioisotope therapy is based on the use of soluble radioactive substances, given orally or 
intravenously to the patient. These substances have typically very similar properties as their 
physiological, non-radioactive form, and are therefore usually indistinguishable from the body. A typical 
example is the use of iodine-131 isotope for the treatment of thyroid diseases. Iodine is physiologically 
necessary for the thyroid to properly synthesize thyroid hormones; therefore the radioactive form 
concentrates within the organ where it emits beta and gamma radiation directly at the site of interest.
Nowadays, systemic radioisotope therapy profits from the development of tumor-specific antibodies, 
which can target the tumor with high specificity. These antibody-conjugated Radioisotopes, for example 
Tositumomab/iodine-131 (Bexxar®) for Non-Hodgkin’s lymphoma, are the main agents used in 
radioimmunotherapy [30].
Figure 2.4 Dose-depth distributions for X-rays of different energies, electrons, high-energy protons (low-
LET) and carbon ions (high-LET).  X-rays and electrons show the highest dose deposition near the 
entry site, the depth being directly proportional to the energy, to then steadily decrease. In contrast, 
particle radiation deposits its energy at a specific depth (called the Bragg peak), to fall abruptly off after 
the peak with almost no dose deposition. Adapted from: Dreebit Ltd.
1.2.3. Proton Radiotherapy
Proton and in general hadron therapy has experienced a steep development over the last decades, 
from a niche treatment option for selected cancers to a broadly used alternative. Interestingly, even 
though particle therapy currently has a fixed place in radiation oncology and has become the preferred 
treatment for several tumors, much is still unknown, especially regarding the biological and physical 
aspects of proton radiation.
1.2.3.1. History and rationale of proton radiotherapy
The existence of proton was first demonstrated in 1908 by Ernst Rutherford [31-32]. It was Robert Wilson 
in 1940 who suggested using accelerated protons for medical purposes [33]. The idea behind it was that 
the dose versus depth curve is nearly up to about 1 cm flat of the final proton range, then increasing 
steeply to yield a localized, high-dose region, to fall abruptly off so that virtually no dose is delivered at 
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the distal end. This peak at the end of the dose range is called Bragg peak (figure 2.4) [34]. This 
particular pattern of dose delivery allowed the treatment of tumors with very difficult localization, for 
example brain tumors which are rather close to the brain stem or nerves.  
The first cyclotron, the machine used to generate and accelerate the energetic particles like protons, 
was built shortly after the Second World War by E. Lawrence, in order to conduct the first experiments 
on animals [35]. The first center using protons was in Harvard, where in 1949 the 160 MeV Harvard 
Cyclotron was commissioned for physics research purposes. Due to a decrease in research interest, by 
1961 it was increasingly used for medical purposes and the first cancer patients would be treated (figure 
2.5) [36]. Proton therapy commenced in Europe around 1957 in Sweden, where small groups of patients 
were treated employing single doses or small fractions. Tumor control rates with proton radiation are 
reported to be around 95% for chondrosarcomas and for uveal melanomas, two types of cancer which 
are typically very harsh to treat with conventional photon therapy [37]. 
Figure 2.5 The first Harvard high-energy cyclotrone (1961) used primarily for physics experiments, 
followed by medical experiments due to reduced interest in high-energy physics. Adapted from: The 
story of the Harvard University cyclotrons. Source: physics.harvard.edu
1.2.3.2. Physics and biological aspects of hadron therapy
Protons are sub-atomical particles that, with neutrons and electrons, are the principal constituents of an 
atom. Theoretical analyses reports that protons have a finite half-life of about 1032 years, decading in a 
neutron, positron and a neutrino. Protons have per definition a unit mass and a unit charge, and are 
1836 times heavier than electrons. Because of their mass and positive charge they attract electrons, 
resulting in the ionization of atoms upon interaction and following formation of loose secondary 
electrons. Protons lose little energy during each ionization process and are, because of their mass, only 
minimally deflected from nuclei, mostly due to Columbus interactions with the positively charged nuclei. 
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The proton can strike a nucleus along its path, thus losing a big fraction of its energy and being 
deflected. During this process, secondary neutrons are produced, which may contribute to the increased 
LET of proton radiation. The rate of energy deposition is inversely proportional to the proton’s mean 
velocity squared, which is in turn directly proportional to its initial energy. High- energy protons are thus 
traveling very fast and can penetrate tissue deeply, but have a reduced dose deposition because do not 
experience strong interaction with matter. Upon reaching a certain velocity, a proton experience 
stronger interactions until it slows down depositing its energy due to the maximal interactions with the 
surrounding electrons, creating the Bragg peak [38]. A single, mono-energetic Bragg peak is not enough 
to cover the size of a tumor, as a single photon beam is not. Therefore, several mono-energetic beams 
of different energies are overlaid to result in a beam able to cover all the desired volume, with the most 
energetic beams covering the distal part and the less energetic beams the proximal portion. The 
resulting ensemble of beams is called the spread-out Bragg peak (SOBP). Normally, the most distal 
portion of the SOBP contains Bragg peak high-LET particles, whereas the proximal portion of the beam 
consists mainly of higher-energy, lower-LET particles. This may cause a variation in the RBE along the 
beam track. The broader the SOBP, the bigger is the entrance dose at the plateau region due to 
overlapping of the single mono-energetic beams, which can be a major issue with protons, as skin can 
get injured severely. To prevent this side effect, typically several beams are used from multiple sides to 
cover the tumor volume by minimizing the damage to the health tissue [39]. The number of ionized 
biomolecules produced per unit dose of charged particles or photons is very similar, but the resulting 
biological effect is very different among the radiation type and the particle energy. When comparing 
particle radiation with conventional photon radiation, the fraction of cells surviving a particular dose of x-
radiation is larger than the fraction of cells surviving a particle radiation fraction. This ratio of the dose of 
standard 250 keV X-rays to produce a specific effect and the dose a specific radiation is called relative 
biological effectiveness (RBE). Typically, cell survival is selected as an end-point (typically 10% or 1%), 
but it may also be mutation rate or tissue damage.  Virtually all types of radiations show an RBE>1, 
meaning the type of radiation is biologically more effective because a lower dose is needed to result in 
the same biological effect. The LET for mono-energetic beams increases to a maximum as the velocity 
of the particles slow near the end of their range (plateau), the region of maximum energy deposition, the 
Bragg peak. Usually, a relation is observed between the change in LET and the RBE. In the case of low 
LET radiation (< 10 keV/ȝm) secondary electrons produced by collisions are the biggest contributor to 
the RBE, whereas as LET increases (> 10 keV/ȝm) their contribution become only minor to the total 
yield of complex lesions, whereas the direct effect (direct DNA damage) plays a key role for high-LET 
particles (> 40 keV/ȝm) [40]. In order to effectively kill the cell, damage to the DNA molecules is the 
primary causative lesion. Because these types of lesions are generated by direct energy deposition to 
the DNA molecules, densely ionizing tracks (high LET) can induce damages which are more difficult to 
be repaired, leading to a higher RBE. Indirect damage by ionization of the surrounding water molecules 
can also cause DNA damage by the generated electron splash, but less efficiently than densely ionizing 
radiation. Therefore, low-LET radiation has typically a lower RBE.
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Table 1 Approximate number of events (DNA damages) in a single mammalian cell after 1Gy low- and 
high-LET ionizing radiation. Both radiations produce approximately 100’000 ionization in the nucleus 
and 1’500 ionization in DNA, resulting from about 1’000 diffuse low-LET tracts and two tracts of densely 
LRQL]LQJ Į-particles. SSB: single-strand breaks; DSB: double-strand breaks; PCC: premature 
chromosome condensation. Adapted from [41].
Table 1 shows the events after low- and high-LET ionizing radiation.  Both radiation types produce the 
same amount of nuclear and DNA ionizations, but they results from a very different number of tracks 
(due to the track pattern of sparsely versus densely ionizing radiation). Even though the initial number of 
DSBs is very similar, the residual (after 8 hours) notably differs, meaning a differential type of damage is 
induced, with significant effects on cell survival. It is important to note that even if the particle radiation 
yield is the same, the distribution varies greatly [42]. This is resulting from a differential energy distribution 
between low and high-LET radiation, with almost all energy deposited in a very narrow volume for high-
LET radiation, leading to a more severe damage and an increase in RBE.
1.2.3.3. Technical aspects of proton therapy and the Gantry 1 at PSI
Protons are positively charged nuclei of hydrogen atoms, which are composed of a positively charged 
proton and a negatively charged electron, resulting in a neutral atom. The primary source of protons is 
hydrogen gas. Typically the most frequently used accelerators contain an external ion source
(Electron Cyclotron Resonance (ECR) ion source from IBA), which is a so-called hot-plasma ion source 
to extract the particles. At the Paul Scherrer Institute, protons are extracted using an internal “cold 
cathode” ion source (Varian/Accel). In general electrons are accelerated and ionize the plasma. Special 
extraction geometry of the source helps to extract the positively charged protons, which otherwise would 
tend to rejoin the negatively charged electrons to keep the plasma neutral. After extraction protons need
to be accelerated to clinically relevant desired energies of 70 - 250 MeV for high-energy protons. There 
are two different types of circular accelerators (LINAC), the devices that control an electric field in such 
a way as to efficiently accelerate the charged particle, namely cyclotrons and synchrotrons (Figure 2.6).
In a cyclotron, which is a vertically divided pillbox, an electric field is applied across the gap between the 
two dees (for the resemblance with the alphabet letter), or halves, and a magnetic dipole field cover 
both dees. Protons are injected perpendicular to the magnetic field and travel along the semicircular 
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path getting accelerated by crossing the electric field. When the beam leaves the electric field, it enters 
the magnetic field regions and it gets bent by 180 degrees, reentering the electric field to be accelerated 
in the opposite direction. Polarity of the electric field is switched at the exact time when the beam 
reaches the gap to ensure acceleration of the beam. Protons have now gained energy and therefore 
speed, and since the magnetic field is constant, the radius of the trajectory increases with the energy, 
assuming the form of a spiral. The particle is then extracted at the desired energy from the edge of the 
cyclotron.
Synchrotrons is a narrow vacuum tube ring (or some closed shape) contained with magnets. The beam 
is injected from outside the synchrotron by typically a LINAC with energy of 3 to 7 MeV. The beam 
circulates within the ring repeatedly through the accelerating structure (ring). In order to keep the beam 
within the closed ring, the magnetic field of the magnet must increase in strength in synchrony with the 
beam energy. Thus, the beam is contained within the ring as the magnetic field increases, in contrast to 
the cyclotron, where the magnetic field remains constant. After reaching the desired energy, the beam is 
extracted and delivered.
       A         B
Figure 2.6 Beam line and electric and magnetic fields in a cyclotron (A) and a synchrotron (B). In a 
cyclotron, the particles are held to a spiral trajectory by a static magnetic field and accelerated by a 
rapidly varying electric field (space-dependent). In a synchrotron, the direct descendent of the cyclotron, 
the guiding magnetic field (bending the particles into a closed path) is time-dependent, being 
synchronized to a particle beam of increasing kinetic energy.
Once the accelerated beam has been extracted, it must be directed to the patient in the appropriated 
direction. The most commonly used mechanism is a fully rotating gantry, which allows the beam to be 
directed to the patient in every desired angle. A typical Gantry for proton is very large, covering up to a
diameter of about 10 meters (Figure 2.7). The beam is spread out to cover the field cross section and 
extend in depth of the planning target volume (PTV) in a section of the beam called the nozzle (beam 
delivery system, analogous to the treatment head in photon LINACs). This can be achieved in two ways,
namely passive beam scattering and pencil beam scanning. The passive beam scattering uses 
arrangements of scatters, usually lead foils, and degraders to spread out the beam. For larger fields the 
energy loss and reduction in beam quality is usually huge and therefore a double-scattering technique is 
applied.
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Figure 2.7 Gantry 1 at Paul Scherrer Institute, characterized by a compact rotational gantry combined 
with an off-axis couch. The spot scanning beam moves along the longitudinal axis only, the other 
dimensions being achieved by couch movement. Source: Protonzentrum.psi.ch
To ensure greater dose delivery in depth, a range modulator is used to spread out the SOBP. Because 
of all these material arrangements, passive scattering has some technical limitations, for example using 
lead foils as scatters cause energy loss up to 10% [43]. Therefore, passive scattering technique can only 
achieve certain combinations of radius, depth and modulation for a given beam energy. The pencil 
beam scanning technique is based on the characteristic that protons are positively charged and 
therefore enables magnetic scanning of narrow pencil beams. The pencil beam scanning delivers the 
dose inside the patient trough the sequential superimposition of many elementary physical pencil beams
(size ı of small size (varying among tumor type, usually PP ıௗௗPP), allowing very fine dose 
distribution, almost close to the physical limits [44]. Beam scanning delivers a true three-dimensional 
dose distribution, which is of advantage for very complex targets. Furthermore, with the scanning 
technique the need for field-specific devices is strongly reduced or even absent, therefore reducing the 
chance of secondary neutron productions, which is of great advantage for pediatric patients [45]. Proton 
beam scanning inherently promotes the delivery of IMPT fields (Figure 2.3). In IMPT, or intensity-
modulated proton therapy, a number of individually inhomogeneous (in-dose) fields are calculated in 
such a way that, when combined, these fields deliver a homogenous and conformal dose to the target 
volume while simultaneously reducing the dose to selected normal tissues [46]. A critical issue in
radiation therapy is the management of intrafraction organ motion. If one spot is delivered to the wrong 
position it can have quite a huge impact, especially for tumors seated near sensible organs [47]. This 
problem is solved by rescanning the volume a second time, with each scan delivering half of the dose. 
Thus, by using IMPT it would be possible to track organ motion, a major issue in dosimetry. At PSI, the 
scanning method was implemented on a proton gantry to meet available space constrains [48]. The first 
veterinary patients were treated in 1994 and in 1996 the first human patient could be treated [49]. IMPT 
has been implemented since 2000 and it is now the standard technique at PSI.
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1.2.4. Combined treatment modalities
Both chemo- and radiotherapy target fast proliferating cell populations, which is the main difference 
between normal tissue and cancer cells. In contrast, molecular targeted therapy is based on highly 
specific drugs, which are able to discriminate between cancer and normal cells based on molecular 
characteristic (e.g. surface receptors) and not on growth kinetics.
The main quantitative difference between chemotherapy and radiotherapy is that radiation treatment is 
designed to cover the whole tumor homogeneously, whereas with pharmacological treatment the dose 
of active drug form is variable within the tumor cells and it depends on several physiological factors. 
These issues are even more relevant in the typical multi-drug regimens adopted in cancer therapy.
In most clinical situations, chemotherapy augments the radiation-induced cell kill within the irradiated 
volume, but often treatment optimization (e.g. schedule of drug and radiation delivery) is necessary. For 
example, it has been shown that continuous infusion of 5-Fluorouracile (5-FU) is better than bolus 
administration in radiation enhancement [50]. An important issue regards cancer stem cells (CSC), which 
are slow-cycling cells and often express multi-drug resistance proteins (MDR) [51]. Often, chemotherapy 
alone fails to kill them, thus giving origin to tumor relapses. New, highly selective chemotherapy drugs 
or combination approaches are therefore needed to eradicate CSC and cure the patient.
Interaction between chemo- and radiotherapy takes place on several levels (figure 2.8) [52]. 
Spatial cooperation describes the use of chemotherapy and radiotherapy to target diseases in different 
anatomical sites, resulting in a net gain in tumor control. Independent cell killing implies that if two 
effective therapeutic modalities can both be given at full doses then, even in absence of direct 
interactive processes, the tumor response (in term of total cell kill) should be greater than that achieved 
with either agent alone. Repopulation plays also a key role, particularly in fractionated regimens. Cell 
loss due to chemotherapy may trigger accelerated cell repopulation, so that a certain radiation dose is 
wasted in counteracting this effect. Therefore, in such a setting the effect of combined treatment is not 
superior compared to radiation alone, but with toxicity resulting from both. Therefore, an accurate and 
rationale treatment planning is fundamental to ensure proper tumor control.
Enhanced DNA damage and repair is an important molecular aspect of the efficacy of the combination 
of radiation and chemotherapy. Several chemotherapeutic agents have been shown to inhibit the DNA 
repair of radiation damage, thus enhancing the effect of radiation. Several substances used are directly 
inhibiting cell division and thus proliferation, they become potentially lethal in some cell cycle phase. As 
a consequence of this cell-cycle synchronization, delivering radiation during the most sensible cell 
phases (e.g. S- and M-phase) increases the efficacy of radiation therapy. Re-oxygenation is usually 
associated with poor response to radiotherapy, because functionally insufficient tumor vascular network 
does not permit adequate oxygen diffusion throughout the tumor mass. Therefore, chemotherapy, by 
inducing some degree of tumor shrinkage, might facilitate a more even diffusion of oxygen and increase 
overall tumor oxygenation, which in turn would increase tumor radiosensitivity. 
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Figure 2.8 Schematic representation of the interplay between spatial cooperation, cytotoxic 
enhancement, biological cooperation, temporal modulation and normal tissue protection. 
RT, radiotherapy; SF, surviving fraction; X, drug. Adapted from [52].
1.3. Molecular biology of ionizing radiation
1.3.1. Molecular aspects of photon versus particle radiation
The principal damaging effect of ionizing radiation arises from its ability to ionize, or eject electrons from 
molecules within cells. Most of the biological damage, however, is done by the ejected electrons 
themselves, which go on to cause further ionizations in molecules they collide with, progressively 
slowing down [53]. At the end of electron tracks, interactions with other molecules become more frequent, 
giving rise to cluster of ionizations. Normally, clusters are such that several ionizations can occur within 
a few base pairs of the DNA [54]. After photon irradiation, typically only few percent of the damage is 
clustered. The cell has particular difficulty to cope with complex damage, particularly when the DNA, 
which is present in only two copies, is severely damaged [55]. Even if the number of ionized biomolecules 
produced by both photon and particle radiation is very similar, the resulting, biological effect is 
substantially different. 
High-LET particle radiation is characterized by deposition of large quantities of energy within a very 
limited space, usually few nanometers. This clustering of energy deposition results in multiple DSBs 
along with single-strand breaks, DNA crosslinks and other types of damage [56-58]. Therefore, the major 
difference between low- and high-LET radiation and high-energy protons versus protons near their 
densely ionizing track ends is the deposition of energy in localized regions of the DNA, nucleosome, or 
chromatin fiber. Although the average macroscopic number of events does not differ, the clustering of 
strand breaks and associated damage is believed to render the lesions less amenable to competent 
repair. Analysis of relative biological effectiveness showed little variation in vivo but rather a huge 
variation in vitro (figure 3.1) [59]. One of the reasons behind these differences may be due to the different 
particle energies used, where typically low energy protons (<30 MeV, LET=20 keV/μm) show greater 
RBE variations, probably due to increased apoptosis or radical formations, compared to high-energy 
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protons [60]. The genetic background of the cells may also play a key role in the determining the radiation 
sensitivity, and thus the RBE of the cells.
Several reports published in the past years suggest that there are differences in the radiation response 
between low-LET proton and photon irradiation [61-64]. Analysis of the response of mutant cell lines 
deficient in various component of the DNA repair machinery, compared to their repair-proficient cells
showed that DSBs produced by low-LET radiation are more amenable to repair than DSBs produced by 
high-LET radiation [65]. Furthermore, despite the clear evidence for DNA being the crucial site for 
radiation insult leading to radiation-induced cell killing, some cells have been shown to activate different 
pathway of cell death in response to high-LET radiation [66]. These studies point out a differential 
molecular response of cells after proton irradiation compared to the conventional, low-LET photon 
radiation. For normal treatment planning a RBE value of 1.1 is generally used, but the response of 
single tumors may be different based on its genetic background, giving very variable clinical responses.
Other unknown parameters could influence the RBE, increasing clinical uncertainty. Furthermore, 
combining chemotherapeutic agents with proton therapy may give completely unexpected results.
1.3.2. DNA damage
As discussed above, the primary critical site for radiation-induced cellular effects is the DNA. Depending 
on LET, ionizing radiation can induce different types of events (Figure 2.6). Certain types of damage are 
structurally more complex, their resolution by the cellular repair machinery may thus be impaired leading 
to the differential biological effectiveness (cluster lesions).
Figure 3.1 Experimental proton RBE values (relative to 60Co) over dose/fraction for (A) cell inactivation 
in vitro and (B) measured in vivo in the center of a SOBP. Circles represent RBEs for beam energies 
less than 100 MeV, triangles for beam energies of more than 100 MeV. Adapted from [56].
1.3.2.1. Single strand breaks
Single-strand breaks (SSBs) are discontinuities in one strand of the DNA double helix and are usually 
accompanied by loss of a single nucleotide and by damaged 5'- and/or 3'-termini at the site of the break 
[67]. SSBs are the most common damage generated after metabolic stress, UV-light or ionizing 
radiation. One of the most common sources of SSBs is oxidative damage by both endogenous and 
exogenous (IR-induced) reactive oxygen species (ROS).
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DNA single strand breaks and base damages are up to 3-5 times more frequent than DSBs, and after 
radiation exposure can be up to 50 times more frequent than DSBs. DSBs are typically the most severe 
damage when not repaired because they can causes loss of complete chromosomal regions [68, 71].SSBs 
can occur directly by disintegration of the oxidized DNA sugar but also indirectly during the DNA base-
excision repair (BER) of oxidized bases or abasic sites, priorly damaged [69-70]. Furthermore, SSBs can 
arise as the result of erroneous activity of cellular enzymatic activity such DNA polymerases. 
The most likely consequence of unrepaired SSBs in proliferating cells is the blockage or collapse of 
DNA replication forks during the S phase of the cell cycle, possibly leading to the formation of DSBs, 
which are then repaired by the Homologous Recombination (HRR) pathway [72]. Typically, SSBs are 
repaired by the single strand break repair pathway (SSBR). End-processing is achieved by specific AP 
endonucleases, and polynucleotide kinase-phosphatase (PNKP), or tyrosyl-DNA phosphodiesterase 
(Tdp1) [73]. To ensure proper resynthesis and end ligation a 3’-hydroxyl end and a phosphate-5’-end is 
needed and are prepared by the AP endonuclease. Then poly-ADP-ribosylation by poly-(ADP-ribose) 
polymerase 1 (PARP1) is thought to promote the sequestration of other DNA repair proteins, like 
XRCC1 and ligase III. If the concentration of SSBs is elevated, prolonged activation of PARP1 leads to 
depletion of cellular NAD+ and ATP and/or release of apoptosis-inducing factor (AIF) from mitochondria, 
causing cell death.
1.3.2.2. Double strand breaks
DNA double strand breaks (DSBs) are generated by different means, typically during replication in case
the replication fork meets a DNA SSB, during the process of V(D)J recombination or through direct 
effects of ionizing radiation. These types of break are very toxic for the cell, and a single, unrepaired 
DSB can lead to cell death. Usually, after exposure to 1 Gy of IR about 20 DSBs are generated, and 
can be located in both the heterochromatic or euchromatic regions of the genome. DSBs provoke an 
extensive reaction in neighboring chromatin, characterized by phosphorylation of histone H2AX on 
serine 139 of its C-terminal tail (to form “JH2AX”) [74] and chromatin relaxation to allow proper repair. 
Two main pathways are involved in repairing DSBs, homologous recombination (HRR) and non-
homologous end joining (NHEJ) [75-76].Both pathways are completely different from each other in respect 
of the set of proteins/enzymes they use, the speed and the accuracy, and activity pattern during the cell 
cycle. Both pathways will be discussed in detail (see below).
1.3.2.3. Oxidative base damages
Oxidative base damages (OBD) are a common form of cellular damage, which can be induced 
endogenously through normal metabolic processes, or exogenously by ionizing radiation. There are 
several types of oxidative base damages, the most common and dangerous type of OBD is 7,8-dihydro-
8-oxo-guanine (8-OHgua) as a major IR-product with a clear mutagenic potential [77]. Every subtype of 
OBD is detected and removed by specialized proteins called glycosylases. Several of these enzymes 
are present within the cell, every one specific for a particular subclass of oxidative base damage.
Glycosylases work by hydrolyzation of the N-glycosidic bond to generate abasic sites (Aps). The DNA 
backbone is then cut by the 5’-AP endonuclease 1 (APE1), a specialized enzyme which then leaves a 
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3’-hydroxyl adjacent to a 5’ deoxyribosephosphate, which in turn generates a SSB. These are repaired 
by the SSBR or the BER pathways.
1.3.3. The DNA damage response
Cells suffer from continuous stress from both endogenous (e.g. metabolic stress or replication) and 
exogenous (e.g. naturally occurring UV-radiation or ionizing radiation) origin. Therefore, the cell has 
evolved mechanisms to sense the damage (sensors), to transduce this signal in order to coordinate the 
cellular response (transducers), to promote their repair (effectors). The ensemble of these processes is 
called the DNA damage response (DDR) [78-79]. The DDR is not a single pathway, but a group of highly 
interrelated pathways, each controlling different effects on the cell and its activation depending upon the 
type of insult induced (Figure 3.2).
There is compelling evidence that the DDR reacts differently to low- and high-LET radiation. Because of 
the differential nature and composition of the damage (both DSBs and OCDLs) induced by the two 
types of radiation [80], both HRR and NHEJ have been shown to be differentially involved in the 
recognition, transduction and repair of the DNA damage [81-83].
Figure 3.2 The DNA damage response (DDR). Depending on the type of damage induced (SSBs, 
DSBs, base alterations or mismatches) different proteins are required to sense and repair the damage.
DDR components are typically subdivided in sensor, transducer and effector proteins. Deficiency in one 
or more of the DDR components leads to tumor development and other syndromes. Adapted from [84].
1.3.4. Sensing of the DNA damage
The initial cellular response to DSBs is characterized by the recruitment of a large number of different 
proteins to the site of DNA damage. It is well established that the following three PI3-like kinases: ataxia 
telangiectasia mutated (ATM), ATM and Rad3-related (ATR), and catalytic subunit of DNA-dependent 
protein kinase (DNA-PKcs) are the conductors of the DSB damage/checkpoint orchestra. ATM is the 
main protein activated upon DNA damage, and cells with impaired ATM functions are typically unable to 
promote DDR through (ATM-dependent) JH2AX foci formation [85].
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These three kinases are not able to recognize the DSB by themselves, but require at least one 
additional protein or protein complex. Recruitment of ATM to the break requires the Mre11-Rad50-Nbs1 
protein complex (MRN). Rad50 binds directly to DNA breaks and the adaptor protein NBS1 recruits 
ATM to the break. Mre11 is an endonuclease responsible for the production of short single-strand 
oligonucleotides, a process called end resection, which further allows DNA processing and ligation [86].
Notably, MRN assembles at DSB sites faster than any other protein and does not depend on any other 
protein to induce repair foci formation [87]. Upon reaching the DSB, ATM undergoes autophosphorylation 
at Ser-1981 and changes from an inactive dimer to an active monomer leading to H2AX 
phosphorylation of relatively large chromatin regions and to alterations in the chromatin structure [88].
DNA Protein Kinase catalytic subunit (DNA-PKcs) is a kinase structurally similar to ATM and which 
plays a key role in NHEJ repair. In absence of ATM, DNA-PKcs can also phosphorylate H2AX, but only 
ATM promotes JH2AX formation to maximal distance and maintains JH2AX densities at DSBs [89]. As for 
the ATM kinase, DNA-PKcs is unable to sense the DNA damage by itself. The sensor function is carried 
out by the Ku70-Ku80 complex which senses DSBs, binds directly to them, and recruits DNA-PKcs 
(forming the DNA-PK complex, also called the synaptic complex). The third kinase capable of 
phosphorylating H2AX is ATR together with ATRIP (ATR interacting protein), which recruits ATR to 
damage sites. ATR does not seem to play a substantial role in DBS recognition, but instead is involved 
in phosphorylation of JH2AX at single-stranded DNA and at stalled or broken replication forks. Because 
DSBs processing can create stretches of single-stranded DNA, ATR will be activated [90]. This activation 
down-stream of ATM is needed to fully activate all components of the DDR effector pathways as ATM 
and ATR phosphorylate not only H2AX but a distinct set of proteins that translate the signal to the DDR 
effectors.
Activation of ATM, ATR and DNA-PKcs leads to the phosphorylation not only of JH2AX, but also of 
many other cellular proteins. Recent studies have shown that as many as 700 proteins are direct or 
indirect substrates for the three kinases in response to DNA damage [91]. Phosphorylation of these other 
proteins act as the ‘signals’ to activate the various different downstream effectors of the DDR, namely 
apoptosis induction, cell cycle arrest through checkpoint activation and DNA repair.
ATM protein plays most probably the most important role in transmitting these signals in response to IR-
induced DSBs and is thus considered to be a master regulator of the DDR, with ATR and DNA-PK
playing more a “support” role [92].
1.3.5. Cell cycle regulation
A major effector pathway of the DDR is the activation of cell-cycle checkpoints. Treatment of cells with 
ionizing radiation causes delays in the movement of cells through the G1, S and G2 phases of the cell 
cycle [93]. This provides more time to the cell-cycle arrested cells to repair the DNA damage.
Checkpoints are specific points in the cell cycle at which progression of the cell into the next phase can 
be blocked. 4 major checkpoints are activated by DDR in response to irradiation that takes place at 
different points within the cell cycle, namely G1, S, early-G2 and late-G2 checkpoints. 
All movements through the cell cycle are driven by cyclin-dependent kinases (CDKs). CDK activity is 
affected by the binding of its specific cyclins, which are differentially expressed during the cell cycle, by 
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its phosphorylation status, and through special CDK inhibitors (CDKIs). CDK inhibition triggers 
checkpoint activation, and therefore cell cycle arrest. 
Transition from G1 to S phase is primarily controlled by activation of the E2F transcription factor, which 
is kept inactive during G1 by the Retinoblastoma protein (Rb), a tumor suppressor gene. As cells 
progress through the cell cycle, Rb gets phosphorylated by cyclin-CDKs, causing its release from E2F, 
allowing E2F to function as a transcription factor and initiate to S-phase.
The G1-checkpoint lies at the transition between G1 and S-phases that play an important normal role in 
the decision of the cell to initiate cell division. Irradiation leads to an ATM-dependent stabilization and 
activation of p53. One of its target genes which get upregulated is CDKI p21 (CDK1A). p21 in turn 
inhibits the G1 cyclin-CDK complexes thereby preventing Rb phosphorylation and entry into the S-
phase. As a result, cells irradiated while in the G1-phase will delay their progression into S-phase [94].
The intra S-phase checkpoint, together with G2-checkpoint is controlled by highly related proteins, the 
checkpoint kinases 1 and 2 (Chk1 and Chk2) [95]. Both are phosphorylated and activated by ATM and
ATR kinase in response to ionizing radiation. Normally, cells which were irradiated react with a fast but 
reversible decrease in DNA synthesis by reducing the rate of origin firing and strand elongation, thus 
increasing time needed for replicate their DNA. The molecular target is the CDK2 kinase, which is 
dephosphorylated by Cdc25A and Cdc25C, upon activation of Chk1 and Chk2 by ATM and ATR they 
phosphorylate Cdc25A/C leading to their inactivation. As a result, CDK2 levels increase and the 
progression through S-phase slows down. Although ATM-Chk2 and ATR-Chk1 activation is the main 
mechanism for initiation of the S-phase checkpoint, several other proteins of DDR are involved. Among 
them, BRCA1 and BRCA2 proteins, two key players of the HRR pathway of DNA repair.
Two additional checkpoints are present in the G2 phase, the early and the late G2 checkpoint. The early-
G2 checkpoint is again dependent on the ATM-Chk2-Cdc25A/C axis, and applies to all cells irradiated 
while in the G2-phase. Target of the ATM-Chk2-Cdc25A/C complex is cyclinB-CDK1 complex [90], which 
must be phosphorylated to be active. Thus, all cells irradiated while in their G2-phase are arrested and 
their entry into the M-phase (mitosis) is prevented [96]. The late-G2 checkpoint is observed after 
irradiation of cells which are in the G1 or S-phase at the time of irradiation. After a transient cell arrest
with attempts of DNA damage repair, cells progress to the G2-phase where they reach hours later and 
could experience a second, usually very long delay, lasting several hours depending on the dose 
applied. Furthermore, this checkpoint is independent of ATM. Instead, the principal signaling axis occurs 
from ATR/ATRIP. ATR kinase activates Chk1, which in turn leads to the degradation of 
Cdc25A/Cdc25C. The late G2 checkpoint is mechanistically very similar to the G1 and S-phase 
checkpoints, but instead of being directly activated by DSBs, it reflects a type of damage that has been 
induced throughout the cell cycle but still persists after the other DNA repair processes have occurred 
but failed to properly activate ATR.
1.3.6. DNA damage repair mechanisms
As discussed above, DSBs are the most relevant type of damage a cell has to repair in order to survive. 
Already a single, unrepaired or misrepaired DSB is enough to cause cell death. Typically, 1Gy of 
ionizing radiation can generate around 20 DSBs. Therefore, the cells need to have highly specialized 
protein machineries to tackle these damages. Specialized proteins can sense DSBs, thereby initiating 
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the DDR, which focuses the cell on repairing these damages by primarily stopping cell proliferation 
(through activation of the checkpoints), properly marking the damage (trough JH2AX accumulation) and 
initiating repair. For DSBs, mammalian cells have two major pathways, HRR and NHEJ. These 
pathways are quite different with regards to a) proteins involved, b) their kinetics, c) phase of the cell 
cycle in which they get activated and d) the accuracy of repair. New evidences suggest that the HRR 
and NHEJ pathways are strongly interconnected to each other through shared gene (e.g. ATM, 53BP1, 
BRCA1 and XRRC4) and they are can mutually regulate after radiation-induced DNA damage.
Furthermore, alternative (back-up) pathways have been reported to kick in if HRR and/or NHEJ are not 
properly functional. However, they are error-prone repair mechanism and their exact mechanism of 
action has not been clearly elucidated yet [97].
1.3.6.1. Homologous recombination repair
HRR uses homologous undamaged DNA (sister chromatid produced while progressing through the S-
phase) as the template to repair the damaged DNA [98]. Because HRR uses DNA with the same 
sequence as the basis for repair, the whole process is usually slow but error-free (Figure 3.3).
The first step is activation of ATM kinase and recruitment of the MRN complex to the damage site, 
therefore initiating HRR. Single-strand regions are then generated around each side of DNA by 
nucleolytic degradation [100], followed by their coating with specialized proteins like SMC5/6, which have 
the primary function of keeping chromatids together [101]. The two proteins involved in the initiation 
process are Mre11 and CtIP. After initiation by Mre11 and/or CtIP, the processive single-strand 
exonuclease Exo1 carries out extensive 5’-3’ resection [102]. When the single stranded DNA is formed, it 
is immediately stabilized and protected by binding of the single strand binding protein replication protein 
A (RPA), a heterotrimeric protein with very high affinity for single-stranded DNA [103]. The RPA protein 
complex is then displaced by RAD51, a central protein in HRR, resulting in the formation of a 
nucleoprotein filament of DNA coated with RAD51. Because RPA has a greater affinity than RAD51 for 
single-stranded DNA, protein mediators are needed for this step, including BRCA2, which directly 
interact with RAD51 promoting its binding to DNA [104]. At this point, the nucleoprotein filaments 
undergoes the search for homologous DNA in the form of the sister chromatid. Several proteins, called 
RAD51 paralogues, help with these processes including RAD51B, RAD51C, RAD51D, XRCC2 and 
XRCC3. From this stage, there are two possible types to complete repair. In synthesis-dependent 
strand annealing (SDSA) the genetic information is copied from the intact strand and afterwards the 
newly synthesized strand reverts to its original position. Alternatively, two sister chromatids exchange 
strands and built a so-called Holliday junction. Helicases, including BLM and other members RecQ 
family with the help of RAD54, an ATP-dependent chromatin remodeler, enlarge the subsequent 
‘bubble’ structure and help untangle the DNA to allow branch migration (called DSBR pathway) [105]. 
Correct pairing of the two strands occurs with the help of RAD52. 
The following DNA synthesis is carried out by DNA polymerases, the identity of which is still uncertain 
but several studies have identified polymerases į, İ and Ș to promote repair synthesis [106].
Finally, the open gaps are sealed by Ligase I. To properly function, HRR requires several highly specific 
proteins and many specific steps have to be completed in an ordered fashion. Homology directed repair 
can take up to 6-8 hours but it is very accurate. 
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Figure 3.3 HRR is a slow but accurate process. Damage recognition by the Mre11-RAD50-NBS1 (MRN) 
complex initiate CtIP-dependent DNA end resection. The single-strand DNA is first bound by RPA, thus 
preventing the ssDNA from forming secondary structures. Later, the nucleoprotein binds to RAD51 and 
its accessories factors and search for homologous sequence in sister chromatids to form Holliday 
Junctions. Finally, resolution of the heteroduplex by several helicases takes place. Adapted from [99].
The single strand annealing (SSA) pathway repairs DSBs between two repeat sequences (patterns of 
nucleic acids that occur in multiple copies throughout the genome) [107]. Opposite to the SDSA or DSBR 
pathways, SSA does not require a separate similar or identical molecule of DNA. In this pathway, the 
two 3’-overhangs are aligned and annealed within the region of the repeated sequences. Overhanging 
single-stranded DNA will be digested, and gaps will be filled and sealed. Furthermore, this process does 
not require RAD51 but involves other HRR proteins like RPA, RAD52 and RAD50. Therefore, SSA may 
play a key role in cells with corrupted RAD51 function [108].
1.3.7.1.1 The nuclease Mre11
Mre11 is a component of the MRN protein complex (Mre11-Rad50-Nbs1) [109]. A stable MRN complex is 
critical to guarantee chromosome stability because of its repairing role in both broken replication forks 
and two-ended DSBs [110]. The MRE11 plays a fundamental role in DSB repair complex, by acting as a 
sensor of DSBs together with RAD50 and NBS1, and governs the activation and activity of the central 
transducing kinases Ataxia telangiectasia mutated (ATM) and ATM and RAD3 related (ATR). Upon 
irradiation, a strong hyperphosphorylation of Mre11 is induced [111].
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The MRN complex functions as DNA end-binding dimer, being able to bind two separate molecules 
through long-range tethering. The Mre11, which possesses both single-strand DNA endonuclease and 
3’-5’ exonuclease activities [112], can bind one or two-ended DSBs together with Rad50, which induces 
an ATP-mediated conformation change upon binding, so that the Mre11-Rad50 complex acts like a 
transient molecular clamp around the damage site [113] to promote DNA end resection. New evidences 
suggest that the Mre11-dimer (Mre112) is able to bind DNA fragments independent of their size and
structure [83,114]. Therefore, the HRR pathway can be activated in response to both low- and high-LET 
radiations, with Mre11 playing a key role in the activation step.
1.3.7.1.2 The DNA repair protein RAD51
The mammalian protein Rad51 is a recombinase which plays a pivotal role in the process of gene 
conversion and its regulation [115]. Maintenance of proper chromosomal stability relies on the high fidelity 
of the HRR repair, which allows DSB repair with virtually no mistakes. Typically, cells harbouring
mutations in the key components of HRR (RAD51, the BRCA genes, RAD paralogues and XRRC3) 
show very high levels of genetic instability [116]. Similarly, non-physiological pathway overactivation, 
observed in several tumors, can also contribute to genetic instability, other than chemo- and 
radioresistance [117]. RAD51 mRNA and protein levels are elevated by approximately 4–6-fold in cancer 
cells due to extreme activation of the RAD51 promoter and with activity increased at least 840-fold 
compared to normal cells [118]. For this reason HR repair has to be tightly regulated in order to prevent 
inaccurate repair leading to genetic instability and tumor formation. For this purpose the essential HRR 
protein Rad51 is regulated carefully at both the expression and activity level. During cell cycle, RAD51 
levels fluctuate, with an increase of gene expression at the beginning of the S-phase, rising until G2, to 
decrease again during G1 [119] thus reflecting the profile of HRR activity. An important regulator of 
RAD51 is p53. Binding of p53 to the Rad51 promoter leads to a suppression of Rad51 mRNA 
transcription and to reduced Rad51 protein levels [120]. RAD51 is also controlled by the Bcr/Abl fusion 
kinase [121], which is overexpressed in CML. Activity of RAD51 is also strictly regulated, likely through is 
binding with RAD paralogues and by BRCA2, which plays a supportive role in RPA displacement from 
the single-stranded filaments to promote RAD51 loading. 
Recently, it has been shown that RAD51 plays an important role in the progression of malignancy in 
addition to its HRR involvement [122], by regulating PHWDVWDWLFJHQHH[SUHVVLRQLQFRQFHUWZLWKF(%3ȕ
possibly acting as a transcriptional co-factor. Overexpression of the RAD51 recombinase activates
F(%3ȕ WUDQVFULSWLRQ DQG WKH VXEVHTXHQW XSUHJXODWLRQ RI PHWDVWDWLF JHQHV WKDW FRQWURO FHOO PRELOLW\
proliferation, adhesion and extra-cellular matrix, promoting tumor progression and dissemination.
1.3.7.1.3 The cancer susceptibility genes BRCA1 and BRCA2
BRCA genes 1 and 2, together with the Fanconi Anemia family [123] are two classes of genes involved in 
HRR. Mutations in one of those genes compromise the correct execution of HRR, although in a different 
fashion, depending on the non-functional gene. The primary role of BRCA2 is to promote RAD51 
loading on single-stranded DNA. Therefore, cells deficient in BRCA2 have an impaired RAD51 foci 
formation [124] which causes radio and chemosensitivity.
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The role of BRCA1 gene is broader, as it is tightly involved in cell cycle regulation and apoptosis other 
than DNA repair [125]. BRCA1 interacts with its partner BARD1 and it can ubiquitinylate other proteins, 
therefore strongly regulating their activity. Furthermore, BRCA1 can interact with the MRN complex to 
modulate the NHEJ pathway. As a result, new evidence suggests is role in being a modulator which
promotes either HRR or NHEJ, depending on the cellular context [126].
1.3.6.2. Non-homologous end joining
The fastest and most straight forward way to repair a DSB is simply to rejoin the broken ends. NHEJ 
does effectively join two DNA DSB ends together without requiring any homologous DNA sequence [127]. 
NHEJ repair is extremely efficient in a quantitative sense, but the fidelity and accuracy of repair usually 
decreases as soon as the pathway gets saturated by excessive DSBs, resulting in chromosomal 
translocations and other rearrangements [128]. Ionizing radiation usually causes the formation of non-
blunt end, which need to be processed before being ligated.  Therefore, NHEJ repair often results in 
small deletions at the breakage site. Even if the process per se is error-prone and can cause loss of 
genetic material, it is still able to allow cell to survive without losing genetic material, as it would be the 
case by unrepaired DSBs. NHEJ is active throughout the cell cycle. It is responsible for the repair not 
only for most of the IR-induced DSB in eukaryotic cells, but it is also strongly involved in V(D)J 
recombination [129]. Notably, patients with deficient components of the NHEJ pathway, like DNA-PKcs or 
XRCC4 are radiosensitive and often immunocompromised. NHEJ starts with the binding of the Ku 
heterodimer (Ku70/Ku80) to the blunt DNA ends, which usually occurs within seconds after break 
formation because of the high abundance of the Ku dimer and its high affinity for DNA ends (figure 3.4.) 
[130-131]. The binding serves both to protect ends from exonucleases degradation and to recruit the 
principal mediator of NHEJ, namely DNA-PKcs. Activation of the kinase activity of DNA-PKcs occurs only 
when it is bound to the Ku complex at a break site, forming the DNA-PK complex, also called the 
synaptic complex [132]. This can only take place after the Ku70/Ku80 heterodimer undergoes a 
conformational change upon DNA binding. The association with Ku bound to DNA activates its 
serine/threonine kinase activity, which promotes its own autophosphorylation at several sites, the two 
more important being Serine-2056 (called the PQR cluster) and Threonine-2609 (called the ABCDE 
cluster) [133] and other targets, including the histone H2AX. Autophosphorylation stimulates dissociation 
of the protein from DNA and the Ku70/Ku80 unit through a conformational change, allowing the next 
repair factors to access to the site [109]. DNA-PKcs exists in complex with Artemis, an endonuclease 
responsible for cleavage of 3’-overhangs, 5’-overhangs, hairpins, flaps, and gaps induced by ionizing 
radiation, making them suitable for ligation [134]. This step is followed by the recruitment of 
polynucleotide kinase (PNK), which is responsible for generating ligatable ends using its 5’-kinase and 
3’-phosphatase activities. 
Now that ends are suitable for ligation, Ku70/Ku80 recruits two main polymerases, namely pol Ȝ and pol 
ȝ, which can fill single-stranded gaps (overhang, or non-blunt ends) produced by radiation. The final 
step is ligation of adjoining ends, which is carried out by the DNA ligase IV-XRCC4-XLF complex [135].
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Figure 3.4 NHEJ consists primarily on three steps: first, DNA break recognition by the ku70/ku80 
heterodimer, which in turn recruits DNA-PKcs to form the DNA-PK complex. This binding step is 
followed by DNA processing to remove non-ligatable ends by several enzymes, including Artemis, MRN 
and several DNA polymerases. End processing promotes the kinase activity of DNA-PKcs, leading to its 
autophosphorylation and release of the autophosphorylated catalytic subunit from the synaptic complex.
Finally, the XRCC4-DNA-Ligase IV complex will relegate the two broken ends. Adapted from [136].
1.3.7.2.1 The Ku70/Ku80 heterodimer
The Ku70/Ku80 heterodimer is an abundant nuclear protein (about 4x105 molecules per cell) that binds
avidly to DNA ends as a ring structure (figure 3.5.) [136]. Ku binding to the DNA ends can occur in 
absence of the DNA-PKcs kinase [138]. Similarly to the Mre11 nuclease in MRN complex, which promote 
end processing and HRR, Ku contributes to DNA end processing as a 5’-dRP/AP lyase, which can 
remove abasic sites near breaks [139]. After initial binding to the end and its procession, the Ku70/Ku80 
complex translocate inward about one to two helical turns upon binding with the DNA-PKcs unit. Then, 
in a DNA-dependent fashion, DNA-PKcs binds to the DNA ends [140] and promotes the recruitment of 
other NHEJ factors, including XRCC4 and LIG4. Electron crystallography studies have shown that DNA-
PKcs molecules promotes the synapsis of the two DNA ends, the Ku70/Ku80 heterodimers promoting 
this process by acting as adaptors proteins to DNA to allow synapsis [141-142]. The Ku70/Ku80 binding 
properties have been recently shown to play a key role in the ability to distinguish between DNA of 
different sizes, thus directly affecting the binding and activation after low- and high LET radiation [83]. 
Due to its very dense and concentrated energy deposition profile, high-LET causes much more 
fragments of smaller size, compared to low-LET photon radiation. The Ku70/Ku80 heterodimer cannot 
bind these fragments due to structural hindrance of the ring structure, therefore ‘positively selecting’ for 
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the low-LET radiation-type of damage. This in turns have consequences for the activation of DNA-PKcs 
and generally NHEJ followed by high-LET radiation, usually promoting HRR [82,143].
Figure 3.5 Crystallographic representation of the Ku70/Ku80 heterodimer bound to DNA (Ku70 is 
colored red and Ku80 orange, DNA in gray). Ku70/Ku80 can form a ring structure with a cavity able to 
accommodate the DNA. Adapted from [137].
1.3.7.2.2 The role of DNA-PKcs in double strand break repair
DNA-dependent protein kinase, catalytic subunit (DNA-PKcs) is the largest cellular kinase known with a
size of about 470 kDa, and for being fundamental player in the NHEJ pathway [76]. As previously 
described, the kinase is activated by binding to DNA ends together with the Ku70/Ku80 complex, 
forming the synaptic complex. Upon activation by Ku70/Ku80 and DNA, DNA-PKcs undergoes 
autophosphorylation and conformational changes to create a platform for the binding of subsequent 
factors. 
Ku70/Ku80 bound to DNA-PKcs is forming a channel where the DNA fits in and differs from the 
conformation of unbound DNA-PKcs [144]. The interaction of DNA-PK complex with next, adjacent 
complex in trans-position at the other break end causes trans-autophosphorylation at both Ser-2056 
and Thr-2609 cluster regions [145]. Several other sites are phosphorylated upon DNA binding, but their 
functional relevance is often not known. Notably, it has been shown that the kinase-death version of the 
enzyme (e.g. with mutations in one of those clusters) or treatment with small molecule inhibitors that 
inactivate DNA- PKcs kinase activity result in radiation sensitivity and defects in DSB repair, even 
stronger than in case of protein absence [146]. This is due to total blockade of end accessibility for not 
only NHEJ, but also end resection by MRN and subsequent HRR [147]. Thus, correct activation of the 
kinase is essential for complete NHEJ.
DNA-PKcs has been shown to play an important role in the process of V(D)J recombination. Recently 
the first human mutation in the DNA-PKcs gene has been identified leading to a radiosensitive and 
immunocompromised T-B-SCID patient [148], whereas before only mutations in the Artemis gene were 
known to be causative of severe SCID syndromes [149].
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1.3.6.3. Alternative end joining
The Alternative end joining (Alternative EJ) is a DNA-PK independent repair mechanism which relies 
primarily on MRN, PARP1 and LIG III for break recognition, processing and repair of DNA damage. It 
can take place in absence of DNA-PKcs but also LIG IV and XRCC4 [150-151]. Alternative EJ is a very 
slow and error-prone process, and often involves increased usage of microhomology-mediated end 
joining (MMEJ) [152]. MMEJ results in the deletion of DNA sequences between short repeats of few 
nucleotides, typically 5-20, flanking the break. Components of NHEJ and HR like MRN, Ku dimers, LIG 
IV, CtIP and Rad52) are all involved in this step and seem to be used when the two classical pathways, 
NHEJ and HRR, have failed to repair the damage. MMEJ is not elusive of cells absent of DNA-PKcs, 
but can also be performed by cells proficient in DNA-PKcs [126]. Notably, in the absence of Ku70/Ku80 or 
the LIG IV-XRCC4 complexes, alternative EJ can result in an elevated rate of chromosomal 
translocations, due to the ligase properties of LIG III, which is strongly associated with high 
chromosomal translocations [153]. PARP-1 plays a key role in a-EJ by transient binding to both single-
and double-strand breaks to activate ribosylation [154]. The affinity for DNA ends is much lower 
compared to Ku, which is also much more abundant in the nucleus. Thus, PARP-1 serves as a ‘sensor’ 
for DNA ends only when Ku70/Ku80 function is impaired. 
1.3.6.4. Choice and hierarchy of double strand break repair
Several factors can determine which pathway will predominantly be used to repair DNA damages
induced by ionizing radiation, like the cell type, chromatin status (euchromatic or heterochromatic DNA), 
complexity of the DNA damage and the degree of DNA damage burden [155]. The first step after DNA 
damage is end resection by nuclease, either Mre11 promoting HRR or Ku70/Ku80 promoting NHEJ, 
and additionally PARP-1 promoting a-EJ. Both Ku and Mre11 have very high affinity for DNA, therefore 
they will compete for binding to determine which pathway is subsequently used. This is called passive 
competition [156]. Another important factor is the template availability. NHEJ is the only repair pathway 
operating in G1-phase, where HRR rarely can occur because no sister chromatid is present, and usually 
RAD51 protein levels are kept very low through active regulation by cyclin-dependent kinases (CDKs) 
[119]. Therefore, choice of the repair pathway is also an active process. In S- and G2-cells, 
phosphorylation of CtIP by CDKs promotes end resection and thus HRR over NHEJ. These specific 
CDKs are mostly active only from the late G1-phase on, thus favoring NHEJ in G1. The damage 
complexity strongly influence which pathway will actively repair damage, because of the different affinity 
of Ku70/Ku80 and (Mre11)2 for damaged DNA ends. In G2 cells usually about 20% of low-LET-induced 
DSBs (simple breaks) are repaired by HRR. In contrast, almost every DSB produced by high-LET 
radiation is processed by HRR [157-158].
53BP1 together with BRCA1 play an important role in pathway choice, as they are reported to promote 
NHEJ other than HRR [159]. 53BP1 is known to associate with DSBs in G1 to promote NHEJ by 
suppressing the inappropriate 5’-resection of DSBs [160]. As cells enter S-phase, the 53BP1-mediated 
barrier to DSB is alleviated by the action of CtIP-mediated BRCA1, which drives the removal of 53BP1 
from DSBs in S/G2, thus allowing resection and error-free repair by HRR [161].
The spectrum of functions of BRCA1 has become more and more complex and interconnected with 
other proteins. It plays multiple roles repair pathway choice, sustaining DSB repair as a scaffold protein 
29
for HRR or to promote precise joining (ensuring high-fidelity of repair) in NHEJ [162], and checkpoint 
activation trough ATM-mediated phosphorylation on several residues. Therefore, ATM protein can be 
seen as a ‘molecular switch’ to promote either HRR or NHEJ.
30
2 Aim of the study
Currently, proton and particle therapy is widely used in the clinical practice for several tumor entities, but 
there is a wide gap between the clinical implementation and the radiobiological data supporting it. The 
first patients were treated with proton therapy almost fifty years ago, and typically today the rationale for 
new indications is rather more physics and technology-based than biology-based. A more in-depth
knowledge on radiobiology of proton irradiation is necessary to allow further implementation of this 
potent treatment technique.
Several radiobiological experiments conducted in the last decades revealed approximately 10% higher 
biological efficacy (RBE) of proton compared to conventional photon radiation. This implies a dose 
adjustment in the clinical set-up when planning treatment with protons [163-164]. However, in vitro and in 
vivo studies highlighted how the effectiveness of protons can strongly vary among cell lines and tissues 
and in general the biological end-point employed [59, 165]. Therefore, using an RBE value of 1.1 in the 
clinical set-up is still reasonable, but a more accurate molecular-biological understanding is 
fundamental, especially to allow expansion of new clinical indications and particularly to implement 
radiochemotherapeutic approaches.
The issue regarding the biological differences between high-energy proton and photon is still far from 
being cleared. High energy protons (classified as low-LET radiation) show the same oxygen 
enhancement ratio compared to photon, which is strongly correlated with the LET [166]. On the other 
hand, it has been demonstrated that apoptosis and micronuclei formation is different [167]. Nevertheless, 
several studies highlighted the importance of genetic background on the cellular response to proton 
radiation, and in particular, the role of HRR and NHEJ has been outlined [168-169]. We have previously 
shown that there is a specific requirement for homologous recombination repair for DNA repair after 
proton irradiation, which may be due to a differential quality of DNA damage [170]. This has potential 
relevance for clinical stratification of patients carrying mutations in the DNA damage response pathways
(e.g. BRCA genes in breast and ovarian cancer, or Ku in bladder carcinoma) and in the development for 
combined radiochemotherapy approaches.
The most important target for ionizing radiation is the DNA. Repair pathways play a key role in the
response of proton radiation. The main goal of our research project was to investigate, in genetically-
defined human cell systems, the effects of proton radiation in respect to DNA damage and repair and 
whether it differs from conventional, photon radiation.
We thus asked the following question, if:
1) Does the quality and quantity of the damage caused by proton irradiation differ from photon 
irradiation?
2) Which roles do the major DNA repair pathway, Homologous recombination repair and Non-
homologous end joining after proton radiation play?
3) Can we exploit eventual differences as part of a combined treatment approach?
We investigated these issues by 1) using human cancer cells with defined genetic defects or by 
downregulation of selected genes using small interfering RNA approaches, 2) quantification of the initial 
DNA damage and the repair kinetics of selected proteins involved in DSB repair, 3) exploiting these 
differences by combining pharmacologically active substances with the two types of ionizing radiation.
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Summary
A differential requirement of
the 2 major DSB repair
pathways in response to
proton versus photon irradi-
ation was demonstrated in an
accepted model of geneti-
cally defined cells with de-
fects in different DNA repair
systems. Cells lacking HR
proteins were specifically
more sensitive to proton than
to photon irradiation, which
translated into an increased
RBE37 and RBE10 for the
Purpose: To investigate the impact of the 2 major DNA repair machineries on cellular survival
in response to irradiation with the 2 types of ionizing radiation.
Methods and Materials: The DNA repair and cell survival endpoints in wild-type, homologous
recombination (HR)-deficient, and nonhomologous end-joining-deficient cells were analyzed after
irradiationwith clinically relevant, low-linear energy transfer (LET) protons and 200-keV photons.
Results: All cell lines were more sensitive to proton irradiation compared with photon irradiation,
despite no differences in the induction of DNA breaks. Interestingly, HR-deficient cells and wild-
type cellswith small interferingRNA-down-regulatedRad51weremarkedly hypersensitive to pro-
ton irradiation, resulting in an increased relative biological effectiveness in comparison with the
relative biological effectiveness determined in wild-type cells. In contrast, lack of nonhomologous
end-joining did not result in hypersensitivity toward proton irradiation. Repair kinetics of DNA
damage in wild-type cells were equal after both types of irradiation, although proton irradiation
resulted inmore lethal chromosomal aberrations. Finally, repair kinetics inHR-deficient cells were
significantly delayed after proton irradiation, with elevated amounts of residual gH2AX foci after
irradiation.
Conclusion: Our data indicate a differential quality of DNA damage by proton versus photon irra-
diation, with a specific requirement for homologous recombination for DNA repair and enhanced
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HR-deficient cells. These
results might become rele-
vant for clinical stratification
of patients carrying muta-
tions in specific DNA dam-
age response pathways.
cell survival. This has potential relevance for clinical stratification of patients carryingmutations in
the DNA damage response pathways.  2013 Elsevier Inc.
Introduction
A generic relative biological effectiveness (RBE) value of 1.1 is
currently used in the clinic for proton radiation therapy. However,
this RBE can vary significantly depending on the tissue, cell line, or
endpoint investigated (1-4). Only a minimal number of studies have
been performed to understand the differential response on the mo-
lecular and cellular levels. For example, free 30 DNA ends are more
abundant 1 hour after proton irradiation (222 MeV) than after
photon irradiation, as demonstrated in thyroid follicular cells.
Micronuclei formation and the immediate apoptotic cell response
are also augmented in these cells in response to protonversus photon
irradiation (5). Furthermore, in vitro experiments performed with
genomic T7 DNA revealed the highest ratio of clustered DNA
double-strand breaks (DSBs) after proton irradiation. Finally, a
significant fraction of complex types of chromosomal aberrations
and an increased frequency of sister chromatid exchanges were
demonstrated in different cell lines after proton irradiation (6, 7).
These studies indicate that either more initial DNA breaks or a
qualitatively different type of damage are induced by these different,
low-linear energy transfer (LET) types of ionizing radiation.
Cells have evolved 2 major DSB repair pathways (8, 9): homol-
ogous recombination (HR) is initiated through the recognition of
DSBs by the Mre11, Rad50 and Nbs1 (MRN)-complex followed by
MRN- and CtBP-interacting protein (CtIP)-dependent 30e50 DNA
resection (10). The resulting single-stranded DNA tails are first sta-
bilized by replication protein A (RPA) that is later replaced by Rad51
(9) to form Holliday junctions. Ultimately, these structures are
resolved by several Holliday junction processing factors (10, 11).
Double-strand break repair by nonhomologous end-joining (NHEJ)
relies on the initial binding of theKu70/80 heterodimer, which results
in the recruitment of DNA-PKcs (9). The XRCC4-DNA Ligase IV
complex will eventually re-ligate the 2 broken strands (12).
In the study reported here we have investigated the treatment
response to photon and proton irradiation in an accepted model of
genetically defined cells with defects in one of the major DNA
repair systems (13-15).
Methods and Materials
Cell lines
The Chinese hamster ovary (CHO) cells AA8, CHO9, UV5,
Irs1sf, and XR-C1 were cultured in Ham F10 cell culture media
containing 10% fetal bovine serum and penicillinestreptomycin
(100 U/mL-100 mg/mL) and kept at 37C, at 5% CO2 atmosphere.
Irradiation procedures
To irradiate exponentially growing cultures, 3  105 cells were
plated into 25-cm2 flasks 24 hours before irradiation. To irradiate
plateau phase cultures, 1  106 cells were plated into 25-cm2
flasks 72 hours before irradiation. Photon irradiation was per-
formed using a Gulmay (Suwanee, GA) 200-kV x-ray unit at 1
Gy/min (kVpZ 200 kV; half-value layer (HVL)Z 1.03 mm Cu;
Filter: 1 mm Al and 0.45 mm Cu). Proton irradiations were
delivered using spot scanning (16). The maximal instantaneous
dose rate at the Bragg peak is 4 Gy/s; however, cells were placed
in the center of the spread-out Bragg peak (SOBP), with a length
of 5 cm and maximum proton energy of 138 MeV. The LET is
generally low in the middle of the SOBP, because most of the dose
is deposited by plateau doses, and very little is deposited from
Bragg peaks. The field size orthogonal to the beam was 15  11
cm. Dosimetry of the fields was performed using both small-
diameter cylindrical ionization chambers (active volume 0.3
cm3) and a farmer-type NE2571 ionization chamber using the
International Atomic Energy Agency TRS-398 protocol.
Clonogenic survival
Twenty hours after irradiation, cells were trypsinized, and single-
cell suspensions were seeded into petri dishes. The number of
plated cells per dish was adjusted to obtain approximately 50-200
colonies under all experimental conditions. After colony formation
for 7-10 days, colonies were fixed (methanol/acetic acid; 3:1) and
stained with crystal violet (2%). Colonies (containing >50 cells)
were counted manually. To calculate RBE values, a and b values
for each survival curve were determined. Survival data were fitted
by weighted, stratified, linear regression to obtain the linear and
quadratic parameters. Linear regression was performed in SPSS
(Chicago, IL) as described in reference 17. The RBE values at 37%
and 10% survival level were calculated according to reference 18.
Transfection of CHO cells
Transfection of AA8 wild-type cells was performed 1 day before
plating for irradiation. Cells were irradiated 48 hours after trans-
fection. Small interfering RNAs (siRNAs) were used at a con-
centration of 40 nM with 1.7 mL/mL Lipofectamine RNAiMAX
(Invitrogen, Carlsbad, CA). The following siRNA sequences were
used: siLuc: 50-CGTACGCGGAATACTTCGAdTdT-30; siRad51:
50-GAGCUUGACAAACUACUUCdTdT-30.
Immunofluorescence microscopy
Twenty-four hours before irradiation, cells were plated onto Ibidi-
m-slides VI0.4 (Ibidi, 80606, Munich, Germany) at the same cell
density as used for clonogenic survival assays. After irradiation,
cells were washed twice with phosphate-buffered saline (PBS),
fixed with 4% formaldehyde/PBS for 20 minutes, washed with
PBS (4  5 minutes), and finally with 0.1 M glycine, for storage at
4C until staining. Cells were permeabilized for 5 minutes with
0.2% ice-cold Triton-X-100, blocked for 30 minutes with 3%
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bovine serum albumin (BSA)/0.1% Tween-20/PBS, followed by
1-hour incubation with primary antibodies, diluted 1:100 in 1%
BSA/PBS (mouse monoclonal anti-H2AX-pSer139 (Millipore,
Billerica, MA), rabbit polyclonal anti-Rad51, and rabbit poly-
clonal anti-DNA-PKcs-pS2056 (Abcam, Cambridge, United
Kingdom). After washing with 1% BSA/PBS (4  10 minutes),
cells were incubated with the appropriate secondary antibody
1:1000 (Alexa-488 and/or Alexa-546; Invitrogen, Gibco, Basel,
Switzerland) and incubated with PBS/40,6-diamidino-2-
phenylindole (1 mg/mL). Slides were examined with a Leica
SP5 confocal microscope and a Leica DFC 350 FX camera (Leica
Microsystems, Wetzlar, Germany). Merged z-stacks were
analyzed with LAS AF Lite software (Leica, free version). At least
50 cells per condition were analyzed.
Chromosomal aberrations
Twenty-one hours after irradiation, cells were blocked in meta-
phase by the addition of 0.2 mg/mL Colcemid (Gibco) for 3 hours.
Thereafter, cells were treated in hypotonic KCl solution (0.075 M)
and fixed 2 in Carnoy’s fixative (3:1; methanol:acetic acid). Cell
concentration was adjusted (approximately 1  106 cells/mL), and
fixed cells were dropped onto wet slides, stained with 2% Giemsa
(Sigma, St. Louis, MO), and embedded with Entellan (Merck,
Whitehouse Station, NJ). Light microscopy pictures of at least 100
metaphases per condition were acquired with a Leica SP5
microscope. Metaphase spreads were screened for fragments,
rings, dicentrics, sister unions, and complex exchanges.
Statistical analysis
Datawere presented as themean standard error of themean (SEM)
or standard deviation (SD) of at least 3 independent experiments.
The results were tested for significance using the 2-sided unpaired
Student t test or the Wilcoxon-Mann-Withney U test. Results were
considered statistically significant atP<.05 (*) or highly significant at
P<.001 (**).
Results
Experiments conducted during the last decades revealed an
approximately 10% higher RBE of proton versus photon irradia-
tion (3). However, the cause for this increased RBE on the
physicalechemical and molecularecellular level is far from clear.
To determine the relevance of intact DNA DSB repair machineries
to the RBE, clonogenic survival assays were performed in a panel
of isogenic CHO cells with known deficiencies in specific DSB
repair pathways in response to clinically relevant proton (low-
LET, 138 MeV) and photon radiation (19). Exponentially growing
cells were exposed to either type of radiation and reseeded 20
hours after irradiation to determine clonogenic survival. Before
reseeding, cells were recounted and analyzed for cell cycle dis-
tribution. No type of radiation-related differences in cell cycle
distribution and amount of cells were observed (Supplementary
Figs. e1-e3, available online). At 37% and 10% clonogenic cell
survivals, all cells were more sensitive to proton versus photon
irradiation, with an RBE37 and RBE10 of 1.25  0.05 and 1.29 
0.04, respectively. As expected, the HR-deficient cell line Irs1sf,
which lacks XRCC3, displayed increased hypersensitivity in
response to both types of irradiation. Interestingly though, the
RBE significantly increased in the HR-deficient cells to an RBE37
and RBE10 of 1.54  0.1 and 1.44  0.06, respectively (Fig. 1,
Table 1).
To confirm enhanced sensitivity of HR-mutated cells to proton
versus photon irradiation, clonogenic survival assays were per-
formed in cells lacking the HR-related key factor Rad51. Chinese
Fig. 1. Clonogenic cell survival of proton- and photon-irradiated cell lines. Chinese hamster ovary wild-type (WT) cells (AA8) and
corresponding homologous recombination (HR)-deficient cells (XRCC3-/-; Irs1sf) were irradiated in exponential growth phase (A) and in
plateau phase (B). Data were pooled from at least 3 independent experiments. (C) Clonogenic survival of Chinese hamster ovary wild-type
cells (AA8) transfected with either control small interfering RNA (siLuc) or with 2 different Rad51-directed small interfering RNAs.
Clonogenic survival data from both siRad51-treated cells were pooled. Points represent mean  SD.
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hamster ovary wild-type cells (AA8) were transfected with either
a control siRNA (siLuc) or siRNA targeting the Rad51 recombi-
nase (Supplementary Fig. e4) and irradiated with increasing doses
of ionizing radiation. Both siLuc- and siRad51-transfected cells
were more sensitive to proton than to photon irradiation, but the
RAD51 knockdown cells were significantly more sensitive to
proton irradiation (RBE37 and RBE10 of 1.32  0.06 and 1.32 
0.06 for the siLuc-transfected cells versus RBE37 and RBE10 of
1.67  0.07 and 1.52  0.04 for the siRad51-transfected cells)
(Fig. 1C).
Homologous recombination requires an intact sister chromatid
and is therefore only active during S and G2 phases of the cell
cycle (9, 20). Thus, confluent (plateau phase) cells, which are
arrested in the G0/G1 phase of the cell cycle, primarily depend on
NHEJ for efficient DSB repair. Wild-type and HR-deficient cells
were grown to confluence, and clonogenic survival was deter-
mined in response to proton and photon irradiation. Overall,
confluent cells were less radiosensitive than their proliferating
counterpart cells. A slightly enhanced radiosensitivity remaining
in the HR-deficient cell population under these conditions might
be due to the small percentage of cells slipping into S/G2 phase
(Fig. 1B; see Supplementary Fig. e5 for cell cycle distribution).
Interestingly, under these conditions, the differentially enhanced
sensitivity of HR-deficient cells to proton irradiation was absent,
supporting a critical role of HR-mediated repair of proton irradi-
ation-induced lesions in dividing cells (see Table 1 and
Supplementary Tables e1 and e2 for RBE values).
Nonhomologous end-joining is the predominant repair
pathway for irradiation-induced DSBs in mammalian cells. As
expected, DNA-PKcs-deficient CHO cells (XR-C1) were hyper-
sensitive to both types of radiation (Fig. 2A, Table 1). However,
compared with the corresponding wild-type cells (CHO9), we
could not detect a statistically significant change of the RBE in the
NHEJ-deficient cells. The NHEJ-deficient cells were also irradi-
ated in plateau phase. Under these conditions radiosensitivity was
further increased toward both types of irradiation but without a
significant change of the RBE (Fig. 2B, Table 1).
Lack of nucleotide excision repair has been found not to affect
clonogenicity in response to irradiation. As an additional control
experiment, clonogenic survival assays were therefore performed
with nucleotide excision repair-deficient hamster cells lacking
ERCC2 (alias XPD, UV-5) (21, 22). No statistically significant
change of the RBE was observed in the nucleotide excision repair-
deficient but otherwise isogenic CHO cells in comparison with the
wild-type cells (Fig. 2C).
These results suggest a specificDNArepairmachineryedependent
treatment response and point to a differential DNA damage
complexity or amount of DNA damage after proton versus photon
irradiation. To test for the amount of initial DSBs, gH2AX foci were
quantified in an RBE-independent approach 12 minutes after irradia-
tion (1 Gy) with the 2 types of ionizing radiation. At this early time
point, we could not detect any significant differences in the amount of
gH2AX foci per cell induced by the 2 types of irradiation and in the
different cell lines (Fig. 3A). Thus, according to the numbers of
irradiation-induced gH2AX foci, enhanced proton sensitivity is
unlikely to be due to an increased number of DSBs induced by proton
versus photon irradiation.
Ultimately it is the amount of residual DNA damage mis-
repaired or left unrepaired that affects treatment outcome in
response to irradiation. Therefore, we analyzed levels of gH2AX
foci per cell over a 24-hour time course in the different cell lines
in response to 1 Gy of ionizing radiation (Fig. 3B) (20, 23-25).
Repair kinetics in the wild-type cell lines were identical in
response to both proton and photon irradiation. As expected,
gH2AX focus removal was delayed in both HR- and NHEJ-
deficient cell lines, with only 20-30% of gH2AX foci disappear-
ing during the initial time period. Remarkably, however, delayed
disappearance of gH2AX foci was most prominent in the HR-
deficient cells in response to proton irradiation, at all time
points measured (Fig. 3B for 1 Gy), with 45% of gH2AX foci still
being detectable 24 hours after proton irradiation (compared with
27% after photon irradiation). Cell cycle analysis at 6, 12, and 24
hours after irradiation displayed no difference in cell cycle dis-
tribution for the HR-mutated cells in response to the 2 types of
radiation (Supplementary Fig. e3). In contrast, the kinetic profile
of gH2AX focus disappearance in NHEJ-mutated cells was
indistinguishable between photon and proton irradiation (Fig. 3B)
(20, 23). It is important to note that the very low levels of gH2AX
foci after 24 hours are due to the fact that only intact and not
already cell death-related, fragmented nuclei were considered.
To further investigate a differential requirement for competing
DSB repair systems in response to proton versus photon irradia-
tion, foci kinetics of the major constituents of HR (Rad51) and
NHEJ (pDNA-PKcs) were determined (Supplementary Fig. e6).
We observed a significant increase in Rad51 foci in DNA-PKcs-
deficient cells in response to both irradiation treatments compared
with wild-type cells. This was most likely due to the absence of
NHEJ, which would normally compete with HR for the recogni-
tion and repair of DSBs (8). In HR-deficient cells, pDNA-PKc foci
persisted much longer in response to both types of irradiation,
which may indicate problems for DNA-PKcs to deal with a certain
class of DNA damage. Furthermore, only minimal differences in
DNA damage signalling in response to the 2 sources of irradiation
could be detected in both wild-type and HR-deficient cells
Table 1 Relative biological effectiveness (RBE) values at
37% and 10% clonogenic survival after proton and photon
irradiation
% Survival Parameter 1 Parameter 2 P
HR-WT log HR-/- log
37 1.25  0.05 1.54  0.10 .02
10 1.29  0.04 1.44  0.06 .03
HR-WT plateau HR-/- plateau
37 1.27  0.08 1.26  0.08 .98
10 1.29  0.03 1.27  0.03 .99
HR-WT siLuc HR-WT siRad51
37 1.32  0.06 1.67  0.07 .03
10 1.32  0.02 1.52  0.04 .03
NHEJ-WT log NHEJ-/- log
37 1.32  0.12 1.08  0.07 .11
10 1.20  0.05 1.09  0.08 .38
NHEJ-WT plateau NHEJ-/- plateau
37 1.27  0.06 1.33  0.05 .31
10 1.25  0.03 1.32  0.05 .21
NER-WT log NER-/- log
37 1.25  0.05 1.41  0.12 .14
10 1.29  0.04 1.28  0.06 .62
Abbreviations: HR Z homologous recombination; NER Z nucle-
otide excision repair; NHEJ Z nonhomologous end-joining; WT Z
wild-type.
The RBE values were calculated with the a and b values derived from
the survival curves, as explained in the Methods and Materials section.
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(Supplementary Fig. e6C; see also Supplementary Figs. e7-e9 for
representative images of irradiation-induced gH2AX, Rad51, and
pDNA-PKc foci).
Quantification of residual chromosomal aberrations in wild-
type and HR-deficient cells (at 2 Gy) revealed a slightly enhanced
total amount of chromosomal aberrations in the HR-deficient cells
in response to both types of irradiation. Proton irradiation resulted
primarily in more fragments, especially in the HR-deficient cells
(Fig. 4; see also Supplementary Fig. e11 for NHEJ-deficient cells).
As previously described by Natarajan et al (26) for these cell lines
in response to photon irradiation, we also observed a shift from
chromosome- to more chromatid-type aberrations in HR-deficient
Fig. 2. Clonogenic cell survival of proton- and photon-irradiated cell lines. Chinese hamster ovary wild-type (WT) cells (CHO9) and
corresponding nonhomologous end-joining (NHEJ)-deficient cells (DNA-PKcs-/-) were irradiated in exponential growth phase (A) and in
plateau phase (B). Chinese hamster ovary wild-type (AA8) cells and corresponding nucleotide excision repair (NER)-deficient (UV-5;
ERCC5-/-) cells were irradiated in exponential growth phase (C). Data were pooled from at least 3 independent experiments. Points
represent mean  SD.
Fig. 3. Quantification of initial and residual gH2AX foci after proton and photon irradiation with 1 Gy. (A) Initial amount of gH2AX foci
in Chinese hamster ovary wild-type cells (AA8, CH9) and corresponding homologous recombination (HR)-deficient (Irs1sf) and nonho-
mologous end-joining (NHEJ)-deficient (XR-C1) cells, detected 12 minutes after irradiation (nZ5, mean  SD). (B) Residual amount of
gH2AX foci 3, 6, and 24 hours after irradiation. The initial amount of foci is set as 1; the dotted line indicates the background level of
gH2AX foci in unirradiated cells; nZ3, mean  SD. *P<.05.
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cells. After proton irradiation the amount of chromatid-type ab-
errations increased even further in the HR-deficient cells but was
still lower than the amount of chromosome-type aberrations,
which include the high level of proton irradiation-induced
fragments.
Discussion
To the best of our knowledge, our study is the first to investigate a
differential requirement of the 2 major DSB repair pathways in
response to proton versus photon irradiation using accepted
models of genetically defined, isogenic wild-type cells and mu-
tants thereof with defined defects in the different DNA repair
systems (13-15). Overall, clonogenic survival in the wild-type cell
lines was lower in all proton-irradiated in comparison with
photon-irradiated cells, which is consistent with the well-known
RBE of high-energy, sparsely ionizing protons (1, 3, 5, 27-29).
Of note, the RBEs determined in these in vitro studies are in
general higher than the generically used RBE value of 1.1 used for
clinical studies (3). This is mainly caused by the cell lines and
endpoints chosen in these studies and does not necessarily point to
a difference between in vivo and in vitro response. Clinically, this
generic RBE value is used because it represents a reasonable
average over various endpoints.
Proliferating cells lacking HR proteins were even more sen-
sitive to proton than to photon irradiation than their corresponding
wild-type cells, which also translated into a further increase in
RBE37 and RBE10 for the HR-deficient cells. On the other hand,
DNA-PKcs-deficient cells with compromised NHEJ did not
display enhanced proton sensitivity. These results suggest an
enhanced dependence of a part of proton-induced DNA DSBs on
HR, which might become relevant for clinical stratification of
patients carrying mutations in specific DNA damage response
pathways. Future studies will determine this HR-dependent shift
of the RBE in other cell line systems and in animal tumor models.
Proton irradiation resulted in more lethal DNA aberrations than
photon irradiation, even though the initial amount of DNA DSB
marks were in the same range. These results suggest that the
spatial distribution or the quality of the DNA damage is different
after proton versus photon irradiation, which eventually could
result in primarily increased levels of fragments and lethal chro-
mosomal rearrangements. Increased amounts of small DNA
fragments could enhance chromosome deletions and cell death.
Within a clinically relevant SOBP the LET varies onlymodestly.
However, experiments with radioresistant melanoma cells revealed
an increased RBE across the SOBP (30), which might be due to a
slight increase of LET across the SOBP, and corresponds to
enhanced cell killing per gray of irradiation as LET increases (30).
We cannot exclude that this minimal enhanced LET contribution
within the multiple near-monoenergetic proton beams might shift
the DNA damage profile also relevant for this study.
Interestingly, enhanced HR dependence was only observed in
proliferating cells. Thus, despite the lack of an intact HR ma-
chinery, confluent, plateau phase cells can sufficiently cope with
proton-induced DNA damage, most probably owing to enhanced
potentially lethal damage repair (31).
Nonhomologous end-joining and HR might compete with each
other, particularly during S/G2 phase, but there are also data
suggesting that initial, fast repair of DNA DSBs is carried out by
NHEJ, whereas the more time-demanding HR occurs at a later
stage (32, 33). This model also suggests that in mammalian cells,
NHEJ first attempts to repair DSBs but grants access for the HR
machinery in case rejoining does not rapidly proceed (15, 34).
Interestingly, the slow repair kinetic in HR-defective cells in-
dicates continuing checkpoint signaling and DNA repair at these
sites. These different phenotypes might indeed result from an
initial but unsuccessful attempt of NHEJ to repair all proton
irradiation-induced DSBs.
Overall, our studies demonstrate that the major DNA DSB
machineries are challenged in a differential way after proton and
photon irradiations. Our data suggest that the overall DNA damage
is different at least to a certain extent, requiring preferentially
homologous recombination after proton irradiation. Future studies
will specifically investigate whether these differential requirements
can be exploited and will translate into biology-based rationales to
choose between proton- and photon-based radiation therapy.
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Abstract:
Purpose:
A 10% higher efficacy of proton- versus photon irradiation (IR) is already implemented in the 
clinics. However little is known about the radiobiology of the relative biological effectiveness 
(RBE). Non-homologous end-joining (NHEJ) and homologous recombination repair (HRR) 
both contribute to promote the repair of radiation-induced DNA double strand breaks (DSBs). 
We previously investigated this higher efficacy of proton-irradiation in genetically-defined 
Chinese hamster ovary cells and observed that HRR-deficient, but not NHEJ-deficient cells 
were significantly more sensitive to proton-IR than to photon-IR when compared to their wild-
type cells. We have now investigated the impact of the two major DNA repair machineries for
cellular survival of human tumor cells in response to irradiation with the two types of ionizing 
radiation.
Methods and Materials:
In this study, DNA-repair and cell survival endpoints were analyzed in wildtype, homologous 
recombination (HR)-deficient and non-homologous end joining (NHEJ)-deficient cells after 
irradiation with clinically relevant, high-energy protons (136 MeV) and 200 keV photons.
We further analyzed DNA damage repair and cell survival endpoints in the non-small cells lung 
cancer (NSCLC) cell line A549 with compromised HRR- and NHEJ-repair and the effect of the 
DNA-PKcs inhibitor NU7026 in response to both types of ionizing radiation.
Results:
A549 cells depleted of DNA-PKcs were equally sensitive to both types of ionizing radiation
(RBE10=0.94), whereas transient inhibition by the DNA-PKcs-inhibitor NU7026 strongly 
radiosensitized the DNA-PKcs-proficient A549 and M059K cell lines to photon, but to a much 
lower extent to proton irradiation (DMF10=1.91 vs 1.49 for A549 cells). Interestingly, we 
observed a reduced phosphorylation of DNA-PKcs at ser-2056 and thr-2609 clusters after 
proton irradiation, compared to photon radiation. In contrast, A549 cells depleted of the 
RAD51 recombinase (HRR) were markedly hypersensitive to proton radiation in comparison to 
control cells (RBE10=1.27 vs 1.0). Likewise, human BRCA2-deficient cells (PEO1), but not the 
DNA-PKcs-deficient cells (M059J) were markedly hypersensitive towards proton irradiation.
Conclusion:
Our data demonstrate an enhanced susceptibility of HRR-deficient cancer cells to proton 
radiation, due to a compromised capability of the DNA-PK-dependent NHEJ pathway in 
repairing proton-induced damages, resulting in an enhanced RBE. This might become relevant 
for clinical stratification of patients carrying mutations in the DNA damage response pathways 
and for combined treatment modalities with specific inhibitors of the two major DNA repair 
machineries to be selectively used with either photon- or proton-based radiotherapy.
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Introduction:
Currently, a generic RBE value of 1.1 is used in the clinic for proton radiotherapy. This value 
however does not always reflect the sensitization observed at the tissue or cellular level [1-5].
Reasons for this variable RBE may be several, including a different type of damage or 
involvement of DNA repair machineries, but only a limited number of studies have been 
performed to understand these differences in detail at the cellular and molecular level. 
Ionizing radiation is usually regarded as a prototypic double-strand break (DSB)-producing 
agent. Unrepaired DBS can be lethal for the cell, by causing chromosomal rearrangements
ultimately leading to cell death [6-7]. Cells have evolved two major pathways to cope with DNA 
damage and genome integrity, namely homologous recombination repair (HRR) and non-
homologous end joining (NHEJ) [8-9].  HRR is a slow process, primarily active through the 
S/G2-phase of the cell cycle and results in preserved sequence integrity. First, damage 
recognition by the Mre11-RAD50-NBS1 (MRN) complex initiate the CtIP-dependent DNA end 
resection [10]. The single-strand DNA (ssDNA) is first bound by RPA, thus preventing the 
ssDNA from forming secondary structures [11]. Thereafter, the nucleoprotein binds to RAD51
and its accessory factors to initiate search for homologous sequence in sister chromatids to 
form Holliday Junctions. Finally, resolution of the heteroduplex by several helicases takes 
place [12].  Non-homologous end joining can be divided in canonical and alternative NHEJ. 
Canonical-NHEJ (cNHEJ, also called Ku-dependent EJ) is active throughout the cell cycle, and 
is responsible for the repair of most IR-induced DSBs in eukaryotic cells, other than being 
involved in V(D)J recombination [13-15]. Although very efficient in a quantitative way, the 
quality of repair can steadily decrease by increasing amount of DNA damage [16]. It consists 
primarily on three steps: first, DNA break recognition by the Ku70/Ku80 heterodimer, which in 
turn recruits DNA-PKcs to form the DNA-PK complex (called, together with DNA, the 
synaptic complex) [17]. This binding step is followed by DNA processing to remove non-
ligatable ends by several enzymes, including Artemis, MRN and several DNA polymerases. 
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End processing promotes the kinase activity of DNA-PKcs, leading to its autophosphorylation 
and release of the autophosphorylated catalytic subunit from the synaptic complex [18]. Finally, 
the XRCC4-DNA Ligase IV complex will relegate the two broken ends [19].
Alternative EJ (aEJ) has recently been identified as a Ku80- or DNA-PKcs-independent 
pathway [20-22] and requires PARP1, MRN and LIG3 for break recognition, processing and 
ligation [23]. It is usually associated with deletions at repair junctions, and thus with high 
mutagenic potential. Several studies using pulsed field gel electrophoresis or JH2AX as DNA 
damage markers indicate that either the initial amount or the quality of the initial DNA damage 
caused by irradiation of different linear energy transfer (LET), including protons, may be 
different [24-26]. These high-LET radiations generate complex DNA damages, called cluster 
damages, are opposite to single isolated damages, which are typical for very low-LET photon 
radiation and can be generally readily repaired by the cell. As the LET increases the number of 
induced DSB/track traversal and the complexity of the break also increases, potentially leading 
to damages which are usually resistant to repair or can be repaired but with a strong mutagenic 
potential [27-28]. Recently, a differential involvement of these two major pathways after particle 
irradiation has been described. Particularly, it has been showed that high-LET particle radiation 
interferes with the Ku-dependent EJ, but not with HRR pathway [29-32]. This is probably due to 
the combined effect of high-LET radiation producing coordinated ionizing events along the 
path resulting in very small DNA fragments, and the inability of the Ku70/Ku80 heterodimer to 
efficiently bind these fragments, therefore preventing NHEJ to properly function. 
In this report we now investigate the treatment response to high energy, low-LET proton (136 
MeV) and photon (200 KeV) irradiation in an accepted model of genetically-defined cells with 
defects in one of the major DNA repair systems. We have now shown that cells with 
compromised HRR are more sensitive to treatment with low-LET hadron therapy compared to 
photon therapy, whereas cells with compromised NHEJ are equally sensitive to both low-LET
proton and photon radiation.
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Materials and Methods:
Cell lines. The human non-small cell lung cancer cell line A549 and the triple-negative breast 
cancer cell line MDA-MB-231 were obtained from ATCC and cultured in RPMI cell culture 
media supplemented with 10% FBS, glutamine (2mM) and penicillin-streptomycin (100U/ml-
1ȝJPO7KHJOLREODVWRPDFHOOOLQHVM059K and M059J were kindly provided by Prof P. 
O’Neil (Oxford University, UK) and maintained in 1:1 MEM/F12 Ham’s mixture 
supplemented with 10% FBS, glutamine (2mM) and penicillin-streptomycin (100U/ml-
100ȝJPO7KH2YDULDQFDQFHUFHOOOLQHV PEO4 and PEO1 were purchased from the Health 
Protection Agency Culture Collections (Salisbury, UK) and maintained in RPMI cell culture 
media supplemented with 10% FBS, glutamine (2mM), sodium pyruvate (2mM) and penicillin-
streptomycin (100U/ml-ȝJPO. All cells were kept at 37°C and 5% CO2 atmosphere.
Drug Treatment. NU7026 [10μM] and KU60019 [1μM] were added to the cells 1 h prior to 
irradiation. Vorinostat [2μM] was added 24 h prior to irradiation. All chemicals were purchased 
from Selleckchem (Huston TX, USA) and dissolved in DMSO.
Antibodies. The following antibodies were used at the specified dilutions: rabbit monoclonal 
anti- H2AX-pSer139 (1:200 immunofluorescence, IF - Abcam, Cambridge, UK); rabbit 
monoclonal anti- H2AX-pSer139 (1:1000  western blot, WB - Cell Signaling, Boston MA, 
USA); rabbit monoclonal anti-RPA32 (1:1000 IF or 1:2000 WB - Bethyl Science, Bethesda, 
USA); rabbit polyclonal anti-DNA-PKcs-pS2056 (1:100 (IF) or 1:1000 (WB) - Abcam, 
Cambridge, UK); mouse monoclonal anti-DNA-PKcs-pT2609 (1:200 (IF) - Abcam, 
Cambridge, UK); mouse monoclonal anti-DNA-PKcs (1:500 (WB) - Abcam, Cambridge, UK); 
rabbit polyclonal anti-53BP1 (1:200 (IF) - Cell Signaling, Boston MA, USA); mouse anti-
ATM-p1981(1:100 (IF) or 1:2000 (WB) - Abcam, Cambridge, UK); mouse anti-ATM (1:2000 
(WB) - Abcam, Cambridge, UK); mouse monoclonal anti-RAD51 (1:100 (IF) or 1:500 (WB) -
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Novus Biological, A-8 Littleton CO, USA); mouse monoclonal anti-Ku80 (1:1000 (WB) -
Abcam, Cambridge, UK); mouse monoclonal anti-BRCA1 (1:1000 (WB) - Abcam, Cambridge, 
UK); mouse monoclonal anti-ȕ-actin (1:1000 (WB) - Sigma-Aldrich, St. Louis MO, USA).
Irradiation procedures. To irradiate exponentially growing cell cultures, 1.5x105 cells were 
plated into 25 cm2 TPP flasks 24 hours prior to irradiation (IR). Photon irradiation was 
performed using a Gulmay 200 kV X-ray unit at 1 Gy/min (kVp = 200kV; Amperage=15mA, 
HVL = 1.03mm Cu, Filter: 1mm Al and 0.45mm Cu). Proton irradiation was delivered using 
spot scanning technique at the Paul Scherrer Institute [33]. The maximal instantaneous dose rate 
at the Bragg peak is 4Gy/s; however cells were placed in the center of the Spread-Out-Bragg-
Peak (SOBP), with a length of 5 cm and maximum proton energy of 138 MeV. The LET was 
estimated at 2 KeV/μM in the center of the SOBP. The field size was orthogonal to the beam 
with an area of 15x11cm. Dosimetry of the field was performed using both small diameter 
cylindrical ionization chambers (active volume 0.3cm3) and a Farmer NE2571 ionization
chamber using the IAEA TRS-398 protocol.
Clonogenic survival. Twenty hours following irradiation, cells were trypsinized and single cell
suspensions were seeded into 10cm-petri dishes. The number of plated cells per dish was 
adjusted to obtain approx. 50-100 colonies under all experimental conditions. After colony 
formation (depending on cell lines, between 7-21 days), colonies were fixed (methanol/acetic 
acid; 3:1) and stained with 2% crystal violet. Colonies were then counted manually. 
,QRUGHUWRFDOFXODWH5%(DQG'0)YDOXHVĮ- and ß-values for each survival curve were 
determined. Survival data were fitted by weighted, stratified, linear regression to obtain the 
linear and quadratic parameters. Linear regression was performed in SPSS (Version 23) as 
described in [34]. RBE and DMF values at the 10 % survival level (termed RBE10 and DMF10)
were calculated according to [35].
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siRNA Transfection. Transfection of A549 cells was performed one or two days before plating 
for irradiation, according to the specific siRNA. Cells were irradiated 48 or 72 h after 
transfection. siRNAs were used at a concentration of 20 nM (siDNA-PKcs) or 40 nM  
(siRAD51ZLWKȝ/PO/LSRIHFWDPLQ51$L0$;,QYLWURJHQ7KHIROORZLQJVL51$
sequences were used: siLuc: 5’-CGTACGCGGAATACTTCGAdTdT-3’.
siRad51: 5’-GAGCUUGACAAACUACUUCdTdT-3’. 
siDNA-PKcs, Dharmacon SMARTpool against human PRKDC (GE Healthcare).
Immunofluorescence microscopy. 24 hours prior to irradiatioQFHOOVZHUHSODWHGRQWR,ELGLȝ-
slides VI0.4 (Ibidi, Munich) at the same cell density as used for clonogenic survival assay. At 
the desired time points, cells were washed twice with PBS, fixed with 4% formaldehyde/PBS 
for 10 min, washed with PBS (4 x 5min) and stored at 4°C until further staining. Cells were 
permeabilized for 5 min with 0.5% ice cold Triton-X-100/PBS, blocked for at least 20 min with 
1% BSA, followed by 1h incubation with the selected primary antibody (diluted in 
1%BSA/PBS). After washing with 1%BSA/PBS (3 x 10min), cells were incubated with the 
appropriate secondary antibody diluted 1:1000 in 1%BSA/PBS (Alexa-488 or/and Alexa-546; 
Invitrogen), washed with 1%BSA/PBS (2 x 10min) followed by PBS (1 x 10min) and 
incubated with DAPI/MethDQROȝJPOIRUPLQ&HOOVZHUHWKHQ mounted in Ibidi mounting 
Medium (Ibidi, Munich) and stored at 4°C. Slides were examined with a Leica SP5 confocal 
microscope and a Leica DFC 350 FX camera. Merged z-stacks (z=0.49μm) were analyzed with 
LAS AF Lite software (Leica, free-version). At least 50 cells per condition were analyzed.
Western blotting. At the indicated time points cells were collected by scratching them on ice 
for 5 min, counted, and lysates were prepared witKDERXWȝ//DHPPOL-buffer/45’000 cells 
(2% SDS, 10% glycerol, 0.004% bromphenol blue, 62.5 mM Tris-HCl, pH 6.8). After 
scratching and collection of the lysates, they were frozen on dry ice and stored at -20°C until 
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analysis. An equal amount of protein was subjected to SDS-PAGE to separate the proteins. Due 
to the different sizes of the proteins different grades of acrylamide polymerization were used 
(ATM, DNA-PKcs and BRCA1: 7.5% SDS-gel/ JH2AX, RAD51, RPA32, Ku80: 12% SDS-
gel). Proteins were blotted from the SDS-gel onto Amersham Hybond-P polyvinylidene 
difluoride membranes. Depending on the molecular mass of the protein of interest, the time for 
transfer was different (> 150 kDa = over-night, 30 V at 4°C/ < 15 0 kDa = 1 h, 60V at 4°C). 
Membranes were blocked for 1 h with 5% milk /TBS. Antibodies were diluted in 5% 
milk/TBS. Primary antibody detection was achieved by enhanced chemiluminescence using a 
corresponding horseradish peroxidase conjugated second antibody, according to the 
manufacturer’s protocol (Amersham, Freiburg, Germany).
Statistical Analysis. Data were presented as the mean ± standard deviation (SD) of at least 
three independent experiments. The results were tested for significance using the two-sided 
unpaired Student’s t-test or the Wilcoxon-Mann-Withney-UTest.
Results were considered statistically significant when p < 0.05 (*) or highly significant 
p < 0.001 (**).
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Results:
In the last years, several reports indicate a differential role for NHEJ and HRR in recognizing 
and repairing DNA damages induced by low- and high-LET radiation [29, 36]. In NHEJ, after 
binding of the high-affine Ku70/Ku80 heterodimer to the free DNA ends [37-38], DNA-
dependent protein kinase catalytic subunit (DNA-PKcs) is recruited within a few seconds to the 
DSB site through its interaction with the Ku heterodimer and DNA, forming the synaptic 
complex. This is followed by its own autophosphorylation at several sites, the two more 
important being Serine-2056 (called the PQR cluster) and Threonine-2609 (called the ABCDE
cluster) [39].
To examine whether high-energy, low-LET proton irradiation (136 MeV) and photon 
irradiation have a different effect on DNA repair and particularly on DNA-PKcs 
phosphorylation, we compared the sensitivities of NSCLC A549 cells to proton and photon 
radiation.  We first determined formation of phospho-DNA-PKcs foci using specific antibodies 
directed against Ser-2056 and Thr-2609 loci. Interestingly, proton irradiation of A549 cells 
resulted in a reduced activation of DNA-PKcs at both Ser-2056 and Thr-2609 sites, in 
comparison to DNA-PKcs activation in response to photon irradiation (Fig 1A and B). 
These results indicated a differential activation and requirement of the Ku-dependent NHEJ 
DNA repair machinery in response to proton irradiation.
Therefore, we decided to investigate the radiosensitizing effect of the selective DNA-PKcs 
inhibitor NU7026 in combination with either type of ionizing radiation [40]. This compound 
reportedly inhibits the PI3-kinase DNA-PKcs with improved selectivity over the ATM and 
ATR kinases by interfering with the Ser-2056 autophosphorylation site, but not with 
phosphorylation at Thr-2609, which is ATM-mediated. As expected, NU7026 sensitized A549 
cells for both types of irradiation, but interestingly to a much higher extent for photon 
irradiation. The DMF10 was significantly increased after photon irradiation, as compared to 
proton, with a DMF10 of 1.91±0.05 and 1.49±0.06, respectively (Fig 1C). 
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Figure 1. Radiosensitizing effect of NU7026 on A549 cells. Phosphorylation of DNA-PKcs at 
the Ser-2056 (A) and Thr-2609 (B) cluster sites in response to 1Gy of low-LET proton and 
photon irradiation. (C) Effect of cellular pretreatment with the selective DNA-PKcs inhibitor 
NU7026 on A549 cells. Cells were incubated for 1 hour with 10μM NU7026 in DMSO 
followed by photon and proton irradiation. Kinetics of JH2AX (D) and pDNA-PK (Thr-2609) 
(E) foci removal after 1Gy of proton and photon irradiation. Cells were treated 1hour prior to 
irradiation and fixed at the indicated time points.
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NU7026 did not further sensitized A549 cells pretransfected with siRNA against DNA-PKcs 
(siDNA-PKcs-A549) supporting the kinase selectivity of the inhibitor (S2B and S2C).  
The amount of DNA damage left unrepaired or misrepaired is a strong determinant of the 
outcome of ionizing radiation [41-42]. Therefore, we analyzed the levels of several DNA damage 
markers over a 24 hour time course in response to 1Gy of proton and photon radiation. 
Treatment of A549 cells with 1Gy of both photon and proton radiation resulted in the same 
amount of initial JH2AX and 53BP1-foci (S3). Likewise, removal of these foci over time was 
similar in response to both types of irradiation. As expected, cellular pretreatment with 
NU7026 strongly delayed JH2AX -foci removal after photon radiation, but surprisingly the time 
course of JH2AX -foci after proton irradiation was only minimally affected (Fig 1D). The same 
foci removal pattern was observed with 53BP1-foci (S4). To exclude a possible involvement of 
a differential cell cycle arrest in response to photon and proton irradiation, cell cycle analysis 
was performed 18 hours after irradiation with 5 Gy. Cell cycle arrest profiles after both proton 
and photon irradiation were identical, with most of irradiated cells in G2 (S5). Pretreatment of 
the cells with NU7026 further increased the amount of cells in G2-arrest, but again no 
difference was observed between photon and proton irradiation (S2D).
To complement the experiments performed with the small molecular inhibitor of DNA-PKcs, 
we investigated the effect of downregulating the NHEJ-factor DNA-PKcs in A549 cells. Cells 
were transfected with either control-siRNA (siLuc) or siRNA targeting the DNA-PK catalytic 
subunit (Fig 2A). As expected, downregulation of DNA-PKcs also rendered A549 cells more 
sensitive to ionizing radiation, but interestingly and in comparison to pretreatment with 
NU7026, we observed a reduction of clonogenic survival in DNA-PKcs-depleted cells to the 
same extent for both types of ionizing radiation (RBE10=0.94±0.07). The kinetics of JH2AX-
focus removal was also equal after photon and proton irradiation in DNA-PKcs-knockdown 
cells (Fig 2B), even though strongly delayed in comparison to siLuc-treated cells. This can be 
due to the fact that in cells with compromised NHEJ, HRR is the only active pathway and 
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usually DSB repair mediated by HRR is a slow process. RPA32-foci resolution analysis 
showed that siDNA-PKcs-transfected cells had a much slower activation of HRR, compared to 
control cells (S6). 
NU7026 treatment inhibits autophosphorylation at the Ser-2056 site, but it does not alter the 
phosphorylation at the Thr-2609 site (ABCDE cluster). Therefore, we further analyzed Thr-
2609 phosphorylation in response to the DNA-PKcs inhibitor. Similar to JH2AX and 53BP1, we 
observed a strong delay in pDNA-PKcs (Thr-2609)-foci removal after photon radiation, but the 
time course of pDNA-PKcs (Thr-2609)-foci after proton irradiation was only minimally 
affected (Fig. 1E). It is known that inhibition of the DNA-PK catalytic by NU7026 subunit not 
only leads to a complete blockade of NHEJ, but also of the HRR pathway [43].
Figure 2. Comparison of low-LET proton and photon radiation-induced cell killing in 
DNA-PKcs-knockdown A549 cells. (A) DNA-PKcs protein levels of siDNA-PKcs-treated 
A549 cells, determined at the indicated time points and clonogenic cell survival of proton- and
photon-irradiated cell lines either treated with control siRNA (siLuc) or siRNA against DNA-
PKcs (siDNA-PKcs). Points represent mean ±SD. (B) Kinetics of JH2AX-foci removal after 
1Gy of proton and photon irradiation in siLuc- and siDNA-PKcs-treated cells.
The autophosphorylation step at Ser-2056 is necessary to promote dissociation of the catalytic 
subunit from the DNA damage site. Inhibition by NU7026 does not allow enzyme dissociation 
to effectively take place by preventing this step, therefore inhibiting not only further repair by 
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NHEJ, but also MRN complex, and thus HRR, to promote repair. We assumed that the delay 
observed in JH2AX-foci repair in NU7026-pretreated cells after photon irradiation would be 
caused by the DNA-PKcs stuck to DNA damage site, preventing efficient repair by NHEJ and 
HRR. In contrast, we reasoned that the reduced activation of DNA-PKcs after proton-induced 
DNA damage, as measured by Ser-2056-foci, would result in a reduced blockade of the DNA 
damage site by NU7026. This would allow HRR or alternative-EJ to properly repair DNA 
damage. To eventually detect a differential HRR activation, we analyzed RPA32-foci 
formation, a known marker for HRR, in absence and presence of NU726 (Fig. 3A and 3B). We 
observed a time-dependent increase of RPA32-foci formation in these cells 1 hour and 4 hour 
after photon ionizing radiation. DNA-PKcs inhibition by NU7026 strongly reduced RPA32-
foci formation in response to photon irradiation, with only about 35% of foci detectable 4 hour 
after photon radiation. Proton irradiation induced similar amount of RPA32 foci compared to 
photon radiation, however foci formation in response to proton irradiation was not affected by 
cellular pretreatment with the DNA-PKcs inhibitor.
Overall, these results indicate a differential sensitivity to DNA-PKcs inhibition with NU7026 
and DNA-PKcs-knockdown in response to photon and proton radiation, respectively. To 
confirm our results in an additional cell system, we investigated cell survival and the kinetics of 
JH2AX-focus removal in the DNA-PKcs-deficient cells M059J and their proficient, isogenic 
counterpart cells, M059K (Fig. 4A and Table 1 and 2) [44]. Similarly to DNA-PKcs-
downregulated A549 cells, the DNA-PKcs-deficient cells M059J were equally sensitive to 
proton and photon radiation (RBE10=0.88±0.05) and the kinetics of JH2AX-focus removal was 
also equal after photon and proton irradiation in DNA-PKcs-deficient cells. Treatment of the 
DNA-PKcs proficient cells M059K with NU7026 resulted in a stronger radiosensitizing effect 
after photon radiation, compared to proton radiation, with a DMF10 of 1.49±0.02 and 1.2±0.11, 
respectively (Fig. 4B and Table 2).
61
In CHO cells, we have previously demonstrated a differential quality of DNA damage by 
proton- versus photon-irradiation with a specific requirement for homologous recombination 
for DNA repair and enhanced cell survival in response to proton irradiation [45]. We reasoned 
that, in a HRR-deficient system, the reduced dependence on NHEJ repair after proton radiation 
would result in a complete abrogation of DSB repair, enhancing proton over photon 
radiosensitisation. 
Figure 3. Analysis of RPA32 recruitment in A549 cells pretreated with NU7026. (A)
RPA32 foci were determined at 1 hour and 4 hour after radiation with 10Gy. Cells were co-
stained for Cyclin-A2 to identify S/G2-phase cells. (B) Representative pictures of RPA32 foci.
We first analyzed RAD51- and RPA32-foci formation in response to proton and photon 
irradiation, two major components of the HRR pathway, and did not observe any quantitative 
difference in response to the two types of ionizing radiation (S1A and S1B). To probe the 
enhanced sensitivity of HRR-mutated cells, we downregulated the key HRR-recombinase RAD51
in A549 cells by siRNA targeting RAD51 (Fig. 5A). A549 cells with siRNA-downregulated 
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RAD51 (siRAD51-A549) were markedly hypersensitive to proton radiation (RBE10 of 1.27±0.08 
for the RAD51-depleted cells vs RBE10 of 1.±0.04 for the siLuc-transfected cells). To confirm 
enhanced sensitivity of HRR-mutated cells to proton radiation, we investigated cell survival in the 
BRCA2-deficient cells PEO1 and their wild-type, isogenic counterpart cells PEO4 in response to 
both types of ionizing radiation (S7A) [46]. Both PEO4 and PEO1 cells were more sensitive to 
proton than to photon-irradiation, but the BRCA2-deficient cells PEO1 were markedly more 
sensitive to proton-irradiation (RBE10 of 1.08±0.06 for PEO4 vs RBE10 of 1.2±0.02 for PEO1 
cells).  To further exclude any cell cycle-related effects, we analyzed the time course of cell cycle 
distribution after both types of irradiation. Both PEO4 and PEO1 cells experienced a G2-arrest
already after 12 hours and up to 48 hours after radiation, with no significant difference between 
proton and photon irradiation (S7B).
Direct pharmacological targeting of the DNA repair pathways, and particularly of the HRR 
pathway, has proven to be unsuccessful in the past years, mostly due to the lack of druggable 
target proteins. Interestingly though, several chemotherapeutic agents exists, which originally 
were designed to target unrelated biological processes, that eventually downregulate the protein 
level of RAD51. Although through different molecular mechanisms, cellular pretreatment with the 
broad-range histone deacetylase inhibitor SAHA (Vorinostat) and the selective Bcr-Abl Tyrosine 
kinase inhibitor Imatinib Mesylate (Gleevec) lead to downregulation of RAD51, and both 
clinically relevant agents sensitize for ionizing radiation in vitro and also in vivo [47-53]. Due to the 
essential role of the RAD51 recombinase and the fact that it is often overexpressed in several 
cancer types, RAD51 is an attractive target for tumor-selective inhibitors. Based on our previous 
results, which showed a strong dependence on HRR to repair proton-induced damages, we tested
if the histone deacetylase inhibitor SAHA would lead to an increased efficacy in combination with 
proton radiation in comparison to photon radiation. Continuous exposure with 2μM SAHA for 24 
hours was sufficient to reduce RAD51 levels down to approximately 10 % of its basal level, but 
without any effect on Ku80 or DNA-PKcs protein levels (Fig. 6A). 
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Pretreatment of A549 cells radiosensitized only mildly to photon irradiation, whereas 
radiosensitization to proton irradiation was much stronger (DMF10 of 1.11±0.07 vs. 1.45±0.15,
Fig. 6 and Table 2).
Histone acetylation has an important role in the recruitment of DNA repair factors at the DSB site. 
Therefore, we investigate the effect of cellular pretreatment with SAHA on JH2AX and DNA-PKcs 
(Thr-2609) foci formation after both proton and photon irradiation (Fig. 6C). Similar to the results 
obtained in RAD51-knockdown cells, JH2AX foci removal was strongly delayed after proton 
irradiation, but only minimally after photon irradiation. In contrast, pDNA-PKcs (Thr-2609) foci
removal was almost identical after both types of irradiation.
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Figure 4. Clonogenic survival and DSB repair in cells pretreated with NU7026 or DNA-
PKcs deficiency. Clonogenic survival of DNA-PKcs-proficient (M059K) and DNA-PKcs-
deficient (M059J) cells in response to low-LET proton and photon radiation (A) and DSB 
repair by JH2AX -foci removal (B). Clonogenic survival of M059K cells pretreated with 
18&DQGȖ+$;-foci removal (D). M059K cells were incubated with 10μM NU7026 
in DMSO for 1 hour prior to radiation.
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Discussion:
In the present study we have investigated the role and differential requirement of the two major 
repair pathways, HRR and NHEJ, in response to DSB induced by photon and proton irradiation 
in a human cancer cells. We previously demonstrated that proliferating cells lacking HRR were 
more sensitive to proton irradiation than photon irradiation. In contrast, lack of NHEJ did not 
result in hypersensitivity towards proton-irradiation [45].
In our human cell system studied, depletion of DNA-PKcs by siRNA treatment in A549 cells or 
genetic deficiency in M059J cells rendered cells more sensitive than their DNA-PKcs proficient
counterpart, but they did not display increased sensitivity toward proton radiation. A549 cells 
depleted of DNA-PKcs showed increased HRR levels after irradiation, as detected by RPA32
recruitment. RPA32-foci occurred mainly in Cyclin-A positive cells, compatible with an S/G2-
arrest in DNA-PKcs-compromised cells [54].
Figure 5. Low-LET proton and photon radiation-induced cell killing in RAD51-knockout 
A549 cells. (A) RAD51 protein levels of siRAD51-treated A549 cells, determined at the 
indicated time points and clonogenic cell survival of proton- and photon-irradiated cell lines 
either treated with control siRNA (siLuc) or siRNA against RAD51. Points represent mean 
±SD. (B) Kinetics of JH2AX-foci removal after 1Gy of proton and photon irradiation in siLuc-
and siRAD51-treated cells.
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We have now demonstrated that DNA-PKcs activation is strongly hampered in response to 
proton irradiation compared to photon irradiation. Furthermore, selective inhibition of the 
catalytic subunit of the kinase by NU7026 strongly radiosensitized cells to photon radiation, but 
to much a less extent to photon radiation. JH2AX- and 53BP1-foci resolution analysis matched
the survival data. Interestingly, in DNA-PKcs-deficient cells we observed a strong delay in 
JH2AX-foci resolution after both types of radiation. In contrast, when the enzyme was present 
but its catalytic activity inhibited, the strong delay in JH2AX-foci resolution was observed after 
photon, but not proton irradiation. The reason may rely in the fact that cells with absent DNA-
PKcs primarily depend on HRR to repair DNA damage. ATM is expressed at low levels in 
DNA-PKcs-null cells, but restored to wild-type level in cells expressing a kinase-death form of 
DNA-PKcs [59]. Therefore, DNA-PKcs-null cells or where the enzyme has been downregulated 
by siRNA would show a strongly hampered JH2AX-foci resolution, which is strongly ATM 
dependent. Furthermore, pathway oversaturation may further slowdown the repair process. On 
the contrary, enzyme inhibition would result in a delay of JH2AX-foci resolution after photon 
radiation, because DNA-PKcs would be stuck at the DSB site not allowing HRR other than 
NHEJ to promote repair. Because DNA-PKcs is much less involved in the repair of proton-
induced damages, its inhibition would not particularly affect HRR and its ability to promote 
DNA-damage repair after proton irradiation. This would translate in the fast JH2AX-foci 
resolution observed after proton radiation in cells pretreated with NU7026, but not where 
DNA-PKcs is missing. It has been reported that an alternative form of end joining can repair 
damages, independently of Ku70/Ku80 or DNA-PKcs [21, 55]. This pathway mainly requires 
PARP1 and Ligases 1 and 3 to repair DSBs. Wang et al. [36] showed that PARP1-dependent EJ 
is not inhibited by high-LET radiation. Despite this, we cannot completely exclude an 
involvement of this pathway in repairing complex, proton-induced damages.
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In our study, A549 cells depleted of RAD51 or treated with the chemotherapeutic agent SAHA
were significantly more sensitive to proton radiation than photon radiation. These results point 
towards an enhanced cellular dependence on HRR to repair proton-induced DNA damages.
Figure 6. Effect of SAHA (Vorinostat) in A549 cells. (A) Levels of DSB-repair proteins in 
A549 cells pretreated with SAHA. Cells were incubated with SAHA at the indicated 
concentrations, irradiated (either mock or 5Gy photon) and cell lysates prepared 24 hours 
thereafter. (B) Clonogenic survival of A549 cells pretreated with SAHA. Cells were incubated 
for 24 hour with 2μM SAHA, followed by radiation at the indicated doses. Points represent 
mean ±SD. (C) Quantification of initial and residual JH2AX and pDNA-PKcs (Thr-2609) foci 
after 1Gy of proton and photon irradiation.
ATM kinase plays a key role in DSB recognition and signaling [56, 57]. ATM is essential in 
promoting HRR through DNA-PKcs [58]. Therefore, inhibition of ATM may results in an 
increased sensitivity to proton radiation. In A549 cells pretreated with KU-60019, a potent and 
selective ATM inhibitor, a strong radiosensitizing response was observed, with higher DEF10
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values after proton irradiation, compared to photon irradiation (data not shown). Because of the 
broad effects of the ATM kinase on the cells, we cannot exclude DSB repair-unrelated effects, 
as for example p53-dependent effects, to be partially responsible. In conclusion, taken together 
our results suggest a differential role of NHEJ factors in the recognition and repair of proton-
induced DNA damage. In our study, we have shown that NHEJ, but not HRR is inhibited by 
high energy, low-LET proton radiation, as depicted by the RBE10 values of DNA-PKcs-
knockdown cells and RAD51-knockdown cells (respectively 0.94±0.07 and 1.27±0.08 vs. 
1±0.04 for wild-type). The reason may rely in the inability of DNA-PKcs to fully promote 
NHEJ repair of complex, proton radiation-induced DNA damage; therefore leading to a 
situation in which HRR becomes the main repair pathway available. Consequently, cells with 
reduced or absent HRR are highly susceptible to proton-induced complex damages. 
To further develop and exploit novel combined treatment options with proton irradiation, new 
chemotherapeutic agents have to be developed. We have shown that the histone deacetylase 
inhibitor SAHA, through its effect on RAD51 protein levels, can lead to an increased 
radiosensitivity in combination with proton therapy compared to photon therapy. Due to the 
broad and unspecific effects of these substances on the cell, their specificity and efficacy is 
strongly cell-type dependent. Recently, selective inhibitors of the RAD51 protein have been 
developed, like RI-1 and IBR2, widening the spectrum of potential agents which could be used 
in combination with proton irradiation [51-53]. On the contrary, we have shown that inhibition of 
DNA-PKcs by NU7026 potently radiosensitize cells in combination with conventional, photon 
radiation but it is not particularly effective in combination with proton radiation. 
Altogether, this may translate in the future in a clinical advantage for proton therapy over the 
conventionally used, photon-based radiotherapy for selected patients carrying specific 
mutations or new combined treatment approaches using selective HRR inhibitors, whereas 
patients treated with conventional, photon-based radiotherapy should strongly profit from 
DNA-PKcs inhibitors.
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Table 1 Relative biological effectiveness (RBE) values at 10% clonogenic survival after proton and 
photon irradiation
Cell line Genetic deficiency RBE10
A549 wild type 1 ± 0.04
 
A549 siDNA-PKcs DNAെ PKcs 0.94 ± 0.07
 
A549 siRAD51 RAD51 1.27 ± 0.08
 
M059K wild type 1.02 ± 0.11
 
M059J DNAെ PKcs 0.88 ± 0.05
 
PEO4 wild type 1.08 ± 0.06
 
PEO1 BRCA2 1.20 ± 0.02
Table 2 Dose modifying factors (DMF) values at 10% clonogenic survival after proton and photon 
irradiation
Cell line inhibitor DMF10 Photon DMF10 Proton
A549 
 
NU7026 [ͳͲɊ] 1.91 ± 0.05 1.49 ± 0.06
A549+siDNA-PKcs 
 
NU7026 [ͳͲɊ] 1 ± 0.07 -
M059K 
 
NU7026 [ͳͲɊ] 1.49 ± 0.02 1.2 ± 0.11
A549 
 
KU60019 [ͳɊ] 2.32 ± 0.07 3.19 ± 0.34
A549 SAHA [ʹɊ] 1.11 ± 0.07 1.45 ± 0.15
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Supplementary procedures:
Proliferation Assay. Growth inhibition was measured using the Thiazoyl blue tetrazolium 
bromide assay. 24 h prior to drug treatment, cells were plated at a density of 500 cells/well in a 
96-wells plate. Cells were then treated with different concentration of NU7026 and incubated 
for 72 h. Thiazoyl blue tetrazolium bromide solution (Sigma–Aldrich) was then added for 4 
hours followed by optical density measurement in a 96-well plate reader at 750 nm.
Cell cycle. Cells were SUHWUHDWHGZLWKȝ018IRUKRXU before being either treated 
with mock or 5Gy radiation. 30 min before the desired time point after irradiation, 
Bromodeoxy-uridine (10ȝM) was added to the growing cell. Cells were then washed, 
harvested, and fixed with ice-cold ethanol. Cells were then co-stained with PI (Sigma–Aldrich, 
Germany) and anti- Bromodeoxy-uridine Fluorescine antibody (Roche Diagnostic GmbH, 
Germany) and analyzed by flow cytometry (FACS Canto II, BD Biosciences). Cell cycle
distribution was analyzed using the FlowJo 7 software package (FlowJo LLC, Oregon, USA).
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Supplementary figure 1. Analysis of RPA32 and RAD51 recruitment in A549 cells. (A)
RAD51 and RPA32 foci were determined at 1 hour, 4 hours and 24 hours after radiation with 
10Gy. Cells were co-stained for Cyclin-A2 to identify S/G2-phase cells.
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Supplementary figure 2. NU7026 pretreatment strongly affects DNA-PKcs-proficient, but 
not DNA-PKcs-deficient cells. (A) NU7026 pretreatment potently inhibits 
autophosphorylation of DNA-PKcs at Ser-2056 site, but not at Thr-2609 site. (B) Clonogenic 
cell survival of photon-irradiated cell lines pretreated with NU7026 and with siRNA against 
DNA-PKcs (siDNA-PKcs). Points represent mean ±SD. Cells were incubated for 1 hour with 
10μM NU7026 in DMSO followed by photon and proton irradiation. (C) SiLuc-treated and 
siDNA-PKcs-treated A549 cells were incubated for 72 hours with increasing concentrations of 
NU7026, and after 72 hours absorption was measured by MTT-assay (D) cell cycle distribution 
analysis of A549 cells in presence and absence of NU7026. Cells were fixed 18 hours after 
irradiation with 5Gy of either photons or protons, double-stained for Propidium Iodide and anti-
BrdU and cell cycle distribution measured by FACS.
79
Supplementary figure 3. JH2AX- and 53BP1-foci resolution profile in A549 cells. A549 cells 
were irradiated with either 1Gy (JH2AX) or 5Gy (53BP1) of both types of ionizing radiation and 
fixed at the indicated time points.
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Supplementary figure 4. 53BP1-foci resolution profile in A549 cells pretreated with 
NU7026. A549 cells were incubated for 1 hour with 10μM NU7026 in DMSO followed by
irradiation with 5Gy of proton and photon irradiation and fixed at the indicated time points.
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Supplementary figure 5. Cell cycle distribution analysis in A549 cells. A549 cells were 
fixed at the indicated time points after irradiation with 5Gy of either photons or protons, 
double-stained for Propidium Iodide and anti-BrdU and cell cycle distribution measured by 
FACS.
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Supplementary figure 6. Analysis of RPA32  recruitment in A549 cells treated with 
siRNA against Luciferase or DNA-PKcs. (A) RPA32 foci were determined at 1 hour, 4 hours 
and 24 hours after radiation with 10Gy. Cells were co-stained for Cyclin-A2 to identify S/G2-
phase cells.
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Supplementary figure 7. Comparison of low-LET proton and photon radiation-induced 
cell killing in BRCA2-deficient PEO1 cells and BRCA2-proficient PEO4 cells.
(A) Clonogenic cell survival of proton- and photon-irradiated PEO4 and PEO1 cell lines. Points 
represent mean ±SD. (B) cell cycle distribution analysis of PEO4 and PEO1 cells. Cells were 
fixed at the indicated time points after irradiation with 5Gy of either photons or protons, 
double-stained for Propidium Iodide and anti-BrdU and cell cycle distribution measured by 
FACS.
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SUMMARY
Radiotherapy induces DNA damage and cell death,
but recent data suggest that concomitant immune
stimulation is an integral part of the therapeutic ac-
tion of ionizing radiation. It is poorly understood
how radiotherapy supports tumor-specific immunity.
Here we report that radiotherapy induced tumor cell
death and transiently activated complement both in
murine and human tumors. The local production of
pro-inflammatory anaphylatoxins C3a and C5a was
crucial to the tumor response to radiotherapy and
concomitant stimulation of tumor-specific immunity.
Dexamethasone, a drug frequently given during
radiotherapy, limited complement activation and
the anti-tumor effects of the immune system. Overall,
our findings indicate that anaphylatoxins are key
players in radiotherapy-induced tumor-specific im-
munity and the ensuing clinical responses.
INTRODUCTION
It is now well accepted that the immune system can control
tumors (Schreiber et al., 2011). For example, there is a positive
correlation between tumor infiltration by effector T cells and sur-
vival (Fridman et al., 2011), and the risk to develop cancer is
increased in immunosuppressed patients (Dunn et al., 2006),
and dormant tumors are kept in check by the adaptive immune
system (Koebel et al., 2007). Despite the presence of tumor-spe-
cific immunity in many cancer patients, complete rejection of
clinically apparent tumors by the immune system is rare, pre-
sumably due to mechanisms that locally inhibit tumor-specific
protective immunity (Schreiber et al., 2011). The clinical efficacy
of so-called checkpoint blockade, antibodies that target co-
inhibitory molecules such as CTLA-4 or PD-1, underscores the
potential of tumor-specific immunity (McDermott and Atkins,
2013; Mellman et al., 2011).
Radiotherapy is a standard treatment for cancer that induces
irreversible damage to DNA, thus targeting mainly rapidly
dividing cells (Prise and O’Sullivan, 2009). Although radiotherapy
was considered an immunosuppressive treatment (Merrick et al.,
2005), there is accumulating evidence that it supports local
tumor-specific immunity (Apetoh et al., 2007; Matsumura et al.,
2008) and, in fact, that immune activation might be an integral
part of radiotherapy (Formenti and Demaria, 2012; Gupta et al.,
2012; Ma et al., 2010; Sharma et al., 2013). This is clinically rele-
vant because tumor-specific immunity can target dormant
lesions (Postow et al., 2012) that are presumably insensitive to
radiotherapy. Several studies have addressed the question
of how radiotherapy supports tumor-specific immunity, and
various factors were suggested, including increased presence
or function of tumor-infiltrating CD8+ T cells (Gupta et al.,
2012; Lugade et al., 2005; Takeshima et al., 2010), type I inter-
feron (IFN) resulting in enhanced antigen cross-presentation
(Burnette et al., 2011; Fuertes et al., 2011), increased expression
of major histocompatibility complex (MHC) class I glycoproteins
and tumor-associated antigens (Reits et al., 2006), and matura-
tion of tumor-associated dendritic cells (DCs) (Gupta et al.,
2012), however, an initial event has not been identified.
We therefore performed an unbiased analysis of immune
response-related transcripts after radiotherapy in a preclinical
model and noted a strong and transient upregulation of genes
associated with the complement pathway. This was unexpected
as complement was described as tumor-promoting (Markiewski
et al., 2008; Pio et al., 2014), although other studies have shown
that complement supports adaptive immunity (Farrar and Sacks,
2014; Kopf et al., 2002; Lalli et al., 2007; Liszewski et al., 2013;
Strainic et al., 2013). Becauseweobserved similar changes in hu-
man tumor samples, we investigated the impact of complement
on the anti-tumor immune response following radiotherapy.
RESULTS
Radiotherapy Induces Complement Activation
To identify the initial event in radiotherapy-induced tumor-spe-
cific immunity, we performed an unbiased analysis of immune
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response-related transcripts after radiotherapy. Local irradiation
with a single dose of 20 Gy significantly reduced progression of
B16F10-OVA tumors in C57BL/6 mice (Figures 1A and 1B).
Because transplantable mouse tumors only allow for a short
therapeutic window, radiotherapy must be applied as a single
high dose (Lugade et al., 2005). To dissect which pathways are
crucial to radiotherapy-induced stimulation of the immune
response, we quantified immune response-related transcripts
in tumors at different time points 4, 24, 96, and 168 hr after local
irradiation (Figures 1C and S1A). We observed an upregulation of
the complement system (represented in this panel only by C3)
and the inflammation cascade at 4 and 24 hr, whereas both path-
ways were downregulated at 96 and 168 hr after irradiation (Fig-
ure 1C). Because 20 Gymight be of limited clinical relevance, we
performed the same analysis 24 hr after irradiation with a single
dose of 5 Gy and observed a similar transcriptional upregulation
(Figure S1B).
C3 is the central protein of the complement cascade at which
all three known pathways (classical, alternative, and lectin)
converge and which gives rise to various bioactive components
(Markiewski and Lambris, 2009). Because complement might be
tumor-promoting (Markiewski et al., 2008; Markiewski and
Lambris, 2009; Pio et al., 2014), we investigated whether radio-
therapy-induced upregulation of complement supported or
antagonized the efficacy of this treatment. We first quantified
four different complement-related transcripts in response to
radiotherapy: C3, C1s, Masp2 and Cfb. The classical and alter-
native pathways are the main pathways induced by radiotherapy
on the transcriptional level (Figures 1D and S1C). Because
NF-kB, JAK, and STAT transcriptional pathways (Chen et al.,
2011; Fukuoka et al., 2013; Hasegawa et al., 2014; Huang
et al., 2002), as well as S100 calcium-binding proteins A8 and
A9 (S100A8, S100A9) (Schonthaler et al., 2013) are involved in
the transcription of complement factors, we analyzed such path-
ways by immuno-blot and found an increased production of
STAT 1, STAT 2, STAT 3, NF-kB, and JAK and increased phos-
phorylation of STAT 2, STAT3, and JAK (Figure S1D) 4 hr, but not
Figure 1. Radiotherapy Results in Transient Upregulation and Acti-
vation of Complement in Murine and Human Tumors
(A–E) Mice were injected with B16F10-OVA cells and received radiotherapy
12 days later. (A) Tumor growth curves, (n = 5 mice per group). Representative
data from three independent experiments are shown. (B) Tumor weight
(day 20). (C) Heatmaps of transcripts were created using the log2 value of
the fold increase of irradiated compared to untreated tumors at different
time points after radiotherapy, (n = 6 mice per time point). Representative data
from two independent experiments are shown. (D) Relative expression of C3
mRNA in tumors at different time points after radiotherapy. The data show the
mean ± SD of triplicates from three independent analyses. Radiotherapy, RT.
(E) Immunofluorescence of irradiated and untreated tumors. Sections were
stained with an antibody recognizing C3b, iC3b, and C3c (green), CD31 for
blood vessels (red), and DAPI (blue). Scale bars represent 100 mm (n = 6 mice
per group). Representative images from two independent experiments are
shown.
(F and G) Patient biopsies were collected before and 24–36 hr after radio-
therapy (1.5–2 Gy; upper panel) or only after radiotherapy (lower panel).
Quantification of complement transcripts by qPCR. Data show the mean ± SD
of triplicates from two independent analyses (upper panel). (G) Quantification
of C3-a and -b subunits by immuno-blot.
Data are shown as mean ± SD. *p < 0.05, **p < 0.005, ***p < 0.0005 by Stu-
dent’s t test (A, B, and F) or two-way ANOVAwith the Bonferroni correction (D).
See also Figure S1.
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24 hr, after radiotherapy. Transcripts of S100a8 and S100a9
were unaffected (data not shown).
To show that these translated in different complement factor
amounts, we analyzed the tumors prior to and after radiotherapy
by immunofluorescence (Figure S1E) and by immuno-blot (Fig-
ure S1F). Because C1q and Factor B are more abundant
compared to mannose-binding lectin C (MBL-C), these results
confirmed our qPCR data (Figure S1C). We analyzed the activa-
tion status of complement and found deposition of fragments
derived from C3 cleavage (C3b, iC3b, and C3c) 24 hr after radio-
therapy in the proximity of (green fluorescence) or associated
with (yellow fluorescence) blood vessels (Figure 1E). Similarly
to C3 cleavage products, we observed C1q and Factor B mainly
associated to blood vessels, whereas MBL-C showed a mark-
edly different pattern of deposition. We obtained similar results
using B16F10 cells, both at the transcriptional (data not shown)
and protein level (Figure S1G). We confirmed radiotherapy-
induced complement activation by immuno-blotting using an
antibody recognizing C3 plus its fragments C3b, C3c, and
C3dg (Figure S1H). Because deposition of C3b, iC3b, and C3c
was not detected at other time points besides 24 hr after radio-
therapy, this suggests that radiotherapy-induced complement
activation is a rapid and transient response.
We analyzed the expression of complement-related tran-
scripts and proteins in paired human tumors that were collected
before and 24–36 hr after a single, low dose of radiotherapy (1.5
or 2 Gy) and detected upregulated expression (Figure 1F) and
activation of complement (Figure 1G). To exclude that taking
the first biopsy prior to radiotherapy rather than radiotherapy
was responsible for complement activation, we analyzed addi-
tional four biopsies that were taken 24–36 hr after irradiation
with 1.5–2 Gy but without previous intervention. The amounts
of complement transcripts were comparable to those after radio-
therapy in the paired samples, excluding this option (Figure 1F).
Together, we found that radiotherapy induces transient, local
production, and activation of the classical and alternative com-
plement pathway in both human and murine tumors.
Therapeutic Efficacy of Radiotherapy Depends on C3a
and C5a
To investigate the impact of complement activation on therapeu-
tic efficacy, we applied radiotherapy to tumor-bearing C3/
mice. Because tumors grew more slowly in C3/ mice (Figures
2A and S2A) (Markiewski et al., 2008; Qing et al., 2012), C3/
and C57BL/6 mice were irradiated at two different time points,
i.e., 13 (Figure 2A) or 17 days (Figure S2B) after tumor injection.
Comparison of C57BL/6 mice irradiated at day 13 (Figure 2A, left
panel) with C3/ mice irradiated at day 17 (Figure S2B, right
panel) shows the response of tumors with a similar size (36–
40 mm2) at the time point of irradiation. Radiotherapy was not
efficient in C3/mice irrespective of the day of therapy (Figures
2A, S2A, and S2B), suggesting that complement activation is
crucial to efficacy.
Anaphylatoxins (C3a and C5a) modulate adaptive immunity
(Schmudde et al., 2013; Strainic et al., 2013). As we observed
higher local amounts of C3a and C5a (Figure S2C) and their
receptors (Figures S2D) upon radiotherapy, we investigated
their role in the response to radiotherapy using C3ar1/,
C5ar1/, and C3ar1/C5ar1/ mice. As these mice were
only available on a BALB/c background, we confirmed that
radiotherapy resulted in local complement activation (Fig-
ure S2E), showing that radiotherapy-induced complement
activation is a general phenomenon independent of the strain
or tumor cell line used. Similar to C3/ mice, C5ar1/,
Figure 2. C3a and C5a Are Crucial to the Therapeutic Efficacy of
Radiotherapy
(A) Control and C3/mice were injected with B16F10-OVA cells and received
radiotherapy 13 days later. Growth curves, (n = 5 mice per group). Represen-
tative data from two independent experiments are shown. Radiotherapy, RT.
(B) BALB/c, C3ar1/, C5ar1/, and C3ar1/C5ar1/ were injected with
CT26 cells and received radiotherapy 13 days later. Tumor growth curves
(BALB/c n = 5 mice per group; C3ar1/, C5ar1/, and C3ar1/C5ar1/
n = 8mice per group). Representative data from two independent experiments
are shown.
(C) Mice were injected with B16F10-OVA cells and received radiotherapy
12 days later. SB290157 was administered at 2 mg/kg to block C3aR1 and
anti-C5aR1 mAb 20/70 or an isotype control at 0.6 mg/kg to block C5aR1
(administered every second day starting on day 12 until day 19). (n = 5mice per
group).
Data are shown as the mean ± SD. **p < 0.005, ***p < 0.0005, ****p < 0.00005
by two-way ANOVA with the Bonferroni correction. See also Figure S2.
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C3ar1/, and C3ar1/C5ar1/ mice showed no significant
impact of radiotherapy on tumor progression, whereas BALB/c
mice did (Figures 2B, 2C, and S2F). To avoid the issue of inherent
different tumor growth rates in various genetically ablated
strains, we blocked C3aR with an antagonist (C3aRA,
SB290157) or C5aR with a monoclonal antibody (20/70) (Baelder
et al., 2005) just before applying radiotherapy to tumor-bearing
C57BL/6 mice. This treatment blocked the improved antitumor
effect of radiotherapy (Figures 2D and S2G), which is in line
with the results observed in C3/, C3ar1/, C5ar1/, and
C3ar1/C5ar1/ mice. These data suggest that radiotherapy
induces the intratumoral generation of anaphylatoxins, which
are crucial to the therapeutic efficacy.
Radiotherapy-Induced Cell Death Locally Activates
Complement
Despite the fact that complement deposition was observed in
the vicinity of blood vessels, we failed to detect activated
complement in serum irrespective of whether mice received
radiotherapy or bore a tumor (Figure 4A). This excludes that
Figure 3. Radiotherapy-Induced Tumor
Cells Death Activates Complement
(A and B) B16F10-OVA cells were irradiated in vitro
with 20 Gy or left untreated. Serum from C57BL/6
or C3/ mice was added to the cultures immedi-
ately after irradiation and C3 cleavage products
were analyzed 4 and 24 hr later in the supernatants
by immuno-blot using a polyclonal anti-C3 anti-
body (n = 3 mice per group). Representative data
of two independent experiments are shown. (B)
Relative intensities were calculated using Bio1D
software. Radiotherapy, RT.
(C) Ultrastructural analysis of tumor response to
radiotherapy. B16F10-OVA tumors were isolated
from mice prior to and different times after radio-
therapy. Fixed tumor tissue was epon embedded
and analyzed by EM. Shown are images of tumor
tissues before (0 h), 1, 4, and 18 hr after radio-
therapy. Left column, overview; Right column,
zoom-in of region indicated in left image. Bar in-
dicates magnification. N, nucleus; M, mitochon-
drion; black arrow, cell boundaries; F, fat bodies;
C, collagen; *, melanosomes.
(D and E) B16F10-OVA cells were irradiated in vitro
with 20 Gy or left untreated. Serum from Rag1/
mice was added to the cultures immediately after
irradiation and C3 cleavage products were
analyzed as described in (A), (n = mice 3 per
group). (E) Relative intensities were calculated
using Bio1D software.
Data in (B) are shown as the mean ± SD. *p < 0.05,
**p < 0.005, by two-way ANOVA with the Bonfer-
roni correction.
radiotherapy or a local tumor results in
systemic activation of complement. Local
radiotherapy results in apoptosis (Wang,
2008), mitotic catastrophe, and necrosis
(Eriksson and Stigbrand, 2010), all of
which can be potent activators of comple-
ment (Basu et al., 2000; Kemper et al.,
2008; Markiewski and Lambris, 2007). We first evaluated the
possibility of direct complement activation by radiation and
exposed serum from C57BL/6 or C3/ mice in vitro to a single
dose of 20 Gy or left them untreated and analyzed sera 4 and
24 hr after irradiation by immuno-blot. We did not detect any sig-
nificant changes upon irradiation (data not shown). To investi-
gate whether irradiated tumor cells can activate complement,
we either or not exposed B16F10-OVA cells in vitro to a single
dose of 20 Gy. Immediately after irradiation, 10-fold diluted
serum from C57BL/6 mice or C3/ mice was added to irradi-
ated or untreated B16F10-OVA cells. Complement activation
was detected in the supernatants 24 hr after radiation. Because
the culture serum was from C3/mice, the complement should
have been derived from the tumor cells (Figures 3A and 3B).
To identify the mode of tumor cell death upon a single dose of
20 Gy, we performed electron microscopy (EM) on B16F10-OVA
tumors isolated at different time points after radiotherapy as indi-
cated (Figure 3C). The tissue isolated before radiation showed
normal nuclei, cell boundaries, intracellular organelles, and me-
lanosomes (the dark vesicular structures) illustrating healthy
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tumor tissue. Already 1 hr after radiation, the first signs of radia-
tion damagewere detected in the formof extensive vacuolization
of tumor cells with normal nuclei and cell boundaries. Already
4 hr after radiation, cell boundaries were dissolved and cellular
content fragmented. Mitochondrial structures (M) were swollen
and did not show normal cristae. This did not change any further
between 4 and 18 hr after radiotherapy. We did not observe any
nuclear fragmentation and apoptotic bodies; rather, the irradi-
ated tissue showedmarked fields of necrosis withmany intracel-
lular materials now entering the extracellular space.
Because immunoglobulin M (IgM) binds to necrotic cells,
which results in complement activation (Ciurana et al., 2004;
Quartier et al., 2005), we performed the experiment described
above using serum from Rag1/ mice. We observed reduced
complement activation in supernatants containing Rag1/
serum (Figures 3D and 3E), suggesting that IgM binding to
necrotic cells contributes to radiotherapy-induced complement
activation. This suggests that necrotic tumor cells express or
secrete factors that activate complement.
Microenvironmental Complement Is Produced by
Immune Cells
Hepatocytes are the main source of complement proteins,
but also extra-hepatic tissues and immune cells can produce
them (Farrar and Sacks, 2014; Kolev et al., 2014; Pio et al.,
2014; Strainic et al., 2008). To define the source of radio-
therapy-induced, tumor-associated complement, we generated
C3//WT, WT/C3/, WT/WT, and C3//C3/ bone
marrow chimeras. B16F10-OVA bearing chimeras received
radiotherapy or not and tumors were processed 24 hr later.
We detected high amounts of activated complement in
C3//WT and WT/WT mice and less in WT/C3/ mice.
The low amount of complement detected in irradiated tumors
in C3//C3/ mice is presumably tumor-derived (Figures
4B and 4C). This is in agreement with the detection of basal
expression of complement-related transcripts in cultured
B16F10-OVA tumor cells and an increased release of comple-
ment proteins by B16F10-OVA cells upon in vitro irradiation
(Figures 3A, 3B, and 4C). These experiments suggest that a large
fraction of radiotherapy-induced, tumor-associated comple-
ment is produced systemically, with a contribution of local pro-
duction by immune and tumor cells.
Radiotherapy-Induced DC Activation Depends on
Anaphylatoxins
Because several immune cells can produce complement com-
ponents (Li et al., 2007; Strainic et al., 2008), which are essential
for full functional development of antigen-presenting cells (APCs)
and T cell responses (Peng et al., 2009; Strainic et al., 2008), we
investigated which immune cells produce complement or ana-
phylatoxin receptors in irradiated tumors. We sorted DCs,
CD8+ T cells, CD4+ T cells, and other CD45.2+ cells from irradi-
ated and untreated tumors (Figure S3A) and quantified the com-
plement factor related transcripts C3, C1s, Masp2, Cfb, C3ar1,
and C5ar1 by qPCR. Because the impact of radiotherapy on
tumor-associated DCs and T cells is apparent after 24 hr and
5–7 days, respectively (Gupta et al., 2012), we harvested tumors
at these time points after radiotherapy exposure. DCs showed
increased expression of C3, Cfb, C3ar1, and C5ar1 24 hr and
168 hr after radiotherapy (Figure 5A). We failed to detect expres-
sion of C1s and Masp2 transcripts by DCs. The other CD45.2+
cells (mainly containing macrophages) showed upregulated
C5ar1 but no other complement-related transcripts at 168 hr
after radiotherapy (Figure S3B).
Recent studies demonstrate that complement factors, in
particular anaphylatoxins, directly bind to their receptors on
DCs thereby supporting their maturation, which then induces
T cell effector activation (Li et al., 2007; Peng et al., 2009; Strainic
et al., 2008). Furthermore, we showed previously that radio-
therapy-induced activation of tumor-associated dendritic cells
locally supports the function of tumor-specific CD8+ T cells
Figure 4. Radiotherapy-Induced, Tumor-Associated Complement Is
Mainly Liver-Derived but Partially Produced Locally
(A) Measurement of complement activation by immuno-blot in pooled blood
samples from naive, tumor-bearing, and irradiated tumor-bearing mice (24 hr
after radiotherapy), (n = 3 mice per group). C3 cleavage products were de-
tected using a polyclonal anti-C3 antibody. Radiotherapy, RT.
(B and C) Bone-marrow chimeras were injected with B16F10-OVA cells and
received radiotherapy 13 days later. Tumors were collected 24 hr after
radiotherapy (B) Immunofluorescence of irradiated and untreated tumors.
Sections were stained with an antibody recognizing C3b, iC3b, and C3c
(green), CD31 for blood vessels (red) and DAPI (blue). Scale bars represent
100 mm. Representative images from two independent experiments are shown
(n = 4 mice per group). (C) C3 cleavage products in the tumors were analyzed
by immuno-blot using a polyclonal anti-C3 antibody, (n = 3 mice per group).
Relative expression measured by Bio-1D software. Representative data from
two independent experiments are shown.
Data in (C) are shown as the mean ± SD. *p < 0.05, ***p < 0.0005 by two-way
ANOVA with the Bonferroni correction.
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and that this is crucial to therapeutic efficacy (Gupta et al., 2012).
Therefore, we analyzed the activation status of DCs upon irradi-
ation in C3/ and in C57BL/6 mice 2 days after radiotherapy.
DCs were equally present in untreated and irradiated tumors of
complement-proficient and -deficient mice, however, DC activa-
tion as measured by surface expression of CD70 and CD86 (Kel-
ler et al., 2008) was observed only in irradiated C57BL/6, but not
in C3/ mice (Figure 5B). These results were confirmed using
C3ar1/, C5ar1/, and BALB/c mice (Figure 5C). Thus, radio-
therapy induces upregulation of anaphylatoxins, and their recep-
tors in tumor-associated DCs controls radiotherapy-induced DC
activation.
Radiotherapy-Induced CD8+ T Cell Activation Depends
on Anaphylatoxins
T cells express complement components and anaphylatoxin re-
ceptors that are critical to T cell co-stimulation (Liszewski et al.,
2013; Strainic et al., 2008). CD8+, but not CD4+ T, cells upregu-
lated C3 and the anaphylatoxin receptors slowly at 168 hr, but
not at 24 hr, after radiotherapy (Figures 6A and S3C), whereas
C1s andMasp2were undetectable. C5aR1 and C3aR1 signaling
during cognate interaction between DCs and CD4+ T cells pro-
motes IFN-g production (Liu et al., 2008) and counteracts the
development of FoxP3+ regulatory T cells (Strainic et al., 2013).
We therefore analyzed the impact of radiotherapy on expression
of Ifng and Foxp3 and observed a strong upregulation of
Ifng in CD8+ T cells 168 hr after the treatment (Figure 6A),
but no changes of Foxp3 within the CD4+ T cell compartment
(data not shown).
To investigate the in vivo relevance of those observations,
we analyzed the infiltrate in tumors from BALB/c and
C3ar1/C5ar1/ mice by flow cytometry 168 hr after radio-
therapy. Radiotherapy resulted in higher numbers of CD45.2+
and CD8+ T cells in tumors, which was independent of anaphy-
latoxins (Figure 6B). Radiotherapy had no effect on CD4+ T cell
numbers (Figures 6C and 6D). Therefore, it is unlikely that ana-
phylatoxins act as chemoattractants for T cells. We analyzed
the global IFN-g production by tumor-infiltrating CD8+ T cells
in situ. Therefore, we injected mice with Brefeldin A 4 hr
before euthanasia and measured intracellular IFN-g without
in vitro restimulation. IFN-g production by CD8+ T cells was
significantly increased in irradiated tumors in BALB/c, but not
C3ar1/C5ar1/ mice compared to untreated controls (Fig-
ures 6C, S4A, and S4B). This presumably involves anaphyla-
toxin-mediated DC maturation (Strainic et al., 2013), although a
direct activity of anaphylatoxins on CD8+ T cells cannot
be excluded. In agreement with earlier data (Strainic et al.,
2013), we observed higher numbers of FoxP3+ T cells in
C3ar1/C5ar1/ mice independent of radiotherapy (Figures
6D, S4C, and S4D). Flow cytometry results thus confirmed the
qPCR data on sorted cells (Figure 6A). We obtained similar
results using B16F10-OVA-bearing C57BL/6 mice in which
C3aR1 and C5aR1 were blocked (Figure S4E). A recent pub-
lication shows that blocking C3 improves the efficacy of fraction-
ated radiotherapy given as multiple daily fractions of 1.5 Gy
(Elvington et al., 2014), which is an apparent controversy with
our findings. We found that 53 1.5 Gy equally diminished tumor
growth as 13 20 Gy did. However, in contrast to a single high
dose, 53 1.5 Gy resulted in prolonged activation of complement
and did not support accumulation of CD8+ T cells nor their func-
tion in the tumor (Figures S4G–S4I).
To generate a complete immune cell profile related to
irradiation responses, we analyzed CD19+ B cells and found
low numbers (Figure S4F), regardless of radiotherapy or
blockade of C5aR1 and C3aR1. Tumors contained substantial
numbers of NK1.1+ cells that significantly increased upon
Figure 5. Radiotherapy Induces Upregula-
tion of Transcripts for Complement and
Anaphylatoxins Receptors by DCs and Is
Essential to Their Maturation
(A) Mice were injected with B16F10-OVA cells and
received radiotherapy 12 days later. DCs (CD45.2+
TCRb CD11c+ MHC-IIhigh gated on live singlets)
were sorted from untreated and irradiated tumors
24 and 168 hr after radiotherapy. Complement-
related transcripts were quantified by qPCR (n = 5
mice per group). Radiotherapy, RT.
(B) Control and C3/ mice were injected with
B16F10-OVA cells and received radiotherapy
12 days later. CD70 and CD86 expression on
tumor-associated DCs in irradiated (48 hr after
radiotherapy) and untreated tumors plotted as
geometric mean fluorescence intensity (gMFI).
(C) BALB/c, C3ar1/, and C5ar1/ mice were
injected with CT26 cells and received radiotherapy
12 days later. DCs were analyzed as described
in (B).
(B and C) Each symbol represents an individual
mouse. Pooled data from two independent ex-
periments are shown. Data are shown as the
mean ± SD. *p < 0.05, **p < 0.005, ***p < 0.0005 by
two-way ANOVA with the Bonferroni correction.
See also Figure S3.
772 Immunity 42, 767–777, April 21, 2015 ª2015 Elsevier Inc.
radiotherapy and seemed independent of anaphylatoxin recep-
tor blockade. We observed very low numbers of NKp46+ cells
that remained similar in all four groups (Figure S4F). Thus,
following a single dose of 20 Gy, the DC-CD8-arm of the im-
mune system appears to be selectively activated in irradiated
tumors, which is essential for tumor control and depends on
complement.
Dexamethasone (DEX) is a glucocorticoid with anti-inflamma-
tory and immunosuppressive properties (Auphan et al., 1995). In
addition, it inhibits the activation of complement (Engelman
et al., 1995; Packard and Weiler, 1983). Given the important
role of complement in promoting adaptive immunity and sup-
porting the efficacy of radiotherapy, we treated mice with DEX
starting 1 day before radiotherapy. DEX treatment significantly
reduced the extent of local complement activation (Figure 7A)
and importantly, also the efficacy of radiotherapy (Figures 7B
and 7C).
Thus, radiotherapy-induced, local production of anaphylatox-
ins is essential to activation of DCs and protective effector
function of CD8+ T cells in the tumor and as such to therapeutic
efficacy.
Figure 6. Radiotherapy Induces Upregulation of Transcripts for
Complement and Anaphylatoxins Receptors by CD8+ T Cells and
Supports Tumor-Specific Immunity
(A) C57BL/6 mice were injected with B16F10-OVA cells and received radio-
therapy 12 days later. CD8+ T cells (CD45.2+ TCRb+ CD8+ gated on live sin-
glets) were sorted from untreated and irradiated tumors 24 and 168 hr after
radiotherapy. Complement-related transcripts were quantified by qPCR (n = 5
mice per group). Radiotherapy, RT.
(B–D) BALB/c and C3ar1/C5ar1/ mice were injected with CT26 cells and
received radiotherapy 12 days later. Flow cytometric analysis was performed
7 days after radiotherapy. (B) The total number of infiltrating leukocytes
(CD45.2+), (C) CD8+ cells (left panel), and CD8+ T cells that produce IFN-g
in vivo (right panel), (D) CD4+ (left panel) and FoxP3+ CD4+ T cells (right panel)
were determined per gram tumor tissue. Mice were injected with Brefeldin A
4 hr before euthanasia.
Each symbol represents an individual mouse. Data are shown as the mean ±
SD. *p < 0.05, **p < 0.005, ***p < 0.0005 by two-way ANOVA with the Bon-
ferroni correction. See also Figure S4.
Figure 7. Dexamethasone Inhibits Complement Activation and
Reduces the Clinical Efficacy of Radiotherapy
(A–C) Mice were injected with B16F10-OVA cells and received radiotherapy
14 days later. DEX (0.3 mg/kg) was injected daily from day 12 until day 22,
(n = 6 mice per group). (A) Immunofluorescence of irradiated (24 hr) and
untreated tumors. Sections were stained with an antibody recognizing C3b,
iC3b, and C3c (green), CD31 for blood vessels (red), and DAPI (blue). Scale
bars represent 100 mm. Representative images are shown. (B) C3 cleavage
products in the tumors 24 hr after radiotherapy were analyzed by immuno-blot
using a polyclonal anti-C3 antibody. Relative expression measured by Bio-1D
software. Representative data are shown. (C) Tumor growth curves.
The data are shown as the mean ± SD. *p < 0.05 by two-way ANOVA with the
Bonferroni correction. Radiotherapy, RT.
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DISCUSSION
In this study, we have demonstrated that radiotherapy induces
an acute and transient local activation of complement, which is
pivotal for tumor-specific immunity and therapeutic efficacy.
Complement has traditionally been considered only to ‘‘comple-
ment’’ the action of the immune system in the antibody-mediated
defense against pathogens. The current appreciation is that
complement is involved in many different pathological pro-
cesses such as transplant rejection, autoimmunity, neurodegen-
eration, and cancer.
The role of complement in cancer is still confusing as the pro-
duction of complement-inhibiting proteins by tumor cells or
stroma has been suggested to promote tumor growth (Kolev
et al., 2011), whereas it is also proposed that complement in
the context of chronic inflammation promotes tumor growth,
migration and angiogenesis (Markiewski et al., 2008; Pio et al.,
2014). This is in line with a previous publication (Elvington
et al., 2014) showing increased efficacy of fractionated radio-
therapy when C3 was blocked. Repeated irradiation might thus
induce a chronic inflammatory response that interferes with pro-
tective adaptive immunity. In addition, the infiltrating T cells
might be killed by the next dose before they could execute their
anti-tumor effect. A different radiotherapy protocol that either
introduces a radiotherapy holiday of 7–10 days between the frac-
tions of radiotherapy or provides a single high-dose of radio-
therapy might be required to optimally support tumor-specific
immunity (Favaudon et al., 2014).
Pathogen- and damage-associated molecular patterns can
activate C1q, MBL, and the alternative complement pathway.
The latter can also be activated by spontaneous hydrolysis of
C3 or by non-complement proteins (Markiewski and Lambris,
2007). Furthermore, modified membranes of late apoptotic and
necrotic cells are potent activators of complement (Ricklin
et al., 2010). In fact, every disturbance of homeostasis or assault
might result in activation of complement (Kolev et al., 2014). Our
data suggest that factors released from necrotic tumor cells
upon radiotherapy are responsible for local complement activa-
tion. The leakiness of tumor-associated blood vessels (Carmeliet
and Jain, 2011) might further promote accumulation of comple-
ment in the tumor.
The liver is the main source of complement, but many comple-
ment components can be produced by a variety of tissues and
immune cells either constitutively or in response to stress (Kolev
et al., 2014; Li et al., 2007). For example, locally produced C1q
contributes to removal of apoptotic material and immune com-
plexes (Roumenina et al., 2011) and supports T cell responses
(Baudino et al., 2014). We have shown here that tumor-associ-
ated T cells, DCs, other CD45+ cells, as well as tumor cells can
be a source of anaphylatoxins and their receptors in response
to radiotherapy. It is plausible to consider that tumor-associated
stroma might also contribute to the production of complement
upon radiotherapy.
Sensing immune cell-derived complement during cognate in-
teractions between T cells and DCs is essential for development
of protective immunity (Lalli et al., 2007; Liszewski et al., 2013;
Peng et al., 2009; Strainic et al., 2008). Moreover, when signaling
through C3aR1 and C5aR1 is prevented during cognate interac-
tions, CD4+ T cells develop into FoxP3+ regulatory T (Treg) cells
instead of effectors (Strainic et al., 2013), in line with our obser-
vation that tumors contained more Treg cells in the absence of
anaphylatoxin receptor signaling. We found that tumor-associ-
ated DCs produced complement factors and upregulated the
expression of C3aR1 and C5aR1 upon radiotherapy, which
appeared to be essential for radiotherapy-induced DCs matura-
tion. It has been shown that anaphylatoxins directly can induce
DC maturation in vitro and that C3 upregulation precedes the
expression of IL-1, IL-12, and IL-23 (Strainic et al., 2008), sug-
gesting a direct effect of anaphylatoxins on DCs. DC maturation
is crucial to development and/or maintenance of T cell effector
function within the tumor and efficacy of radiotherapy (Gupta
et al., 2012), and indeed, tumor-infiltrating CD8+ T cells failed
to produce IFN-g after radiotherapy in the absence of signaling
through C3aR1 and C5aR1.
Given the importance of complement activation and immune
response following local radiotherapy, the administration of glu-
cocorticoids, anti-inflammatory, and immunosuppressive drugs
for managing post-radiation symptoms (Hempen et al., 2002;
Hughes et al., 2005) might have a modulating impact on the effi-
cacy of radiotherapy. Indeed, DEX given around the time of
radiotherapy significantly diminishes its efficacy, suggesting
that treatment with glucocorticoids or other anti-inflammatory
or immunosuppressive drugs might decrease the clinical
response of cancer patients to radiotherapy.
The stimulation of tumor-specific immunity by standard thera-
pies including radio- and chemotherapy has been documented
in several publications (Formenti and Demaria, 2012; Gupta
et al., 2012; Matsumura et al., 2008; Reits et al., 2006; Sharma
et al., 2013) and this phenomenonmight actually be of great clin-
ical importance: dormant metastases are intrinsically resistant to
standard treatments that mainly target rapidly dividing cells but
might still be susceptible to immune-mediated control (Koebel
et al., 2007). The abscopal effect—a situation in which not only
the irradiated tumor but also distant lesions show a clinical
response—can be explained as such. When radiotherapy is
combined with immune stimulation by anti-CTLA-4 antibodies,
the abscopal effect becomes readily apparent (Postow et al.,
2012; Verbrugge et al., 2014).
Our data expand the role of complement in the defense
against tumors. Tumor-specific immunity is unleashed by locally
produced anaphylatoxins in response to radiotherapy that acti-
vate DCs and then CD8+ T cells for optimal tumor control
following radiotherapy.
EXPERIMENTAL PROCEDURES
Mice and Cell Lines
C57BL/6, C3/, BALB/cJ, C5ar1/, C3ar1/, and Rag1/ mice were pur-
chased from the Jackson Laboratory. C3/ mice were on a C57BL/6.129S4
background; C3ar1/ and C5ar1/ mice on a BALB/cJ background,
Rag1/ mice were on a C57BL/6 background. We generated C5ar1/
C3ar1/ mice by crossing C5ar1/ and C3ar1/ mice. All mice were bred
and maintained in specific pathogen-free facilities at the University of Zurich
and University Hospital of Zurich. C57BL/6 / C3/, C3/ / C57BL/6,
C3/ / C3/, and C57BL/6 / C57BL/6 bone-marrow chimeras were
generated as previously described (Probst et al., 2003). All experiments
were performed with age- and sex-matched mice in accordance with the
guidelines of the Swiss federal and cantonal laws on animal protection.
B16F10 melanoma cells (ATCC) and B16F10-OVA (B16F10 stably trans-
fected to express chicken ovalbumin as neo-antigen, provided by Melody
774 Immunity 42, 767–777, April 21, 2015 ª2015 Elsevier Inc.
Swartz, EPFL) were cultured in Dulbecco’s modified Eagle’s medium (DMEM,
GIBCO Invitrogen), CT26 murine colon carcinoma (ATCC) cells in MEM
medium (Invitrogen). Media were supplemented with 10% fetal calf serum,
5 3 105 M 2-mercaptoethanol, 10 mM sodium pyruvate 2 mM L-glutamine,
and antibiotics.
In Vivo Experiments
23 105 B16F10-OVA, B16F10 or CT26 were injected s.c. in 100 ml of a 1:1 mix
of PBS and Matrigel Basement Membrane Matrix (BD Biosciences).
Local radiotherapy with a single dose of 20 or 5 Gy was performed at indi-
cated time points using a Xstrahl 200 kV X-ray unit at 1 Gy/min as described
(Gupta et al., 2012). Prior to radiotherapy, mice were anaesthetized by i.p. in-
jection of 50 mg/kg ketamine and 10 mg/kg xylazine.
The C3aR1 antagonist (C3aRA) N2-[(2,2-Diphenylethoxy)acetyl]-L-arginine
(SB290157, Calbiochem) was administered i.p. at 2 mg/kg body weight in
100 ml PBS. Anti-C5aR1 mAb 20/70 (Hycult Biotech) or an isotype control
(rat IgG2b anti-HLA-DR, clone SFRF8B6) was administered i.p. at 0.6 mg/kg
in 100 ml PBS (Baelder et al., 2005; Godau et al., 2004; Sun et al., 2011).
C3aRA and anti-C5aR1 mAb were administered every second day starting
at the day of radiotherapy until the end of the experiment.
To measure the cytokine production in vivo, we injected Brefeldin A (BFA,
Sigma-Aldrich). A 20-mg/ml stock was prepared in DMSO. Further dilution
to 0.5 mg/ml was made in PBS, and 500 ml was injected i.p. 4 hr before
mice were sacrificed (Liu andWhitton, 2005). DEX (Sigma-Aldrich) was admin-
istered daily at 0.3 mg/kg in PBS p.o., starting 1 day before radiotherapy.
Tumors were measured with a caliper every 2–3 days in two dimensions
(length and width). Excised tumors were weighed and processed for flow
cytometry, histology, or isolation of RNA and proteins.
In Vitro Experiments
C57BL/6 and C3/ mice were bled from the sublingual vein and sera were
collected with Microtainer SST tubes (BD). Sera were diluted 1:10 with PBS,
irradiated with 20 Gy (YXLON Y.SMART582, YXLON International GmbH,
Hamburg, D) and subsequently incubated at 37C. B16F10-OVA cells were
cultured in 6-well plates (106 cells per well) and irradiated as described above.
Immediately after irradiation, 60 ml of serum from C57BL/6 or C3/ mice
diluted in 500 ml of PBS was added to the cells. Control samples were not
irradiated but treated similarly otherwise. Supernatants were taken 4 hr and
24 hr after irradiation and were stored at 80C until further use.
Human Samples
Two sets of biopsies were provided by the Department of Dermatology, Uni-
versity Hospital Zurich. Patients signed informed consent. The ethical commit-
tee of the canton of Zurich approved this study (EK647). (1) Paired biopsies
were collected from two patients with basal cell carcinoma and one with
lentigo maligna melanoma immediately before and 24–36 hr after radiotherapy
(1.5–2 Gy) and were snap frozen. (2) Four biopsies were collected from four
patients (two with basal cell carcinoma, one with melanoma, and one with
squamous cell carcinoma) 24–36 hr after radiotherapy (1.5–2 Gy) but without
previous interventions and were snap frozen.
Statistical Analysis
Results are presented as mean ± SD. Statistical significance was determined
by ANOVA using GraphPad Prism 5 software (GraphPad). When multiple
groups were compared, we used the Bonferroni post-test correction. When
two groups were compared, we used the two-tailed Student’s t test. *, p <
0.05; **, p < 0.01; ***, p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.immuni.2015.03.009.
AUTHOR CONTRIBUTIONS
L.S., A.K., A.G., and M.v.d.B. conceptualized the study and designed experi-
ments; L.S. conducted the majority of the experiments; V.L. and A.B. per-
formed immuno-blot experiments; M.O. created heatmaps and performed
bioinformatics analyses; A.O.F. and M.P. irradiated mice; V.C. sorted cells
and performed some experiments; R.D. provided patient biopsies; H.J. and
J.N. performed electron microscopy; and L.S. and M.v.d.B. wrote the
manuscript.
ACKNOWLEDGMENTS
We thank Melody Swartz (EPFL Lausanne, Switzerland) for providing the
B16F10-OVA cell line; Jovan Pavlovic (Institute of Medical Virology, University
of Zurich) for providing antibodies against JAK and STAT; James Di Santo
(Department of Immunology, Institute Pasteur, Paris) for providing anti-
NK1.1 antibody; Claudia Matter (Clinic for Oncology, University Hospital
Zurich, Switzerland) and Karina Silina (Institute of Experimental Immunology,
University of Zurich) for technical assistance; personnel from the Biologisches
Zentrallabor (University Hospital of Zurich) for expert animal care; Alessandra
Curioni-Fontecedro (Clinic for Oncology, University Hospital of Zurich) for
helpful discussion; and Burkhard Becher, Christian Mu¨nz, Ali Bransi (Institute
of Experimental Immunology, University of Zurich), Sabine Werner (Institute
of Cell Biology, ETH, Zurich), Stefano Ferrari (Institute of Molecular Cancer
Research, University of Zurich), Mark Robert Nicolls (Department of Medicine,
Stanford Medicine), and John Lambris (Department of Pathology, University of
Pennsylvania) for scientific support and critically reading the manuscript. This
work was financially supported by the Swiss National Science Foundation
(SNSF), the Vontobel Foundation Zurich, and the University Research Priority
Program (URPP) ‘‘Translational Cancer Research.’’
Received: July 1, 2014
Revised: January 16, 2015
Accepted: March 21, 2015
Published: April 14, 2015
REFERENCES
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A.,
Mignot, G., Maiuri, M.C., Ullrich, E., Saulnier, P., et al. (2007). Toll-like receptor
4-dependent contribution of the immune system to anticancer chemotherapy
and radiotherapy. Nat. Med. 13, 1050–1059.
Auphan, N., DiDonato, J.A., Rosette, C., Helmberg, A., and Karin, M. (1995).
Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity
through induction of I kappa B synthesis. Science 270, 286–290.
Baelder, R., Fuchs, B., Bautsch, W., Zwirner, J., Ko¨hl, J., Hoymann, H.G.,
Glaab, T., Erpenbeck, V., Krug, N., and Braun, A. (2005). Pharmacological
targeting of anaphylatoxin receptors during the effector phase of allergic
asthma suppresses airway hyperresponsiveness and airway inflammation.
J. Immunol. 174, 783–789.
Basu, S., Binder, R.J., Suto, R., Anderson, K.M., and Srivastava, P.K. (2000).
Necrotic but not apoptotic cell death releases heat shock proteins, which
deliver a partial maturation signal to dendritic cells and activate the NF-kappa
B pathway. Int. Immunol. 12, 1539–1546.
Baudino, L., Sardini, A., Ruseva, M.M., Fossati-Jimack, L., Cook, H.T., Scott,
D., Simpson, E., and Botto, M. (2014). C3 opsonization regulates endocytic
handling of apoptotic cells resulting in enhanced T-cell responses to cargo-
derived antigens. Proc. Natl. Acad. Sci. USA 111, 1503–1508.
Burnette, B.C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N.N.,
Weichselbaum, R.R., Fu, Y.X., and Auh, S.L. (2011). The efficacy of radio-
therapy relies upon induction of type i interferon-dependent innate and adap-
tive immunity. Cancer Res. 71, 2488–2496.
Carmeliet, P., and Jain, R.K. (2011). Molecular mechanisms and clinical appli-
cations of angiogenesis. Nature 473, 298–307.
Chen, G., Tan, C.S., Teh, B.K., and Lu, J. (2011). Molecular mechanisms for
synchronized transcription of three complement C1q subunit genes in den-
dritic cells and macrophages. J. Biol. Chem. 286, 34941–34950.
Ciurana, C.L., Zwart, B., van Mierlo, G., and Hack, C.E. (2004). Complement
activation by necrotic cells in normal plasma environment compares to that
Immunity 42, 767–777, April 21, 2015 ª2015 Elsevier Inc. 775
by late apoptotic cells and involves predominantly IgM. Eur. J. Immunol. 34,
2609–2619.
Dunn, G.P., Koebel, C.M., and Schreiber, R.D. (2006). Interferons, immunity
and cancer immunoediting. Nat. Rev. Immunol. 6, 836–848.
Elvington, M., Scheiber, M., Yang, X., Lyons, K., Jacqmin, D., Wadsworth, C.,
Marshall, D., Vanek, K., and Tomlinson, S. (2014). Complement-dependent
modulation of antitumor immunity following radiation therapy. Cell Rep. 8,
818–830.
Engelman, R.M., Rousou, J.A., Flack, J.E., 3rd, Deaton, D.W., Kalfin, R., and
Das, D.K. (1995). Influence of steroids on complement and cytokine generation
after cardiopulmonary bypass. Ann. Thorac. Surg. 60, 801–804.
Eriksson, D., and Stigbrand, T. (2010). Radiation-induced cell death mecha-
nisms. Tumour biology: the journal of the International Society for
Oncodevelopmental Biology and Medicine 31, 363–372.
Farrar, C.A., and Sacks, S.H. (2014). Mechanisms of rejection: role of comple-
ment. Curr. Opin. Organ Transplant. 19, 8–13.
Favaudon, V., Caplier, L., Monceau, V., Pouzoulet, F., Sayarath, M., Fouillade,
C., Poupon, M.F., Brito, I., Hupe, P., Bourhis, J., et al. (2014). Ultrahigh dose-
rate FLASH irradiation increases the differential response between normal and
tumor tissue in mice. Science translational medicine 6, 245ra293.
Formenti, S.C., and Demaria, S. (2012). Radiation therapy to convert the tumor
into an in situ vaccine. Int. J. Radiat. Oncol. Biol. Phys. 84, 879–880.
Fridman, W.H., Galon, J., Page`s, F., Tartour, E., Saute`s-Fridman, C., and
Kroemer, G. (2011). Prognostic and predictive impact of intra- and peritumoral
immune infiltrates. Cancer Res. 71, 5601–5605.
Fuertes, M.B., Kacha, A.K., Kline, J., Woo, S.R., Kranz, D.M., Murphy, K.M.,
and Gajewski, T.F. (2011). Host type I IFN signals are required for antitumor
CD8+ T cell responses through CD8alpha+ dendritic cells. J. Exp. Med. 208,
2005–2016.
Fukuoka, Y., Hite, M.R., Dellinger, A.L., and Schwartz, L.B. (2013). Human skin
mast cells express complement factors C3 and C5. J. Immunol. 191, 1827–
1834.
Godau, J., Heller, T., Hawlisch, H., Trappe, M., Howells, E., Best, J., Zwirner,
J., Verbeek, J.S., Hogarth, P.M., Gerard, C., et al. (2004). C5a initiates the in-
flammatory cascade in immune complex peritonitis. J. Immunol. 173, 3437–
3445.
Gupta, A., Probst, H.C., Vuong, V., Landshammer, A., Muth, S., Yagita, H.,
Schwendener, R., Pruschy, M., Knuth, A., and van den Broek, M. (2012).
Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic
cell activation. J. Immunol. 189, 558–566.
Hasegawa, M., Yada, S., Liu, M.Z., Kamada, N., Mun˜oz-Planillo, R., Do, N.,
Nu´n˜ez, G., and Inohara, N. (2014). Interleukin-22 regulates the complement
system to promote resistance against pathobionts after pathogen-induced in-
testinal damage. Immunity 41, 620–632.
Hempen, C., Weiss, E., and Hess, C.F. (2002). Dexamethasone treatment in
patients with brain metastases and primary brain tumors: do the benefits
outweigh the side-effects? Support. Care Cancer 10, 322–328.
Huang, Y., Krein, P.M., Muruve, D.A., and Winston, B.W. (2002). Complement
factor B gene regulation: synergistic effects of TNF-alpha and IFN-gamma in
macrophages. J. Immunol. 169, 2627–2635.
Hughes, M.A., Parisi, M., Grossman, S., and Kleinberg, L. (2005). Primary brain
tumors treated with steroids and radiotherapy: low CD4 counts and risk of
infection. Int. J. Radiat. Oncol. Biol. Phys. 62, 1423–1426.
Keller, A.M., Schildknecht, A., Xiao, Y., van den Broek, M., and Borst, J. (2008).
Expression of costimulatory ligand CD70 on steady-state dendritic cells
breaks CD8+ T cell tolerance and permits effective immunity. Immunity 29,
934–946.
Kemper, C., Mitchell, L.M., Zhang, L., and Hourcade, D.E. (2008). The comple-
ment protein properdin binds apoptotic T cells and promotes complement
activation and phagocytosis. Proc. Natl. Acad. Sci. USA 105, 9023–9028.
Koebel, C.M., Vermi, W., Swann, J.B., Zerafa, N., Rodig, S.J., Old, L.J., Smyth,
M.J., and Schreiber, R.D. (2007). Adaptive immunitymaintains occult cancer in
an equilibrium state. Nature 450, 903–907.
Kolev, M., Towner, L., and Donev, R. (2011). Complement in cancer and can-
cer immunotherapy. Arch. Immunol. Ther. Exp. (Warsz.) 59, 407–419.
Kolev, M., Le Friec, G., and Kemper, C. (2014). Complement—tapping into
new sites and effector systems. Nat. Rev. Immunol. 14, 811–820.
Kopf, M., Abel, B., Gallimore, A., Carroll, M., and Bachmann, M.F. (2002).
Complement component C3 promotes T-cell priming and lung migration to
control acute influenza virus infection. Nat. Med. 8, 373–378.
Lalli, P.N., Strainic, M.G., Lin, F., Medof, M.E., and Heeger, P.S. (2007). Decay
accelerating factor can control T cell differentiation into IFN-gamma-produc-
ing effector cells via regulating local C5a-induced IL-12 production.
J. Immunol. 179, 5793–5802.
Li, K., Sacks, S.H., and Zhou, W. (2007). The relative importance of local and
systemic complement production in ischaemia, transplantation and other
pathologies. Mol. Immunol. 44, 3866–3874.
Liszewski, M.K., Kolev, M., Le Friec, G., Leung, M., Bertram, P.G., Fara, A.F.,
Subias, M., Pickering, M.C., Drouet, C., Meri, S., et al. (2013). Intracellular
complement activation sustains T cell homeostasis and mediates effector dif-
ferentiation. Immunity 39, 1143–1157.
Liu, F., and Whitton, J.L. (2005). Cutting edge: re-evaluating the in vivo cyto-
kine responses of CD8+ T cells during primary and secondary viral infections.
J. Immunol. 174, 5936–5940.
Liu, J., Lin, F., Strainic, M.G., An, F., Miller, R.H., Altuntas, C.Z., Heeger, P.S.,
Tuohy, V.K., and Medof, M.E. (2008). IFN-gamma and IL-17 production in
experimental autoimmune encephalomyelitis depends on local APC-T cell
complement production. J. Immunol. 180, 5882–5889.
Lugade, A.A., Moran, J.P., Gerber, S.A., Rose, R.C., Frelinger, J.G., and Lord,
E.M. (2005). Local radiation therapy of B16 melanoma tumors increases the
generation of tumor antigen-specific effector cells that traffic to the tumor.
J. Immunol. 174, 7516–7523.
Ma, Y., Kepp, O., Ghiringhelli, F., Apetoh, L., Aymeric, L., Locher, C., Tesniere,
A., Martins, I., Ly, A., Haynes, N.M., et al. (2010). Chemotherapy and radio-
therapy: cryptic anticancer vaccines. Semin. Immunol. 22, 113–124.
Markiewski, M.M., and Lambris, J.D. (2007). The role of complement in inflam-
matory diseases from behind the scenes into the spotlight. Am. J. Pathol. 171,
715–727.
Markiewski, M.M., and Lambris, J.D. (2009). Is complement good or bad for
cancer patients? A new perspective on an old dilemma. Trends Immunol.
30, 286–292.
Markiewski, M.M., DeAngelis, R.A., Benencia, F., Ricklin-Lichtsteiner, S.K.,
Koutoulaki, A., Gerard, C., Coukos, G., and Lambris, J.D. (2008). Modulation
of the antitumor immune response by complement. Nat. Immunol. 9, 1225–
1235.
Matsumura, S., Wang, B., Kawashima, N., Braunstein, S., Badura, M.,
Cameron, T.O., Babb, J.S., Schneider, R.J., Formenti, S.C., Dustin, M.L.,
and Demaria, S. (2008). Radiation-induced CXCL16 release by breast cancer
cells attracts effector T cells. J. Immunol. 181, 3099–3107.
McDermott, D.F., and Atkins, M.B. (2013). PD-1 as a potential target in cancer
therapy. Cancer Med 2, 662–673.
Mellman, I., Coukos, G., and Dranoff, G. (2011). Cancer immunotherapy
comes of age. Nature 480, 480–489.
Merrick, A., Errington, F., Milward, K., O’Donnell, D., Harrington, K., Bateman,
A., Pandha, H., Vile, R., Morrison, E., Selby, P., and Melcher, A. (2005).
Immunosuppressive effects of radiation on human dendritic cells: reduced
IL-12 production on activation and impairment of naive T-cell priming. Br. J.
Cancer 92, 1450–1458.
Packard, B.D., and Weiler, J.M. (1983). Steroids inhibit activation of the alter-
native-amplification pathway of complement. Infect. Immun. 40, 1011–1014.
Peng, Q., Li, K., Wang, N., Li, Q., Asgari, E., Lu, B., Woodruff, T.M., Sacks,
S.H., and Zhou, W. (2009). Dendritic cell function in allostimulation is modu-
lated by C5aR signaling. J. Immunol. 183, 6058–6068.
Pio, R., Corrales, L., and Lambris, J.D. (2014). The role of complement in tumor
growth. Adv. Exp. Med. Biol. 772, 229–262.
Postow, M.A., Callahan, M.K., Barker, C.A., Yamada, Y., Yuan, J., Kitano, S.,
Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012). Immunologic
776 Immunity 42, 767–777, April 21, 2015 ª2015 Elsevier Inc.
correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med.
366, 925–931.
Prise, K.M., and O’Sullivan, J.M. (2009). Radiation-induced bystander signal-
ling in cancer therapy. Nat. Rev. Cancer 9, 351–360.
Probst, H.C., Lagnel, J., Kollias, G., and van den Broek, M. (2003). Inducible
transgenic mice reveal resting dendritic cells as potent inducers of CD8+
T cell tolerance. Immunity 18, 713–720.
Qing, X., Koo, G.C., and Salmon, J.E. (2012). Complement regulates conven-
tional DC-mediated NK-cell activation by inducing TGF-b1 in Gr-1+ myeloid
cells. Eur. J. Immunol. 42, 1723–1734.
Quartier, P., Potter, P.K., Ehrenstein, M.R., Walport, M.J., and Botto, M.
(2005). Predominant role of IgM-dependent activation of the classical pathway
in the clearance of dying cells by murine bone marrow-derived macrophages
in vitro. Eur. J. Immunol. 35, 252–260.
Reits, E.A., Hodge, J.W., Herberts, C.A., Groothuis, T.A., Chakraborty, M.,
Wansley, E.K., Camphausen, K., Luiten, R.M., de Ru, A.H., Neijssen, J.,
et al. (2006). Radiation modulates the peptide repertoire, enhancesMHC class
I expression, and induces successful antitumor immunotherapy. J. Exp. Med.
203, 1259–1271.
Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J.D. (2010).
Complement: a key system for immune surveillance and homeostasis. Nat.
Immunol. 11, 785–797.
Roumenina, L.T., Se`ne, D., Radanova, M., Blouin, J., Halbwachs-Mecarelli, L.,
Dragon-Durey, M.A., Fridman, W.H., and Fremeaux-Bacchi, V. (2011).
Functional complement C1q abnormality leads to impaired immune com-
plexes and apoptotic cell clearance. J. Immunol. 187, 4369–4373.
Schmudde, I., Laumonnier, Y., and Ko¨hl, J. (2013). Anaphylatoxins coordinate
innate and adaptive immune responses in allergic asthma. Semin. Immunol.
25, 2–11.
Schonthaler, H.B., Guinea-Viniegra, J., Wculek, S.K., Ruppen, I., Xime´nez-
Embu´n, P., Guı´o-Carrio´n, A., Navarro, R., Hogg, N., Ashman, K., and
Wagner, E.F. (2013). S100A8-S100A9 protein complex mediates psoriasis
by regulating the expression of complement factor C3. Immunity 39, 1171–
1181.
Schreiber, R.D., Old, L.J., and Smyth, M.J. (2011). Cancer immunoediting:
integrating immunity’s roles in cancer suppression and promotion. Science
331, 1565–1570.
Sharma, A., Bode, B., Studer, G., Moch, H., Okoniewski, M., Knuth, A., von
Boehmer, L., and van den Broek, M. (2013). Radiotherapy of human sarcoma
promotes an intratumoral immune effector signature. Clinical cancer research:
an official journal of the American Association for Cancer Research 19, 4843–
4853.
Strainic, M.G., Liu, J., Huang, D., An, F., Lalli, P.N., Muqim, N., Shapiro, V.S.,
Dubyak, G.R., Heeger, P.S., and Medof, M.E. (2008). Locally produced com-
plement fragments C5a and C3a provide both costimulatory and survival sig-
nals to naive CD4+ T cells. Immunity 28, 425–435.
Strainic, M.G., Shevach, E.M., An, F., Lin, F., andMedof, M.E. (2013). Absence
of signaling into CD4+ cells via C3aR and C5aR enables autoinductive TGF-b1
signaling and induction of Foxp3+ regulatory T cells. Nat. Immunol. 14,
162–171.
Sun, S., Guo, Y., Zhao, G., Zhou, X., Li, J., Hu, J., Yu, H., Chen, Y., Song, H.,
Qiao, F., et al. (2011). Complement and the alternative pathway play an impor-
tant role in LPS/D-GalN-induced fulminant hepatic failure. PLoS ONE 6,
e26838.
Takeshima, T., Chamoto, K., Wakita, D., Ohkuri, T., Togashi, Y., Shirato, H.,
Kitamura, H., and Nishimura, T. (2010). Local radiation therapy inhibits tumor
growth through the generation of tumor-specific CTL: its potentiation by com-
bination with Th1 cell therapy. Cancer Res. 70, 2697–2706.
Verbrugge, I., Gasparini, A., Haynes, N.M., Hagekyriakou, J., Galli, M.,
Stewart, T.J., Abrams, S.I., Yagita, H., Verheij, M., Johnstone, R.W., et al.
(2014). The curative outcome of radioimmunotherapy in a mouse breast can-
cer model relies on mTOR signaling. Radiat. Res. 182, 219–229.
Wang, S. (2008). The promise of cancer therapeutics targeting the TNF-related
apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 27, 6207–
6215.
Immunity 42, 767–777, April 21, 2015 ª2015 Elsevier Inc. 777
4 Discussion
4.1 Role of homologous recombination and non-homologous end joining in the repair of 
proton-induced DNA damages
Radiobiological properties of high energy protons have long been considered to be comparable to the 
sparsely ionizing radiation properties of X-rays. Both are considered low-LET radiation, thus acting 
primarily through the induction of indirect damage and only minimally by directly damaging the DNA. 
The oxygen enhancement ratio is indeed very similar for high-energy protons and photons [1-2], as it is 
the dependence on the two major pathways, HRR and NHEJ, which repairs DNA damage. Therefore, 
the main focus has been to better understand the physical properties of proton radiation, like the Bragg
peak improve physical and technology-related aspects of proton radiation, like dose delivery and 
conformity, development of IMPT or 4D proton therapy, which takes the organ motion into account, 
rather than deeply understanding the subtle variations in the biological effect of proton radiation.
It is now widely accepted in the clinic to employ an RBE of 1.1 for proton therapy. It is defined as the 
ratio of the dose of photons (typically 250 keV x-rays) divided by the dose of protons which is needed to 
result in the same biological effect. This generic value has derived from several in vitro studies with 
tumor or untransformed cell lines. The reasons behind this value have not been clearly identified yet, as 
there are probably several factors contributing to the RBE. The main differences may rely on different 
quality (e.g. structure) and/or on quantity (e.g. amount) of proton-induced damage. Furthermore, there 
may be a differential involvement of the DNA repair pathways, which may become significant only in 
specific situations where one of them is dysfunctional, for example in tumors bearing specific mutations.
In this PhD study, I have investigated the molecular and biological endpoints after irradiation with high-
energy protons and conventional photons using both genetically defined biological systems and 
pharmacologically active compounds. A special focus has been put on the involvement of DNA double 
strand break repair machineries after proton vs. photon irradiation in human cancer cell lines. A panel of 
cell lines with either wild-type status or harboring specific mutations in the DNA repair machinery was 
used to unravel possible differential sensitivity toward proton radiation. We further implemented our 
study by employing pharmacologically active compounds to selectively exploit these differences with 
regards to the clinical perspective.
As has been demonstrated by our group and others, the present work could corroborate the enhanced
efficacy of proton irradiation versus photon irradiation with specific regard to cell killing by the proton 
spot scanning beam used at the Paul Scherrer Institute (PSI). 
The increase in RBE points towards a more severe damage after proton radiation compared to photon 
radiation, which specifically requires the homologous recombination repair pathway to be properly 
repaired. 
The RBE is usually dependent on the dose or survival level chosen, with a decrease in RBE by increase 
of dose or at low survival levels, specifically with systems with low Į/ȕ-ratio [4]. We therefore analyzed 
the RBE values at the 10% survival level throughout our study, termed RBE10. 
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In a first set of experiments, published in the Int. J. Radiat. Oncol. Biol. Phys., we have investigated the 
differential treatment response of photon and proton irradiation in genetically-defined Chinese hamster 
ovary cells (CHO cells) [3]. These cells are well known in the field of radiation biology to study the effect 
of ionizing radiation, especially photon radiation. We have used this defined cell system for our initial 
studies.
We initially have shown that exponentially growing  mutant CHO cells deficient in HRR were significantly 
more sensitive to proton irradiation than photon irradiation, compared to cells with intact homologous 
recombination repair (HRR) (relative biological effectiveness, RBE10 of 1.44±0.06 vs. 1.24±0.03). When 
these cells were irradiated in plateau (growth arrested) phase, there was no longer a difference in the 
RBE of the two cell lines (RBE10 of 1.29±0.03 vs. 1.27±0.03). In contrast, exponentially growing non-
homologous end joining (NHEJ)-deficient cells did not show a specifically enhanced sensitivity to proton 
irradiation (RBE10 of 1.2±0.05, vs. 1.09±0.10). However, after irradiation in plateau phase, these cells 
became highly radiosensitive and significantly more sensitive to proton radiation. Cells lacking classical, 
Ku-dependent NHEJ possess only minor backup repair pathways in plateau phase, which possibly can 
deal with some photon-induced DNA damages but not with proton-induced DNA damages. We further 
determined initial DNA DSBs, repair kinetics, cell-cycle distributions, and chromosomal aberrations in 
CHO cells with different genetic mutations. No quantitative differences in initially induced JH2AX and
53BP1 foci could be determined in response to the two types of ionizing radiation. The repair kinetics of 
DNA damage in wild type cells were the same after both types of radiation (JH2AX, RAD51, and 53BP1 
foci), even though proton irradiation resulted in more residual chromosomal DNA fragments and lethal 
chromosome aberrations. Interestingly, the repair kinetics in HRR-deficient cells was significantly 
delayed after proton irradiation, leading to an elevated amount of residual JH2AX-foci 24 h after 
irradiation (45 % vs. 27 % JH2AX foci after protons vs. photons, respectively). Thus, these data show 
the same amount of initial DNA DSBs after both types of radiation and rather point to a differential 
damage pattern. 
As all previous experiments have been performed with Chinese hamster ovary cells, we decided to 
probe if human cancer cells also display the same pattern of differential requirement of the two main 
DNA DSB repair pathways. For our study we chose the non-small cell lung cancer cell line A549 [5-6]. 
A549 cells represent a good model for in vitro studies. They are a p53 wild-type, but harbor a mutation 
in the KRAS oncogene [7]. Therefore, they are fast proliferating cells, with a doubling time rate of 
approximatively 19 hours. Irradiation of A549 cells with high-energy protons resulted in an RBE10 of 
1±0.04. The reasons behind this small RBE10 value may be several, but it is known that NSCLC cells, 
including A549 typically overexpress several HRR proteins, including RAD51 [8]. Increased levels of 
HRR may be responsible for an efficient processing of the more complex, proton-induced DNA damage. 
Therefore, these cells may be more prone to repair proton-induced damages than cells with low HRR 
levels, in which the RBE may draw to a value of 1. The same pattern was also observed in JH2AX-foci 
kinetic analysis, namely irradiation of A549 cells with 1Gy of both radiation types resulted in the same 
foci kinetic profile, e.g. the same amount of initial and residual foci was observed. This was coupled with 
an identical cell cycle profile after both proton and photon radiation, with approximatively 50% of cells in 
G2-arrest after 24 hours. Thus, proton-induced damages in wild-type A549 presumably seem to be 
repaired in a similar way than photon-induced damage. 
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To further investigate the two main pathways in detail, we analyzed the repair kinetics for DNA-PKcs at 
both Ser-2056 and Thr-2609 clusters to investigate NHEJ along with RAD51 and RPA32-foci to 
investigate HRR. We observed a time-dependent increase of RAD51 and RPA32-foci formation in these 
cells 1 hour and 4 hour after photon ionizing radiation. Proton irradiation induced similar amount of foci, 
suggesting HRR is activated in a similar way after both types of ionizing radiation. On the other hand, 
DNA-PKcs activation was strongly hampered after proton radiation compared to photon radiation, with a 
reduction of about 40% after 1 hour for both phosphorylation clusters analyzed. Therefore, even if the 
cell killing in A549 cells appears to be equal, there is a differential involvement of the DNA repair 
pathways present after proton and photon radiation.
We therefore investigated the role of DNA-PKcs in more detail by selectively inhibiting the catalytic 
subunit with the novel compound NU7026, which interferes with Ser-2056 auto-phosphorylation, 
therefore blocking the synaptic resolution process [9]. 
After DBS induction by ionizing radiation, DNA break recognition by the high-affine Ku70/Ku80 
heterodimer takes place, which in turn recruits DNA-PKcs to form the DNA-PK complex. Ku70/Ku80
bound to DNA-PKcs is forming a channel where the DNA fits in and differs from the conformation of 
unbound DNA-PKcs. The interaction of two DNA-PKcs molecules on adjacent sides of the DSB (a 
configuration often referred to as a synaptic complex) stimulates the protein kinase activity of DNA-PKcs
and causes trans-autophosphorylation at both Ser-2056 and Thr-2609 cluster regions, leading to the 
dissociation of the DNA-PK catalytic subunit from the synaptic complex.
NU7026 is a potent chemo- and radiosensitizing compound, and it is currently in clinical evaluation for 
several malignancies. Again, we observed potent radiosensitization toward photon, but to a much lesser 
extent toward proton radiation. 
As expected, JH2AX removal was strongly delayed in treated cells after photon radiation, but it was 
surprisingly only minimally affected after proton radiation. The same pattern was observed in the levels 
of 53BP1 foci, a marker for DNA DSB repair. Because NU7026 does not affect the phosphorylation at 
the ABCDE cluster, we analyzed Thr-2609 phosphorylation in response to the DNA-PKcs inhibitor, and 
observed the same pattern as for JH2AX and 53BP1, in cells treated with NU7026 and in response to 
photon and proton irradiation. Because NU7026 affects the auto-phosphorylation at the Ser-2056 site, 
but not at the Thr-2609 site, which is mainly ATM-mediated, we analyzed DNA-PKcs (Thr-2609)
phosphorylation kinetics in response to the DNA-PKcs inhibitor NU7026. Again, we observed the same 
pattern as for JH2AX and 53BP1, suggesting that NU7026 directly blocks the catalytic subunit to the 
damage site, avoiding its release.
Because of this enzyme blockade, we speculate that HRR would equally be inhibited, thus leading to a
strong delay in repair. We therefore analyzed RPA32-foci formation, a known marker for HRR, in the 
presence of NU726. DNA-PKcs inhibition strongly reduced RPA32-foci formation, with only about 35% 
of foci detectable 4 hours after photon radiation, whereas almost no reduction was observed after 
proton radiation. 
We then studied the effect of NHEJ deficiency by downregulating the NHEJ-factor DNA-PKcs in A549 
cells. Although significantly more radiosensitive than control cells, no statistically significant variation in 
RBE10 value was observed in the DNA-PKcs-transfected cells after both types of irradiation. The Kinetic 
profile of JH2AX-focus repair was also equal after photon and proton irradiation although it was strongly 
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delayed. This could be explained by the fact that in NHEJ-deficient cells, HRR is the only active 
pathway and it is usually slower in repairing damage. Furthermore, ATM kinase is expressed at low 
levels in DNA-PKcs-null cells, but restored to wild-type level in cells expressing a kinase-death form of 
DNA-PKcs. Therefore, DNA-PKcs-null cells or where the enzyme has been downregulated by siRNA 
treatment would show a strongly hampered JH2AX- and RAD51-foci resolution, which is strongly ATM 
dependent. Indeed, analysis of RPA32-foci resolution showed that siDNA-PKcs-transfected cells had a 
much slower activation of HRR, compared to control cells.
To confirm differential sensitivity of DNA-PKcs inhibition over DNA-PKcs deficiency, we have 
investigated cell survival and JH2AX-focus repair in the DNA-PKcs-deficient cells M059J and their 
proficient, isogenic counterpart M059K. Although M059J were significantly more radiosensitive than 
their proficient counterpart, once again, we observed no difference between photon and proton radiation 
at the level of clonogenic survival and JH2AX-focus repair. Pretreatment of the DNA-PKcs-proficient 
M059K cells with NU7026 resulted in a stronger radiosensitizing effect after photon radiation, compared 
to proton radiation. 
We as well as others have previously demonstrated that there is a specific requirement for homologous 
recombination repair for DNA repair after particle radiation [3, 10-11]. To confirm the enhanced sensitivity of 
HRR-mutated cells, we have downregulated the key HRR-recombinase RAD51. A549 cells with siRNA-
downregulated RAD51 were markedly hypersensitive to proton radiation, compared to wild-type cells 
which were equally sensitive to both types of radiation.
To confirm enhanced sensitivity of HRR-mutated cells to proton radiation versus photon radiation, we 
investigated the BRCA2-deficient cells PEO1 and their wild-type, isogenic counterpart PEO4. Both 
PEO4 and PEO1 cells were more sensitive to proton than to photon-irradiation, but the BRCA2-deficient 
cells PEO1 were more sensitive to proton-irradiation. These results are in accordance with data 
gathered in CHO systems, therefore confirming the enhanced cell killing in HRR-deficient cells after 
proton radiation in a human cancer cell system. Many open questions still remain to be answered: how 
the two main pathways, HRR and NHEJ deal with proton-induced DNA damage, compared to photon-
induced DNA damage, especially what are the structural differences between proton- and photon-
induced DNA damage, and what is exactly generating these presumably differential types of DNA 
damage.
4.2 Mechanistic insight into the repair after DNA damage induction by high energy proton 
radiation
In our study, we compared the radiobiological efficacy of high-energy proton radiation versus photon
radiation. Proton therapy treatments are based on a proton RBE of 1.1. The use of this generic, spatially 
invariant RBE within tumors and normal tissues disregards the evidence that proton RBE varies with 
linear energy transfer (LET), physiological and biological factors, and clinical endpoint. Furthermore, the 
biological (genetic) background of the cell line analyzed may influence the RBE value [4,14]. Our 
experiments were primarily performed in A549 cells, and we observed an RBE value of 1. As discussed 
before, the reasons behind this value may be several, including an overexpression of key components 
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of the HRR pathway. One of the reasons for the improved cell killing of proton radiation over photon 
radiation observed in several cell lines could be that proton radiation initially induced more DNA 
damage, specifically DSBs than photon radiation. Therefore, we analyzed the initial amount of damage 
by determining at the formation of JH2AX and 53BP1 foci. Both proteins have been shown to localize at 
the DNA damage site immediately after induction of a breakage site, only to be removed after the 
damage has been fixed [15-16]. JH2AX and 53BP1 foci formation was identical in both wild-type A549 
cells and glioblastoma M059K cells after both types of irradiation. Interestingly, these cells showed the 
same repair kinetics after 1Gy of both types of ionizing radiation, meaning that cells with properly
functional DNA repair machinery can repair both photon- and proton-induced damage equally. 
The quality of DNA damage in terms of structural complexity cannot be solely identified via markers
such as JH2AX or 53BP1. These proteins localize around the DNA damage to form scaffolds of several 
units together, and a putative increase of small fragments within few helical turns would be so close in 
space, that the foci scaffold would be completely overlying, which makes complex damages (cluster 
damages) indistinguishable from classical DSB. Therefore, we approached this challenge in an indirect 
way, by assessing the involvement of the two main repair pathways, HRR and NHEJ after both types of 
radiation. Interestingly, analysis of DNA-PKcs autophosphorylation, a marker for NHEJ revealed a 
stronger activation after photon radiation, compared to proton radiation, whereas RAD51 and RPA32 
activation was identical after both types of irradiation. The reason behind the impaired activation of 
DNA-PKcs after proton radiation may be due to the quality of the DNA damage induced by high-energy
protons. Several studies have shown that both the yield and the spatial distribution of DSBs are strongly 
dependent on the radiation quality [17]. Due to their physical properties, highly energy, low-LET proton 
particles have different energy deposition around critical structures like DNA [18-23]. The particle energy is 
usually deposited in a very narrow space, hence the increased LET value, and can generate very 
complex DNA damage. As a direct consequence, several smaller fragments may be generated (direct 
DSBs) or proton radiation may produce more oxidative cluster lesions, like abasic and oxybase lesions. 
These lesions can be then converted to DSBs by early repair processes like the base excision repair 
(indirect DSBs). Therefore, the overall result of proton radiation may induce a more complex damage, 
with more small fragments produced. A few studies have been performed to analyze the fragmentation 
pattern and yield of particle radiation [24-25]. They reported a decreased yield of all damage (both DSBs 
and base damages) with increasing LET. This is probably due to the more localized deposition of the 
energy of heavy particles leading to less but highly complex DNA damage. High-energy, low-LET 
protons were in the same range of damage induction as X-rays [54]. Nevertheless, the frequency of 
DSBs versus abasic and oxybase clusters was higher for the high-energy protons than for X-rays. 
Therefore, proton irradiation induces the same amount of complex clusters as photon irradiation but 
more non-DSB cluster lesions (oxidative cluster lesions). The higher frequency of smaller fragments 
may be the reason why NHEJ activation is impaired after proton radiation. Detailed crystallographic 
analysis of the Ku70/Ku80 complex revealed the formation of a ring structure, which accommodates the 
DNA helix within [26], where the fragment length seems to be a key determinant in the binding efficacy 
of the heterodimer [11,27]. The detailed molecular aspects for this size-dependent binding between Ku 
heterodimer and the DNA fragments are not yet clear, but is seems that the cut-off size is around 40 
Megabase [10]. 
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Interestingly, a detailed analysis of the Mre11 nuclease binding properties to DNA revealed its ability to 
bind fragments independent of their size [11, 28]. Therefore, the repair through the HRR pathway can take 
place to repair damages of any complexity, independently on the LET of the radiation beam.
   
WT NU7026    DNA-PKcs-/-
WT                                           NU7026      DNA-PKcs-/-
Differential sensitivity to proton and photon irradiation in NU7026-pretreated, DNA-PKcs-
inhibited cells in comparison to DNA-PKcs-knockdown cells and wild-type cells.
In wild-type, untreated cells treatment with ionizing radiation activates the DDR machinery to promote 
DNA repair. DNA damage is primarily repaired by the non-homologous end joining (NHEJ) pathway, 
which is strongly activated already at low dose and only in a minor way by the homologous 
recombination repair (HRR). Proton-irradiated cells display a reduced activation of DNA-PKcs, but equal 
involvement of RAD51. Because A549 have high expression of HRR proteins, proton-induced DNA 
damages can be properly repaired, leading to an RBE10 value of 1 in this cell line. Pretreatment with 
NU7026 selectively inhibits the DNA-PKcs autophosphorylation at Ser-2056, therefore blocking the 
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enzyme resolution and the consequent release from the DNA damage site. After photon irradiation, 
DNA-PKcs gets stuck at the DNA damage site, not allowing further damage processing by either NHEJ 
or HRR, causing a strong delay in DNA damage repair (as depicted by JH2AX, 53BP1 and pDNA-PKcs-
Thr-2609 repair kinetics) (continues to next page).
Proton radiation generates a different type of DNA damage (simple and more complex, cluster DNA 
damages), which cannot be properly repaired by the Ku80-dependent NHEJ pathway. Consequently, 
DNA-PKcs involvement is strongly hampered in repair response to proton-induced DNA damage.
Therefore, treatment with NU7026 will only minimally affect the NHEJ repair pathway in combination 
with proton radiation, and the HRR is the main pathway involved in the repair of proton-induced DNA 
damage. This lead to a reduced DMF10 in combination with proton radiation, compared to photon 
radiation. An involvement of the error-prone, Ku80-independent alternative end-joining (a-EJ) cannot be 
excluded. In DNA-PKcs-deficient cells, the NHEJ repair is not available. Therefore, these cells primarily 
rely on HRR, which is usually slow in DSB repair but can repair photon- and proton-induced damages 
equally well. This is due to the ability of the Mre11 nuclease to bind and repair DNA fragments 
independent of their size, whereas the Ku70/Ku80 heterodimer cannot. Therefore, the RBE10-value for 
DNA-PKcs-deficient cells is around 1.
In our study we observed that HRR-deficient cells were hypersensitive to proton radiation, whereas 
NHEJ-deficient cells were equally sensitive toward proton and photon radiation. The reason behind this 
differential sensitivity of HRR-deficient cells is pointing towards an impaired functionality of the NHEJ 
pathway to repair proton-induced DNA damage. Our experiments are highlighting, although indirectly, 
that DNA-PKcs activation is strongly hampered after proton radiation, leading to a reduced activation of 
NHEJ. Therefore, HRR becomes even more important as it is the main pathway involved in the repair of 
proton-induced damages, which would otherwise not be repaired at all (see graphic representation). In 
this respect, the alternative end joining pathway may also play an important role. It is known that this 
process is slow, but error-prone and most importantly does not require Ku70/Ku80 or DNA-PKcs to work 
properly [13-14]. Therefore, this enhanced cell killing in HRR-compromised cells after proton radiation may 
be due to either unrepaired damage, which would lead to enhanced mutagenesis and cell killing, or 
alternatively to damage misrepaired by the alternative end joining. In this respect, the involvement of the 
alternate end joining pathway should be investigated in more detail in the near future.
4.3 Combined treatment modalities
Radiotherapy alone is a very potent tool to control and eventually cure cancer. Its combination with 
chemotherapy further increases the efficacy of radiotherapy via several mechanisms [29]. Several 
chemotherapeutic compounds have been approved in the past decades to be combined with 
conventional radiotherapy. However, their combination with proton therapy, although often clinically 
employed, has not always been investigated in detail at a molecular and cellular level so far. Currently, 
DNA-PKcs and in general the NHEJ pathway represent a very interesting target in radiation therapy. 
Autophosphorylation of DNA-PKcs after genotoxic stress is a key step in the activation of the NHEJ 
pathway [30]. After ionizing radiation, about 90% of the DSBs are repaired by the NHEJ pathway, 
whereas only minimal involvement of HRR has been described [31]. We therefore investigated the role 
and effect of DNA-PKcs inhibition by NU7026 in combination with both photon and proton radiation. This 
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compound selectively blocks Ser-2056 autophosphorylation site, which is necessary to allow the release 
of the synaptic complex from the damaged site. Indeed, inhibition of DNA-PKcs strongly prolonged 
JH2AX and DNA-PKcs (Thr-2609) phosphorylation after photon irradiation and potent radiosensitisation 
was also observed in vitro in both A549 and M059K cells. 
We speculated that the strong radiosensitization observed in cells pretreated with NU7026 in 
combination with photon radiation would be strongly impaired in combination with proton radiation. The 
reason would be the impaired binding and activation of the DNA-PKcs enzyme, as observed by the
diminished Ser-2056 and Thr-2609 activation in response to proton radiation, compared to photon
irradiation. Indeed, combination of NU7026 with proton radiation resulted in a much weaker level of 
radiosensitisation in response to proton radiation, and there was no delay in foci resolution in the 
presence of the inhibitor. Based on our mechanistic data, we can conclude that the combination of 
proton therapy with DNA-PKcs inhibitor, and more widely with NHEJ inhibitors does not represent a 
favorable approach, due to the limited involvement of NHEJ after proton radiation. 
Our study highlighted how a compromised HRR cause hypersensitivity toward proton, but not photon 
radiation. Therefore, combining proton therapy with chemotherapeutic agents targeting HRR would be 
of great clinical significance.
Pharmacological targeting of the HRR pathway has proved to be unsuccessful in the past years, mostly 
because of the lack of clearly druggable target proteins. Several chemotherapeutic agents, already widely 
used in the clinic are known to downregulate RAD51, however through different molecular mechanisms. 
The broad-range histone deacetylase inhibitor SAHA (Vorinostat) and the selective Bcr-Abl Tyrosine kinase 
inhibitor Imatinib (Gleevec) lead to downregulation of RAD51 and showed radiosensitizing properties in 
vitro and also in vivo [32-35]. Due to broad range of effects, of these substances on the cell, their specificity 
and efficacy is strongly cell-type dependent. Recently, selective inhibitors of the RAD51 protein have been 
developed, such as RI-1 and IBR2 [36-38]. However, they did not prove to be highly efficient in our hands. 
Due to the essential role of the RAD51 recombinase and the fact that it is often overexpressed in several 
cancer types, RAD51 is an attractive target molecule for developing tumor-selective inhibitors.
Our previous results in A549 cells demonstrated that RAD51 is a key factor in repairing proton-induced 
damages. We therefore decided to test whether the histone deacetylase inhibitor SAHA would lead to 
an increased efficacy in combination with proton radiation. 
Continuous exposure with 2μM SAHA for 24 hours strongly reduced RAD51 protein levels, but without 
any significant effect on the Ku80 or DNA-PKcs protein levels, thus only affecting the HRR but not the 
NHEJ pathway. The radiosensitizing effect of SAHA with photon radiation was relatively weak, again 
highlighting the primary role of the NHEJ pathway in repairing the simple, photon-induced damage [31]. 
Pretreatment of A549 cells with SAHA in combination with proton radiation produced a much stronger 
response. The strong radiosensitizing effect was independent of NHEJ, as demonstrated by the strong 
delay in JH2AX but not pDNA-PKcs (Thr-2609) foci resolution observed in pretreated cells in 
combination with proton radiation.
Our study further supports the evidence to rationally combine proton radiation with agents directly or 
indirectly modulating the HRR pathway. This unique and selective combination can further increase the 
efficacy of proton therapy and broaden the spectrum of combined treatment approaches.
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4.4 Insight into the relative biological effectiveness of proton radiation
As discussed above, the RBE, or relative biological effectiveness, is the ratio of the dose of photons 
(typically 250 keV x-rays) divided by the dose of protons which is needed to result in the same biological 
effect. It is obtained by dividing the dose necessary to obtain a certain cell survival (for example 10%) 
with a certain radiation type, to the dose necessary to obtain the same cell survival with a reference 
radiation, usually X-rays. RBE is usually dependent on the dose or survival level (endpoint) chosen, with 
a decrease in RBE by increase of dose or at low survival levels [4] and also on the proton beam energy.  
The concept of RBE is clinically significant only if two basic assumptions hold true, namely that the dose 
chosen is meant to be the macroscopic dose in a well-defined volume (for example a cell culture sample
irradiated) because at the microscopic level (e.g. cellular level) inhomogeneity is generated due to the 
track structure and the energy deposition profile. Furthermore, a homogeneous dose distribution is 
assumed in the region of interest (usually an organ or a part of it). Small inhomogeneities in the 
radiation field can translate into an incorrect RBE prediction [39]. It is widely accepted to use an RBE 
value of 1.1 for clinical proton therapy, which means protons are 10% more effective than photons 
(considering a determined endpoint) when a defined dose is applied. On the physico-chemical level, the 
difference between photon and proton irradiation exposure is still unclear. Although high-energy protons 
are considered low-LET radiation, thus similar to photon radiation, protons are charged particles, which 
have different properties than simple photons. It has been demonstrated that the RBE is dependent on 
the charge other than the energy of the particle [40]. The result is a different track structure and energy 
deposition profile compared to photon radiation at the microscopical level. Damage induced by protons 
may result from a direct effect (to the DNA) or indirect effect through generation of secondary electrons 
and eventually neutrons.
Typically, photons generated from X-UD\VRUȖ-rays show the highest dose deposition near the entry site, 
the depth being directly proportional to the energy, to then steadily decrease. Due to the charge and the 
size of the proton, protons particles deeply penetrate within the cells and the energy is released during 
the slowing process in a very limited space, generating the Bragg peak and causing an increase in LET. 
The secondary radiation generated through this process also usually increases, which can cause further 
damage to the DNA. Furthermore, clinically relevant proton beams are the sum of several 
monoenergetic beams, and are generated through the actions of collimators to create the SOBP. 
Nevertheless, there is always a fraction of protons which may have lower energy, altering the profile of 
the SOBP and thus the LET. All these factors combined contribute to the differential DNA damage 
complexity observed with proton radiation.
4.5 Translational significance: biology as stratification criteria in the clinic?
Nowadays, proton beam therapy plays a very important role in the treatment of malignancies. For some 
defined tumors, like chondrosarcomas and uveal melanoma protons represent the primary treatment 
option. This is due to the physico-chemical properties of particle radiation, namely the different dose-
energy distribution profile of protons compared to photons. At the tissue entrance, proton particles 
deposit a very low dose, whereas the maximal dose deposition occurs within the Bragg peak, whose 
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tissue depth is dependent upon the beam energy. Upon reaching a certain (threshold) velocity due to 
particle interactions, protons lose most of their energy. Therefore, no significant dose is deposited 
behind this region. Several mono-energetic beams of different energies are overlaid to result in a beam 
able to cover all the desired volume, with the most energetic beams covering the distal part and the less 
energetic beams the proximal portion. In clinical applications, the resulting ensemble of beams is called 
the spread-out Bragg peak (SOBP).
In contrast, photons deposit their maximum dose close to the entrance surface, usually where the tumor 
is located (therefore, high-energy beams are used to treat deeply-seated tumors) but also behind this 
critical structure (see figure 2.4). Therefore, due to their physical properties, protons provide a more 
localized dose delivery, which is a critical factor for some tumors seated near critical organs. This 
improved dose can therefore lead to higher dose deliveries without any relevant increase in normal 
tissue toxicity. 
The use of a generic RBE-value of 1.1 is currently widely accepted for clinical proton therapy. Although 
this value is currently applied for almost every tumor entity treated, variations in the RBE values have 
been reported [4]. The RBE is strictly dependent on the beam energy used, with high-energy beams 
being generally considered low-LET radiation. The RBE is also dependent on the biological properties 
of the cellular system investigated [4, 41]. Some cells line exhibit an RBE close to 1 or even lower, which 
means they can repair proton-induced damage very well, whereas other cell systems have high RBE 
values, and they struggle to properly repair proton-induced damage. The reasons for these variations in 
the RBE are still a matter of debate, but there is more evidence pointing toward a role of the DNA 
damage response, which is responsible for orchestrating the repair of radiation-induced damage. In our 
study, we assessed that photons and high-energy protons induce the same amount of initial damage 
and display identical repair kinetics, with respect to JH2AX and 53BP1 foci. Nevertheless, detailed 
analysis of the two major pathways involved in the repair of radiation-induced damage revealed a 
differential involvement of NHEJ, but not of HRR. Therefore, we can conclude that protons do induce 
differential DNA damage compared to photons. Several proton-radiations DNA repair products are of 
worse quality, typically misrepaired cluster damages resulting in chromosomal rearrangements; this 
result in increased mutation rate and cell killing, leading to a superior effectiveness of proton radiation 
and thus an increased RBE value.
Homologous recombination repair and non-homologous end joining are differentially involved in the 
repair of complex, proton-induced damage. Cells with compromised HRR repair are highly sensitive 
toward proton radiation compared to photon radiation, which reveal the essential role of this pathway in 
repairing proton-induced damage. On the contrary, cells deficient in the NHEJ pathway, although 
generally very radiosensitive, exhibit the same radiosensitivity toward photon and proton radiation. 
Thus, these data reveal how photon and proton irradiation can induce differential involvement and 
activation of these two pathways: simple, photon-induced radiation damages are mainly repaired by the 
NHEJ pathway, which primarily involves Ku78/Ku80 and DNA-PKcs. Therefore, an intact and functional 
NHEJ is of major importance to ensure proper repair of photon-radiation induced damage, but less for 
the repair of more complex, proton-induced damage. 
HRR is a very slow but precise process, taking place primarily in S- and G2-phase cells. Cells lacking 
HRR are not significantly more sensitive to photon radiation, especially at low radiation doses, probably 
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because of the efficacy and speed of NHEJ in repairing such damage [42]. On the other hand, deficiency 
in the HRR apparatus renders cells more sensitive to proton radiation. This is probably due to the 
incapacity of NHEJ to properly repair the damage, thus the additional deficiency of HRR leaves the cells 
with no proper functional pathway.
This phenomenon is of great clinical relevance. Nowadays tumors are not stratified based on their 
biological properties (e.g. mutational status) for radiotherapy treatment. A stratification based on the 
mutational status of HRR proteins would increase the efficacy of treatment. This is also of great 
relevance with regard to normal tissue toxicity. Usually, tumors acquire mutations during their 
development [43-44], so that the normal tissue does not usually harbor specific mutations, or it is only 
heterozygous for them. Examples are the BRCA genes, namely BRCA1 and BRCA2. These genes are 
strongly involved in the HRR pathway [45], where they play a role in promoting IR-induced repair. Usually 
patients harbor a heterozygotic mutation in one of those proteins, but because one copy of the gene is 
still functional, the cells have a properly active HRR. During tumor development, a second mutation is 
acquired (loss of heterozygosity) within the tumor, but not in the normal tissue. Thus, the tumor
compartment might respond significantly more to proton irradiation, whereas the normal, surrounding 
tissue would not experiment any additional, toxic radiosensitivity. 
The issue of normal tissue toxicity and tumor control becomes important also with regard to combined 
treatment modalities. Most tumors do not harbor any specific mutation in the DNA repair machinery;
therefore a pharmacologically active agent able to target the DNA repair machinery may be employed. 
We have demonstrated that SAHA (Vorinostat), a non-selective histone deacetylase inhibitor may 
specifically radiosensitize cells to proton but to a less extent to photon radiation. The radiosensitizing 
effect is primarily due to the downregulation of the RAD51 nuclease by SAHA. Due to the broad range 
of effects on gene expression, eventual cell type-specific off-target effects of SAHA cannot be 
completely excluded.
Still, cell lines with apparently intact repair machinery react very different to proton radiation. Every cell 
line expresses their proteins at a very specific level, and the process of gene expression and regulation 
is tightly regulated [46]. Differential gene expression and the subsequent protein levels of DNA damage 
repair proteins may strongly influence the response to proton radiation. Triple negative breast cancers 
have reported a diminished expression of DNA repair genes, especially HRR genes [47]. The same 
pattern has been observed in ovarian cancer [48]. These tumors may clinically be similar to tumors with 
mutations in the HRR pathway and respond very well to proton radiotherapy. 
Other tumor entities are instead overexpressing high levels of HRR proteins, as it is the case of lung 
cancer [49]. Typically, overexpression of DNA repair proteins is associated with high resistance to 
chemotherapy, and eventually also to radiotherapy [50-51].
Lung cancer progression is typically associated with increased gene expression of several DNA 
damage repair (DDR) proteins involved in the homologous recombination repair, like RAD51, BRCA1/2 
and FANC proteins [55-56]. Overexpression of these DDR proteins may lead to some sort of protective 
effect specifically toward proton radiation, as HRR pathway upregulation may allow these cells to repair 
a considerable amount of the complex, proton-induced damage by reducing process-related misrepair. 
Therefore, several HRR proteins like BRCA1 or RAD51 are currently evaluated as possible prognostic 
markers in NSCLC to predict tumor response to chemotherapy or radiotherapy [52-53].
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In our study we have evaluated the response to proton radiation of the non-small cell lung cancer cells 
A549 and H460 and the Triple-negative breast cancer cells MDA-MB-231 and MDA-MB-436. 
Interestingly though, A549 cells (p53-positive) did not show any significant sensitivity to protons, with an 
RBE of about 1. Instead, MDA-MB-231 and MDA-MB-436 cells (both p53-negative) were markedly 
hypersensitive to proton radiation, with RBE10 values of approximatively 1.35. Therefore,  stratification in 
the clinic could be carried out not only on patients with tumors bearing mutations in the DNA repair 
machinery, as it is the case for BRCA-deficient breast and ovarian cancer, but also on those tumor 
entities with differential expression levels of selected proteins. Tumors with low HRR protein levels 
would be more suited to proton therapy, whereas tumors with high HRR protein levels may respond 
equally to proton and photon therapy. Because nowadays several tumor entities (e.g. lung, breast and 
prostate cancer) are under evaluation for proton therapy, not only a technical evaluation (e.g. feasibility 
to irradiate the tumor due to its localization) but also a biological evaluation (gene expression profile) of 
such tumors may be an important criterion in deciding which tumors may be more suited for clinical 
proton therapy, and which may not.
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5 Outlook
Here we demonstrate that the homologous recombination repair pathway plays a fundamental role in 
the repair of complex, proton-induced damage. Genetic deficiency in key components of the pathway, 
like RAD51 or BRCA2, causes hypersensitivity toward proton, but not photon radiation. It is important to 
consider that the various components of the HRR pathway may play a differential role in the repair of 
DNA damage, e.g. RAD51-mediated DNA filament processing is an essential step in HRR, whereas 
XRCC3 or BRCA2 have more of a supportive role. Therefore, a deficiency or low expression level of 
RAD51 may have a stronger impact in tumor treatment response than BRCA2 deficiency, especially at 
low doses used as part of fractionated treatment regimen. 
A promising strategy to exploit this increased dependence on the HRR would be to use compounds 
which can selectively target key components of the pathway. Nowadays, only few compounds target 
HRR, mostly indirectly. We have shown that SAHA (Vorinostat), an histone deacetylase inhibitor 
currently approved for the clinical treatment of cutaneous T-cell lymphoma. SAHA has been shown to 
work by modulating the gene expression of several genes, among them RAD51. Due to its broad effect 
on cellular gene expression, a certain degree of side-effects should be taken into account. Other 
compounds are known for their (indirect) effect on RAD51, e.g. Imatinib (Gleevec) and Methotrexate, 
both widely used in the clinic for several malignancies as part of chemotherapy regimens. It is therefore
clear that any combined approach currently used for photon radiotherapy should be accurately 
evaluated for proton therapy, due to possible new interaction mechanisms. 
The ultimate experiment to provide proof on clinical relevance of our finding would be to treat HRR-
deficient tumor xenografts with proton and photon radiotherapy, or pharmacological agents specifically 
targeting the HRR. This would have a great impact on tumor treatment planning for patients with HRR-
deficient tumors, where the dose delivered could be reduced, thereby diminishing normal tissue toxicity
and at the same time achieving better tumor control. Unfortunately, almost no established HRR-deficient 
tumor models suited for in vivo experiments are in place, therefore establishing a proper tumor model 
will be of highest priority in the future.
In our study we further demonstrated for the first time that a potent and specific DNA-PKcs inhibitor, 
NU7026 can selectively radiosensitize cells to photon radiation, but to a much lesser extent to proton 
radiation. This compound is currently under evaluation for several malignancies, including leukemia and 
glioblastoma, in combination with Topoisomerase inhibitors and radiation. Due to the key role of DNA-
PKcs and NHEJ in repairing DSBs, it is expected that clinical indications for this promising compound 
and other will be broadened. Here we have shown that DNA-PKcs inhibitors may less be suited for the 
combination with proton radiation therapy, but more so far in combination with photon therapy.
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This data also provides precious insight into the mechanism of how proton radiation works. We have 
shown that pharmacological inhibition of DNA-PKcs has a selective effect by strongly radiosensitization 
human cancer cells toward photon radiation than toward proton radiation, whereas genetic deficiency of 
DNA-PKcs renders cells equally sensitive to both radiation types. These results highlight the role of 
Ku70/Ku80 heterodimer together with DNA-PKcs (the synaptic complex) in recognizing and promoting 
the repair of photon-induced DNA damage, and how this process is impaired in the recognition of 
proton-induced DNA damage, probably because of the different structure of the DNA damage induced 
by proton radiation, compared to photon radiation.
In conclusion, the present work illustrates the unique role of the homologous recombination pathway in 
repairing proton-induced damage. On one hand, it provides insight on the molecular mechanism of 
proton radiation, thus helping to better understand its biological and molecular basis, but on the other, 
our results open the door to new, clinically relevant implications for proton radiation therapy and new 
combined treatment approaches. 
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